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A B S T R A C T
Background
Stillbirth affects at least 2.6 million families worldwide every year and has enduring consequences for parents and health services.
Parents entering a subsequent pregnancy following stillbirth face a risk of stillbirth recurrence, alongside increased risks of other adverse
pregnancy outcomes and psychosocial challenges. These parents may benefit from a range of interventions to optimise their short- and
longer-term medical health and psychosocial well-being.
Objectives
To assess the effects of different interventions or models of care prior to and during subsequent pregnancies following stillbirth on
maternal, fetal, neonatal and family health outcomes, and health service utilisation.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (6 June 2018), along with ClinicalTrials.gov and the
WHO International Clinical Trials Registry Platform (ICTRP) (18 June 2018).
Selection criteria
We included randomised controlled trials (RCTs) and quasi-randomised controlled trials (qRCTs). Trials using a cluster-randomised
design were eligible for inclusion, but we found no such reports. We included trials published as abstract only, provided sufficient
information was available to allow assessment of trial eligibility and risk of bias. We excluded cross-over trials.
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Data collection and analysis
Two review authors independently assessed trials for eligibility and undertook data extraction and ’Risk of bias’ assessments. We extracted
data from published reports, or sourced data directly from trialists. We checked the data for accuracy and resolved discrepancies by
discussion or correspondence with trialists, or both. We conducted an assessment of the quality of the evidence using the GRADE
approach.
Main results
We included nine RCTs and one qRCT, and judged them to be at low to moderate risk of bias. Trials were carried out between the years
1964 and 2015 and took place predominantly in high-income countries in Europe. All trials assessed medical interventions; no trials
assessed psychosocial interventions or incorporated psychosocial aspects of care. Trials evaluated the use of antiplatelet agents (low-dose
aspirin (LDA) or low-molecular-weight heparin (LMWH), or both), third-party leukocyte immunisation, intravenous immunoglobulin,
and progestogen. Trial participants were women who were either pregnant or attempting to conceive following a pregnancy loss, fetal
death, or adverse outcome in a previous pregnancy.
We extracted data for 222 women who had experienced a previous stillbirth of 20 weeks’ gestation or more from the broader trial data
sets, and included them in this review. Our GRADE assessments of the quality of evidence ranged from very low to low, due largely
to serious imprecision in effect estimates as a result of small sample sizes, low numbers of events, and wide confidence intervals (CIs)
crossing the line of no effect. Most of the analyses in this review were not sufficiently powered to detect differences in the outcomes
assessed. The results presented are therefore largely uncertain.
Main comparisons
LMWH versus no treatment/standard care (three RCTs, 123 women, depending on the outcome)
It was uncertain whether LMWH reduced the risk of stillbirth (risk ratio (RR) 2.58, 95% CI 0.40 to 16.62; 3 trials; 122 participants;
low-quality evidence), adverse perinatal outcome (RR 0.81, 95% CI 0.20 to 3.32; 2 trials; 77 participants; low-quality evidence),
adverse maternal psychological effects (RR 1.00, 95% CI 0.07 to 14.90; 1 trial; 40 participants; very low-quality evidence), perinatal
mortality (RR 2.58, 95% CI 0.40 to 16.62; 3 trials; 122 participants; low-quality evidence), or any preterm birth (< 37 weeks) (RR
1.01, 0.58 to 1.74; 3 trials; 114 participants; low-quality evidence). No neonatal deaths were reported in the trials assessed and no data
were available for maternal-infant attachment. There was no clear evidence of a difference between the groups among the remaining
secondary outcomes.
LDA versus placebo (one RCT, 24 women)
It was uncertain whether LDA reduced the risk of stillbirth (RR 0.85, 95% CI 0.06 to 12.01), neonatal death (RR 0.29, 95% CI 0.01
to 6.38), adverse perinatal outcome (RR 0.28, 95% CI 0.03 to 2.34), perinatal mortality, or any preterm birth (< 37 weeks) (both
of the latter RR 0.42, 95% CI 0.04 to 4.06; all very low-quality evidence). No data were available for adverse maternal psychological
effects or maternal-infant attachment. LDA appeared to be associated with an increase in birthweight (mean difference (MD) 790.00
g, 95% CI 295.03 to 1284.97 g) when compared to placebo, but this result was very unstable due to the extremely small sample size.
Whether LDA has any effect on the remaining secondary outcomes was also uncertain.
Other comparisons
LDA appeared to be associated with an increase in birthweight when compared to LDA + LMWH (MD −650.00 g, 95% CI −1210.33
to −89.67 g; 1 trial; 29 infants), as did third-party leukocyte immunisation when compared to placebo (MD 1195.00 g, 95% CI
273.35 to 2116.65 g; 1 trial, 4 infants), but these results were again very unstable due to extremely small sample sizes. The effects of
the interventions on the remaining outcomes were also uncertain.
Authors’ conclusions
There is insufficient evidence in this review to inform clinical practice about the effectiveness of interventions to improve care prior
to and during subsequent pregnancies following a stillbirth. There is a clear and urgent need for well-designed trials addressing this
research question. The evaluation of medical interventions such as LDA, in the specific context of stillbirth prevention (and recurrent
stillbirth prevention), is warranted. However, appropriate methodologies to evaluate such therapies need to be determined, particularly
where clinical equipoise may be lacking. Careful trial design and multicentre collaboration is necessary to carry out trials that would be
sufficiently large to detect differences in statistically rare outcomes such as stillbirth and neonatal death. The evaluation of psychosocial
interventions addressing maternal-fetal attachment and parental anxiety and depression is also an urgent priority. In a randomised-
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trial context, such trials may allocate parents to different forms of support, to determine which have the greatest benefit with the least
financial cost. Importantly, consistency in nomenclature and in data collection across all future trials (randomised and non-randomised)
may be facilitated by a core outcomes data set for stillbirth research. All future trials should assess short- and longer-term psychosocial
outcomes for parents and families, alongside economic costs of interventions.
P L A I N L A N G U A G E S U M M A R Y
Interventions for improving outcomes in pregnancies that follow stillbirth
We aimed to compare the effectiveness of different interventions or models of care in improving pregnancy outcomes for parents who
have had a previous stillbirth at 20 weeks’ gestation or more. The care could be initiated before pregnancy, or during pregnancy, labour,
or birth.
What is the issue?
Every year at least 2.6 million families experience the tragedy of stillbirth. This is a devastating event that can have long-term consequences
and change parents’ attitudes to future pregnancies. Many different causes can lead to stillbirth, and sometimes multiple causes occur
together. Causes such as long-term health problems in the mother are still present in subsequent pregnancies. The parents may therefore
benefit from special care before becoming pregnant again. Such care may be highly diverse, addressing a range of risk factors, conditions,
and other considerations. This care can take the form of counselling or social support programmes to assist with dealing with grief,
anxiety and depression; better managing a mother’s health before conception to address health issues; and assisting with high-risk
behaviours or risk factors such as being overweight, smoking, or alcohol use. Once pregnant, the mother can be closely watched,
possibly with extra antenatal visits or by attending special antenatal clinics. A planned early birth may also be considered.
Why is this important?
Parents who have had a stillborn baby are more likely to have another stillbirth than parents who have not had a stillborn baby before.
In their next pregnancy, parents often experience anxiety and depression, and ongoing worry about whether their baby will survive.
It is important to be able to work out from high-quality clinical studies which interventions are helpful in preventing stillbirth from
happening again, and in improving the health and well-being of these parents and families.
What evidence did we find?
We searched for evidence from randomised controlled trials published up to June 2018. We included 10 studies at low to moderate
risk of bias. All but one study were from high-income countries, mainly in developed areas of Europe. The women in the studies were
either pregnant or attempting to conceive after having a miscarriage, a stillborn baby, or a serious complication in a previous pregnancy.
The interventions included two types of drugs (low-dose aspirin and low-molecular-weight heparin) that reduce blood clotting and
may help the placenta to function (six trials), pre-conception injection of blood cells (third-party leukocyte immunisation) to help
mothers’ immune systems to cope with pregnancy (one trial), a special type of antibody (intravenous immunoglobulin) given into a
vein to improve the functioning of the pregnant woman’s immune system (two trials), and injections of a medication (progestogen)
that acts like the pregnancy hormone progesterone (one trial). We evaluated data from 222 women who had previously had a stillborn
baby at 20 weeks’ gestation or more.
We were unable to determine whether any of these interventions reduced the chance of having another stillborn baby in the subsequent
pregnancy; or whether the interventions reduced the chances of babies dying or having serious complications in the first month of
life, because the studies not large enough for us to have confidence in the findings. Largely because of this, we judged the quality of
evidence in this review to be very low to low. Two interventions (low-dose aspirin and third-party leukocyte immunisation) appeared
to increase the birthweight of babies, but these findings are not reliable due to the small numbers of babies included.
The included studies provided very little information about psychological outcomes of parents or longer-term outcomes of children
and families.
What does this mean?
There is insufficient evidence from the studies included in this review to know which interventions are helpful in preventing subsequent
stillbirths and improving the health and well-being of parents and families in pregnancies that follow a stillbirth. More targeted studies
are needed, which include larger numbers of women/parents who have previously experienced a stillbirth. We urgently need studies
3Care prior to and during subsequent pregnancies following stillbirth for improving outcomes (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
testing what forms of psychological support are most helpful in reducing anxiety and depression for these parents. Any studies carried
out in future should measure the financial costs of interventions, and longer-term health outcomes of families and children.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Low-molecular-weight heparin compared to no treatment/ standard care for improving outcomes
Patient or population: women with a previous st illbirth of ≥ 20 weeks’ gestat ion who are pregnant or considering a subsequent pregnancy
Setting: obstetric units and outpat ient clinics in Germany, Austria, Canada, and Italy
Intervention: low-molecular-weight heparin
Comparison: no treatment/ standard care



















17 per 1000 43 per 1000
(7 to 277)




No neonatal deaths re-
ported
see comment see comment
Adverse perinatal out-
come (composite out-









100 per 1000 85 per 1000
(13 to 577)
Adverse maternal psy-
chological ef fects (anx-
iety, depression or com-
plicated grief )







50 per 1000 50 per 1000
(4 to 745)
























































































































17 per 1000 43 per 1000
(7 to 277)
Any preterm birth (birth
< 37 weeks)





304 per 1000 310 per 1000
(152 to 638)
Maternal-infant attach-
ment - not measured
- - - - - Outcome was not mea-
sured in the trials in-
cluded
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High certainty: this research provides a very good indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erentj is low
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B A C K G R O U N D
Description of the condition
Stillbirth is a devastating outcome of pregnancy, with enduring
psychosocial consequences for parents, including anxiety and de-
pression, guilt, complicated grief, social isolation, and relationship
breakdown (Heazell 2016). Stillbirth also has profound economic
impacts on parents, families, and the wider community (Heazell
2016; Ogwulu 2015). The definition of stillbirth in terms of ges-
tational age varies across geographical settings. For international
comparisons, the World Health Organization recommends report-
ing of stillbirths of 28 weeks’ gestation or more, although most
high-income countries (HICs) adopt a lower gestational age cut-
off point (Flenady 2015). In this review, we define stillbirth as the
death of an unborn baby at 20 weeks’ gestation or more.
Globally, at least 2.6 million babies are stillborn in the third
trimester each year (Lawn 2016). While data from many parts of
the world are incomplete, it is known that the vast majority of
these deaths (98%) occur in low- and middle-income countries
(LMICs), and that over 40% occur in the intrapartum period, of-
ten associated with obstetric emergencies (Lawn 2016; Reinebrant
2018). Wide variation exists across and within countries, with
stillbirth rates estimated to be below five per 1000 births in HICs
(Flenady 2016), compared with approximately 32 per 1000 in
sub-Saharan Africa and South Asia (Lawn 2016).
There are many maternal and fetal conditions associated with still-
birth. These conditions often co-exist, and include maternal in-
fections, non-communicable diseases, nutrition and lifestyle fac-
tors, malaria, fetal growth restriction, and advanced maternal age
(Lawn 2016). In LMICs, limited access to skilled birth attendants
and low rates of caesarean section are also believed to be impor-
tant. Maternal undernutrition is prevalent in many low-income
countries and contributes to various adverse pregnancy outcomes
including fetal growth restriction (Black 2008a), which is an im-
portant risk factor for stillbirth. In HICs, common risk factors
for stillbirth include maternal overweight and obesity, advanced
maternal age, primiparity, and smoking (Flenady 2011).
A systematic review of stillbirth recurrence in HICs, including
over three million women, reported an almost five-fold increase
in the risk of stillbirth in the pregnancy following stillbirth from
all causes (Lamont 2015). However, predicting recurrence risk in
a specific pregnancy is difficult, as the risk depends on a variety
of factors, such as the aetiology of the index stillbirth. For exam-
ple, while there is little evidence to draw upon, it is possible that
deaths related to placental insufficiency or a pre-existing maternal
condition have a greater recurrence risk. Conversely, recurrence is
less likely for isolated events such as maternal injury leading to
placental abruption (Robson 2001).
When the cause of stillbirth is unexplained, the risk of recurrence
is unclear (Lamont 2015). It is possible that recurrence following
truly unexplained stillbirth is no higher than that of the general
population (Onwude 2006; Robson 2001). While this may be re-
assuring for some women and their families, a history of stillbirth
has been shown to be associated with higher frequencies of other
complications in the next pregnancy, including increased rates of
induced labour, elective and emergency caesarean birth, instru-
mental birth and other adverse outcomes, such as preterm birth,
low birthweight, placental abruption, pre-eclampsia, gestational
diabetes (Black 2008b; Heinonen 2000; Robson 2001), chorioam-
nionitis, and neonatal death (Getahun 2009). Some of these out-
comes may be in part due to care providers’ and women’s hyper-
vigilance, rather than inherent biological risk (Robson 2006).
Previous stillbirth is also commonly associated with intense anx-
iety and fear in the next pregnancy, with some women feeling a
lack of confidence in their capacity to maintain a healthy preg-
nancy (Gravensteen 2018; Meaney 2017; Mills 2014). The fear
of experiencing another loss may further increase risk, as stress
during pregnancy has also been associated with adverse pregnancy
outcomes, such as preterm birth (Dunkel Schetter 2011; Van den
Bergh 2005) and low birthweight (Baibazarova 2013; Dunkel
Schetter 2011; Su 2015; Van den Bergh 2005), possibly medi-
ated by placental function (O’Donnell 2009). Anxiety and fear
may also prompt some parents to refrain from attachment to their
baby (Lee 2017; Mills 2014). Disorganised attachment has been
observed in infants born subsequent to stillbirth, which may in
turn increase these infants’ risk of psychological and behavioural
problems in childhood (Hughes 2001).
The global reduction in stillbirth rates has not matched that for
maternal or neonatal mortality (Lawn 2016). A persisting issue
facing providers of maternity care is therefore how to manage the
next and subsequent pregnancies. International data have shown
that parents who experienced a stillbirth in a previous pregnancy
are commonly offered additional antenatal visits and additional ul-
trasound scans in their next pregnancy, particularly following later-
gestation stillbirths (defined as >30 weeks’ gestation (Wojcieszek
2018). Indeed, surveys and interviews have found that women
themselves wanted high levels of surveillance and early birth in
pregnancies following stillbirth or perinatal death (Mills 2016;
Robson 2009; Simmons 2011). Similarly, a survey of Australian
obstetricians found that many health professionals were likely to
recommend close surveillance and early birth in pregnancies af-
ter stillbirth (Robson 2006). However, while early birth has some
potential to reduce the rate of stillbirth, it may also be associated
with iatrogenic complications (caused by treatment or diagnostic
procedures) as alluded to earlier, including prematurity and its as-
sociated adverse outcomes, failed induction, instrumental birth,
emergency caesarean birth, and postpartum haemorrhage (Paull
2013).
Description of the intervention
The care and management of women in the next and subsequent
pregnancies following stillbirth may be different from the care
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of women who have never been pregnant, or who have never
had a complicated pregnancy. It is possible that a number of
management decisions will be required, some guided by causes,
circumstances, or risk factors associated with the prior stillbirth
(Monari 2010; Paull 2013; Reddy 2007; Robson 2010; Saade
2011). Therefore, while discrete interventions may be assessed
to care for women in the next and subsequent pregnancies, care
might also involve different management algorithms, protocols,
guidelines, or models of care, combining multiple interventions
in order to optimise outcomes for families.
Care prior to subsequent pregnancies might first focus on coun-
selling on stillbirth recurrence risk for parents considering a sub-
sequent pregnancy after stillbirth, to provide information and de-
cision-making support on:
• interpregnancy interval; pre-conception health.
Alternatively, or in addition, care prior to or during subsequent
pregnancies might focus on managing/addressing specific defined
causes or circumstances of the index stillbirth, such as interven-
tions to treat, manage or address:
• diabetes; hypertensive disorders; thyroid disorders; acquired
or inherited thrombophilia; systemic lupus erythematosus; blood
group antibodies; maternal cardiac disease; other medical
conditions; chronic infectious conditions (HIV, hepatitis,
syphilis); periodontal disease; preterm labour; and cervical
insufficiency.
Care could also be focused on addressing the presence of modifi-
able high-risk behaviours or risk factors, such as interventions to
reduce:
• obesity; smoking; alcohol use.
In the case of unexplained stillbirth and also where causes, circum-
stances or risk factors have been identified, care may focus on fetal
surveillance and timing and mode of birth, such as:
• maternal assessment of fetal movements; fetal heart rate
monitoring or cardiotocography; early and/or regular ultrasound
surveillance (to assess fetal growth, placental size or structure
amniotic fluid index, Doppler assessment of uterine or umbilical
blood flow); and/or
• elective induction of labour; elective caesarean birth; early
birth; intrapartum monitoring.
Care prior to or during subsequent pregnancies might also focus
on specific psychosocial needs, such as:
• specialised antenatal classes for bereaved parents; peer-
support programmes and grief counselling; and additional
antenatal visits or therapies to address anxiety, depression, and
maternal-infant attachment.
How the intervention might work
Care prior to and during subsequent pregnancies following still-
birth has the potential to be highly diverse, addressing a range
of risk factors, conditions, and other considerations. First, coun-
selling on stillbirth recurrence risk may facilitate informed de-
cision-making for parents considering a pregnancy subsequent
to stillbirth (Fockler 2017; Paull 2013). Such counselling may
include information on interpregnancy interval, preconception
health, and the risks and benefits of delaying a subsequent preg-
nancy in each unique case. For women who become pregnant, un-
derstanding the cause of the index stillbirth (if known) will facili-
tate the development of an individualised management plan in the
subsequent pregnancy to address the cause directly, and therefore
reduce the likelihood of recurrence. For pre-existing maternal con-
ditions that are likely to recur (e.g. diabetes), stabilisation of the
condition may reduce stillbirth recurrence risk. Cessation of smok-
ing and pre-conception interventions addressing maternal over-
weight and obesity may also reduce risk (Monari 2010). Where no
cause of death for the index stillbirth has been identified, frequent
monitoring may enable early detection of developing complica-
tions and may prompt expedited birth where appropriate (Fockler
2017; Robson 2010). Interventions designed to improve mater-
nal mental health may reduce stress in pregnancy, lessening the
likelihood of adverse effects such as low birthweight and preterm
birth, while also enhancing maternal-fetal attachment. Additional
antenatal visits, for example, may provide parents with more op-
portunities for reassurance, and have been welcomed by parents
in pregnancies subsequent to stillbirth or neonatal death (Meaney
2017; Mills 2014).
Interventions might be provided in isolation or in combination; for
example, in the form of a specialised model of care or a dedicated
clinic for families entering a pregnancy after loss (e.g. Meredith
2017).
Why it is important to do this review
Despite the known risk of stillbirth recurrence and the far-reach-
ing impacts of stillbirth on subsequent pregnancies and beyond,
there is a paucity of information on care prior to and during these
pregnancies to improve health outcomes. Women who are preg-
nant after having a previous stillbirth, and their partners, comprise
a small but unique group who may benefit from specialised and
individualised care both medically and psychosocially, but there
are currently little data to inform clinical practice.
O B J E C T I V E S
To assess the effects of different interventions or models of care
prior to and during subsequent pregnancies following stillbirth on
maternal, fetal, neonatal and family health outcomes, and health
service utilisation.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Eligible trial designs included randomised controlled trials (RCTs),
quasi-randomised controlled trials (qRCTs), and cluster-ran-
domised trials. We excluded cross-over trials. We included trials
published as abstract only, provided sufficient information was
available to allow us to assess trial eligibility and risk of bias.
Types of participants
Parents who had experienced a stillbirth of 20 weeks’ gestation or
more who were pregnant or considering a subsequent pregnancy.
We included trials with parents who had experienced a pregnancy
loss prior to 20 weeks’ gestation, or a neonatal death, alongside
parents who had experienced a stillbirth according to our defini-
tion (i.e. a death of 20 weeks’ gestation or more) only if participant
data relating to previous stillbirths of 20 weeks’ gestation or more
could be disaggregated from the broader trial populations.
Types of interventions
We included any single intervention, combination of interven-
tions or tailored model of care/algorithm/guideline/protocol for
improving health outcomes in subsequent pregnancies following
stillbirth, compared with no intervention or standard care.
We also included studies where one intervention/combination of
interventions/tailored model of care was compared with another.
For the trials captured in this review, all interventions began prior
to or during pregnancy. For future updates of this review, we will
also include studies in which the intervention/model of care began
during labour and birth or shortly after birth, if we find such trials.
Eligible interventions for this review could include, for example,
targeted management to address previous causes or circumstances
of prior stillbirth (e.g. diabetes, hypertensive disorders); care to ad-
dress high-risk behaviours/risk factors (e.g. obesity, smoking); care
focused on fetal surveillance and timing and mode of birth; and
care to address specific psychosocial needs (See above Description
of the intervention for further details).
Types of outcome measures




• Adverse perinatal outcome (composite outcome including
stillbirth, neonatal death, and major neonatal morbidity such as
hypoxic-ischaemic encephalopathy; intracranial haemorrhage;
retinopathy of prematurity; necrotising enterocolitis);
• Adverse maternal psychological effects (anxiety, depression
or complicated grief ).
Secondary outcomes
Fetal, neonatal and childhood outcomes
• Perinatal mortality
• Preterm birth (any preterm birth; very preterm birth; late
preterm birth)
• Birthweight, low birthweight, small-for-gestational age
• Apgar score less than seven at five minutes
• Respiratory distress syndrome
• Neonatal jaundice
• Psychological and behavioural problems in childhood
• Anxiety or depression or both in childhood
• Long-term neurodevelopmental and educational outcomes
• Quality of life
Maternal outcomes
• Adherence to the intervention (process outcomes) (i.e.
smoking cessation; lifestyle changes - changes in diet, physical
activity, weight loss) (pre-pregnancy and during pregnancy)
• Caesarean birth (elective; emergency)
• Induction of labour






• Satisfaction with care
• Serious maternal outcome (composite outcome including




• Quality of life
Health service utilisation
• Antenatal care attendance
• Maternal antenatal admission
• Duration of maternal hospital stay (days)
• Duration of neonatal hospital stay (days)
• Admission to the neonatal intensive care unit
• Duration of neonatal intensive care unit stay (days)
• Antenatal ultrasound scans
• Cost
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Family outcomes
• Partner anxiety, depression or complicated grief
• Partner quality of life
• Relationship breakdown/disharmony
Search methods for identification of studies
The following methods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (6 June 2018).
The Register is a database containing over 24,000 reports of con-
trolled trials in the field of pregnancy and childbirth. It represents
over 30 years of searching. For full current search methods used
to populate Pregnancy and Childbirth’s Trials Register including
the detailed search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL; the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service, please follow this link.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches the
Register for each review using this topic number rather than key-
words. This results in a more specific search set that has been fully
accounted for in the relevant review sections (Included studies;
Excluded studies; Ongoing studies).
In addition, we searched ClinicalTrials.gov and the WHO In-
ternational Clinical Trials Registry Platform ( ICTRP) (18 June
2018) for unpublished, planned, and ongoing trial reports using
the terms given in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
We used the following methods for assessing studies identified by
the search.
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies identified as a result of the search strategy. We
resolved disagreements through discussion or, where required, by
consulting a third review author.
We prepared a PRISMA study flow diagram to map out the num-
ber of records identified, included and excluded (Liberati 2009);
see Figure 1.
Data extraction and management
We designed purpose-built electronic forms to manage data ex-
traction. For eligible studies, two review authors extracted the data
using the agreed form(s), or sourced the required data directly
from trialists. We resolved discrepancies through discussion or,
where required, by referral to a third review author. We entered
the data into Review Manager 5 software (RevMan 2014) and
checked them for accuracy. When information about any of the
above was absent or unclear, we attempted to contact trialists to
provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risks of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Handbook) (Higgins 2011). We
resolved any disagreement by discussion or by involving a third
assessor.
We assessed the following domains.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random-
number table; computer random-number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
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(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively-numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to affect results. We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
We note ’Partial’ blinding, if identified.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes; in this review as ’objective’ and
’subjective’ outcomes (a subjective outcome being one that requires
some level of human judgement).
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information is reported, or could be supplied by
trialists, we included missing data in the analyses.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ’as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias. We assessed whether each
study was free of other problems that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it likely to impact on the findings. We explored the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
We found no cluster-randomised controlled trials for inclusion in
this review. If we identify cluster-randomised controlled trials in
future updates, we will assess risks of bias according to the criteria
given in the Handbook (Higgins 2011).
Assessment of the quality of the evidence using the
GRADE approach
We evaluated the quality of the evidence using the GRADE ap-
proach as outlined in the GRADE handbook. The GRADE ap-
proach uses five considerations (trial limitations (risk of bias); con-
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sistency of effect; imprecision; indirectness; and publication bias)
to assess the quality of the body of evidence for specific outcomes.
The evidence can be downgraded from ’high quality’ by one level
for serious (or by two levels for very serious) limitations. In this




• Adverse perinatal outcome (composite outcome including
stillbirth, neonatal death, and major neonatal morbidity such as
hypoxic-ischaemic encephalopathy; intracranial haemorrhage;
retinopathy of prematurity; necrotising enterocolitis).
• Adverse maternal psychological effects (anxiety, depression
or complicated grief ).
• Perinatal mortality.
• Any preterm birth (birth < 37 weeks).
• Maternal-infant attachment.
We conducted assessments of the quality of evidence for two com-
parisons: (1) low-molecular-weight heparin (LMWH) versus no
treatment/standard care (main comparison); and (2) low-dose as-
pirin (LDA) versus placebo. We selected the main comparison for
assessment based on its having the highest number of included
studies. We selected the second comparison based on its relevance
to modern clinical practice, given the already widespread use of as-
pirin for the prevention of placenta-mediated complications (Askie
2007; Bujold 2010; Roberge 2013; Roberge 2016), which has
been extended to the prevention of recurrent stillbirth (Fockler
2017).
We used GRADEpro Guideline Development Tool to import data
from Review Manager 5 (RevMan 2014) in order to create a ’Sum-
mary of findings’ table. We present a summary of the intervention
effect and a measure of quality according to the GRADE approach
in a ’Summary of findings’ table for each of the above outcomes.
Measures of treatment effect
Dichotomous data
For dichotomous data, we present results as summary risk ratio
with a 95% confidence interval.
Continuous data
For continuous data, we used the mean difference if outcomes are
measured in the same way between trials. We used the standardised
mean difference to combine trials that measure the same outcome,
but use different methods.
Unit of analysis issues
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion
in this review, but we may include trials of this type in future
updates. If cluster-randomised trials are included, we will carry out
analyses alongside individually-randomised trials. We will adjust
their sample sizes using the methods described in the Handbook
(Higgins 2011), using an estimate of the intracluster correlation
co-efficient (ICC) derived from the trial (if possible), from a similar
trial or from a study of a similar population. If we use ICCs from
other sources, we will report this and conduct sensitivity analyses
to investigate the effect of variation in the ICC. If we identify
both cluster-randomised trials and individually-randomised trials,
we plan to synthesise the relevant information. We will consider
it reasonable to combine the results from both if there is little
heterogeneity between the study designs and if the interaction
between the effect of intervention and the choice of randomisation
unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
We also plan to include multi-armed trials, ensuring analyses are
independent. If we include multi-armed trials, we will split the
’shared’ group into two or more groups with smaller sample size,
and include two or more (reasonably independent) comparisons.
Alternatively, we will combine groups to create a single pair-wise
comparison.
Cross-over trials
We exclude cross-over designs as these are unlikely to be a valid
study design for Pregnancy and Childbirth reviews.
Dealing with missing data
For included studies, we noted levels of attrition. We explored the
impact of including studies with high levels of missing data in the
overall assessment of treatment effect by using sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat (ITT) basis, i.e. we attempted to include all
participants randomised to each group in the analyses, regardless
of whether they received the allocated intervention. The denomi-
nator for each outcome in each trial was the number randomised
minus any participants whose outcomes are known to be missing.
For some of the outcomes in this review (e.g. caesarean section,
induction of labour, and various fetal and neonatal outcomes),
some participants were known to be ineligible for inclusion (e.g.
due to miscarriage or other pregnancy loss). To account for this, we
conducted analyses both using the as-randomised denominators
and, where provided by trialists, the revised denominators, i.e.
removing from the denominators any participants who could not
have contributed data. We performed sensitivity analyses to assess
the impact of the choice of denominators. Whether the data were
analysed using the as-randomised or revised denominators did not
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influence any of the overall results. We therefore present the data
using the revised denominators.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau2, I2 and Chi2 statistics. We regarded heterogeneity as
substantial if an I2 was greater than 30% and either the Tau2 was
greater than zero, or there was a low P value (less than 0.10) in the
Chi2 test for heterogeneity. Heterogeneity statistics are reported
where data were available for more than one trial in the meta-
analysis. Where there were no events or where events were reported
in only one trial within a meta-analysis (e.g. in only one trial was
there any reported pre-eclampsia), we state ’heterogeneity: not
applicable’.
Assessment of reporting biases
The meta-analyses in the current review included a maximum of
three trials. In future updates of this review, if there are 10 or
more trials in the meta-analysis, we will investigate reporting biases
(such as publication bias) using funnel plots. We will assess funnel
plot asymmetry visually. If asymmetry is suggested by a visual
assessment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using Review Manager 5 soft-
ware (RevMan 2014). We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect, i.e. where trials
were examining the same intervention, and we judged the trials’
populations and methods to be sufficiently similar.
In future updates of this review, if there is clinical heterogeneity
sufficient to expect that the underlying treatment effects differ be-
tween trials, or if we detect substantial statistical heterogeneity, we
will use random-effects meta-analysis to produce an overall sum-
mary, if we consider an average treatment effect across trials to be
clinically meaningful. We will treat the random-effects summary
as the average of the range of possible treatment effects, and we
will discuss the clinical implications of treatment effects differ-
ing between trials. If the average treatment effect is not clinically
meaningful, we will not combine trials.
If we use random-effects analyses, we will present the results as the
average treatment effect with a 95% confidence interval, and the
estimates of Tau2 and I2.
Subgroup analysis and investigation of heterogeneity
Had we identified substantial heterogeneity, we planned to in-
vestigate it using subgroup analyses and to consider whether an
overall summary was meaningful, and if so, to use random-effects
analysis to produce it.
We planned the following subgroup analyses for the review’s pri-
mary outcomes:
• cause(s) of previous stillbirth: known recurrent cause(s)
versus known non-recurrent cause(s) versus unexplained
stillbirth;
• setting: low- or middle-income country versus high-income
country;
• psychosocial support: included in intervention versus not
included (for interventions not primarily focused on
psychosocial support); and
• timing of start or duration of the intervention: pre-
pregnancy versus during pregnancy versus during delivery.
For this version of the review, we were unable to conduct the above
subgroup analyses due to lack of variation in these factors across
the comparison, unavailability of data, or due to there being no
reported events across the primary outcomes.
In future updates of this review, we will conduct the following
additional subgroup analyses:
• subsequent pregnancy order: immediate subsequent
pregnancy versus any subsequent pregnancy;
• target of intervention: mother versus partner.
We will explore subgroup differences by interaction tests available
within RevMan (RevMan 2014). We will report the results of
subgroup analyses quoting the Chi2 statistic and P value, and the
interaction test I2 value.
Sensitivity analysis
We did not conduct any planned sensitivity analyses in this review
due to the low number of included trials. In future updates of this
review we will carry out sensitivity analyses to explore the effects of
high attrition rates with trials showing attrition greater than 20%
excluded from the analyses, to assess whether this makes any dif-
ference to the overall result. We will also carry out sensitivity anal-
yses to explore the effect of bias (including for quasi-randomised
trials), assessed by random-sequence generation and concealment
of allocation, with trials assessed as high or unknown risk of bias
for these domains being excluded from the analyses. Where ICCs
are used, we will carry out sensitivity analyses to explore the effects
of variation in ICC values and in the randomisation unit (i.e. in-
dividual versus cluster). We will limit all sensitivity analyses to the
primary outcomes.
R E S U L T S
Description of studies
Results of the search
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The search of the Cochrane Pregnancy and Childbirth Trials Regis-
ter retrieved 272 reports, equating to 177 unique trials (as some tri-
als were published in multiple reports). A further 90 and 75 records
were retrieved from our searches of ClinicalTrials.gov and the
WHO International Clinical Trials Registry Platform ( ICTRP),
respectively. We removed duplicate records and clearly ineligible
trials at the screening stage. Where there was insufficient informa-
tion to assess eligibility as part of abstract screening, we progressed
the trials to full-text review. See: Figure 1.
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Figure 1. PRISMA study flow diagram. GA: gestational age; ICTRP: WHO International Clinical Trials
Registry Platform; PCG: Pregnancy and Childbirth Group
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We reviewed a total of 157 trials in full text. As reports on many
of the trials used terms such as previous ’pregnancy loss’, ’miscar-
riage’, ’abortion’, and ’fetal death’ without defining these by ges-
tational age, or as they included women with previous pregnancy
losses at various gestational ages, it was unclear whether these trials
would be eligible for inclusion. We progressed such trials to a sec-
ond phase of full-text review, whereby we contacted the associated
trialists for further information about the trial populations, and/
or to determine whether the data from parents who experienced
a previous stillbirth of 20 weeks’ gestation or more could be dis-
aggregated from those of the broader trial populations. We set a
deadline for responses from trialists and, if we did not receive a
response by this time, we excluded the trial. See: Figure 1.
We attempted to contact the primary trialist (or an identified col-
league or co-author of the primary trialist) at least twice before
excluding the trial on the basis on non-response. Given that the
potentially eligible trials were carried out from the year 1964 on-
wards, we took care to identify up-to-date contact details, where
such details were not readily available through the published re-
ports. We sought trialists’ current institution and email address
through Google searches or searches in PubMed, or both, for re-
cent publications from the same author, co-author, or colleague.
We ultimately included 10 trials in the review (Ahmed 2014;
Christiansen 1994; Christiansen 1995; Christiansen 2002; Gris
2004; Levine 1964; Martinelli 2012; Rey 2009; Salim 2016;
Schleussner 2015) and describe them in detail below (See Included
studies and Characteristics of included studies).
We identified a further seven ongoing trials. These trials were being
undertaken in Australia (McLindon 2011); Brazil (Alves 2014);
Canada (Rodger 2017); Egypt (El-refaie 2016); Netherlands (De
Jong 2015); and UK (Hezelgrave 2016 and Schreiber 2017). The
interventions assessed in these ongoing trials were:
• twice daily magnesium citrate capsule starting from 12 to
20 weeks’ gestation and continuing until birth, compared to
placebo (Alves 2014);
• daily 40 mg LMWH subcutaneous injection starting
immediately after randomisation upon confirmation of
pregnancy, compared to standard pregnancy surveillance (alone)
(De Jong 2015);
• daily 400 mg vaginal progesterone suppository compared to
cervical cerclage (El-refaie 2016);
• cervical cerclage compared to daily 200 mg vaginal
progesterone compared to cervical pessary (three-armed trial)
(Hezelgrave 2016);
• nightly 400 mg progesterone pessary from seven to 12
weeks’ gestation compared to placebo (McLindon 2011);
• daily 81 mg LDA from randomisation until birth compared
to LMWH and daily LDA (LMWH dosages at discretion of
attending physician) until 37 weeks’ gestation (Rodger 2017);
• oral hydroxychloroquine compared to placebo (Schreiber
2017).
The Rodger 2017 trial is a feasibility study, aiming to determine
the feasibility of a future multicentre trial of LDA prophylaxis for
recurrent pregnancy loss. For further details in all ongoing trials,
see Characteristics of ongoing studies.
Included studies
Design
Of the 10 included trials, nine were RCTs and one trial (Levine
1964) was a quasi-RCT using alternate allocation. One trial (
Ahmed 2014) adopted a three-arm design, comparing LDA to
combined LDA and LMWH, and placebo.
Sample sizes
Sample sizes for the individual trials ranged from 34 (Christiansen
1995) to 449 women (Schleussner 2015). After extraction of data
exclusively from women who had experienced a previous stillbirth
of 20 weeks’ gestation or more, sample sizes for the individual trials
ranged from four (Christiansen 1994) to 45 women (Rey 2009).
Setting
The trials were undertaken in hospitals and obstetric referral clinics
in Canada (Levine 1964; Rey 2009), Denmark (Christiansen
1994; Christiansen 1995; Christiansen 2002), France (Gris 2004),
Israel (Salim 2016), Italy (Martinelli 2012), and Pakistan (Ahmed
2014). One trial was undertaken across both Austria and Germany
(Schleussner 2015).
Dates of trials, funding and declarations of interest
The trials were carried out between the years 1964 and 2015. With
the exception of Levine 1964, all trials were carried out from 1994
onwards.
Funding sources were reported in seven trials (Christiansen 1994;
Christiansen 1995; Christiansen 2002; Gris 2004; Martinelli
2012; Rey 2009; Schleussner 2015). Sources of funding in-
cluded pharmaceutical companies (Martinelli 2012; Rey 2009;
Schleussner 2015), community charities (Christiansen 1994;
Christiansen 1995; Christiansen 2002), and research grants/insti-
tutional funding (Gris 2004). All trials that reported pharmaceu-
tical company funding stated that the funding body was not in-
volved the study’s design, analysis, interpretation, or reporting of
data. One trial (Levine 1964) did not report funding sources. Salim
2016 was supported by Emek Medical Centre and the Ahmed
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2014 trial reported that no funding was received (information ob-
tained upon correspondence with trialists).
For six trials (Ahmed 2014; Christiansen 1994; Christiansen 1995;
Christiansen 2002; Gris 2004; Levine 1964), the published re-
ports did not state whether the trialists had any declarations of in-
terest. With the exception of Levine 1964, these trialists confirmed
through correspondence that there were no declarations of inter-
est. Declarations of interest were included in the published reports
for two trials (Rey 2009; Schleussner 2015), including speakers’
honoraria, research grants, and personal fees from pharmaceutical
companies such as Pfizer (see Characteristics of included studies).
The authors of Salim 2016 declared no conflicts of interest and
the authors of Martinelli 2012 declared ’no competing financial
interests’.
Participants
All participants were women who were either pregnant or attempt-
ing to conceive following pregnancy loss, fetal death, or an ad-
verse outcome in a previous pregnancy. Most of the trials were
focused on recurrent idiopathic/unexplained pregnancy loss (in-
cluding ’miscarriage’ and ’abortion’). Recurrent pregnancy loss was
variably defined, in terms of the number of previous deaths, their
gestational age cut-off points, and whether the deaths were con-
secutive (see Characteristics of included studies).
Of the six trials (Ahmed 2014; Gris 2004; Martinelli 2012; Rey
2009; Salim 2016; Schleussner 2015) assessing LDA or LMWH
or both, Ahmed 2014 included women with two or more previous
consecutive, unexplained pregnancy losses prior to 24 weeks’ ges-
tation. Gris 2004 targeted women with a prior unexplained fetal
death and a constitutional thrombophilic disorder, and included
women with one single unexplained pregnancy loss of at least 10
weeks’ gestation. Martinelli 2012, Rey 2009, and Salim 2016 tar-
geted women with previous placenta-mediated complications in-
cluding pre-eclampsia, fetal growth restriction (FGR), low-birth-
weight, placental abruption, and fetal death (with varying defi-
nitions). Rey 2009 excluded women with current thrombophilic
disorders, whereas Gris 2004 included these women, provided that
such disorders were not associated with previous pregnancy losses.
Schleussner 2015 included women who had at least two consec-
utive pregnancy losses prior to 12 weeks’ gestation or one preg-
nancy loss at 12 weeks’ gestation or more. Salim 2016 included
women who had three losses prior to 13 weeks’ gestation, two
losses between 14 and 22 weeks’ gestation, or any pregnancy loss
after 23 weeks’ gestation. Gris 2004, Martinelli 2012, Rey 2009,
Salim 2016, and Schleussner 2015 excluded women for whom
previous pregnancy losses could be explained by specific mater-
nal conditions or clinical findings. Such factors varied between
the trials, but included infectious diseases, endocrinological and
immunological disorders, chromosomal abnormalities, and alco-
hol or illicit drug use. Women with an absolute need for heparin
were excluded from Martinelli 2012, Rey 2009, Salim 2016, and
Schleussner 2015. Rey 2009, Salim 2016, and Schleussner 2015
further excluded women with allergies or other contra-indications
to the given interventions. Exclusion criteria for Ahmed 2014 were
not stated.
Levine 1964 assessed progestogen and included women with three
consecutive unexplained pregnancy losses (from six weeks to full-
term of pregnancy) and no symptoms of threatened pregnancy
loss at the time of study enrolment.
Christiansen 1994, which assessed third-party leukocyte immuni-
sation, included women who had three consecutive unexplained
pregnancy losses and a maximum of one pregnancy loss after 14
weeks’ gestation. Women with antiphospholipid syndrome (APS),
including lupus anticoagulant and anticardiolipin antibodies, were
excluded.
Christiansen 1995 and Christiansen 2002 assessed intravenous
immunoglobulin G (IgG). Both trials included women who
had a history of recurrent unexplained miscarriages (with vary-
ing definitions) and no existing immunoglobulin A (IgA) defi-
ciency. Additional inclusion and exclusion criteria are detailed in
Characteristics of included studies.
Interventions and comparisons
Anticoagulant and antiplatelet agents
LDA was assessed in two trials (Ahmed 2014; Gris 2004). LDA
was administered orally at 75 mg (Ahmed 2014) and 100 mg (Gris
2004) daily. LMWH was assessed in six trials (Ahmed 2014; Gris
2004; Martinelli 2012; Rey 2009; Salim 2016; Schleussner 2015).
The LMWH agents administered included enoxaparin (Ahmed
2014; Gris 2004; Salim 2016), nadroparin (Martinelli 2012), and
dalteparin (Rey 2009; Schleussner 2015). All were self-adminis-
tered by subcutaneous injection. LMWH dosages ranged from
3800 IU to 6000 IU, depending on pre-pregnancy bodyweight
(with the exception of Salim 2016 - see below). Where stated,
injections were started in early pregnancy and ceased from 24
weeks’ gestation (Schleussner 2015) to 36 weeks’ gestation or birth
(whichever came first) (Ahmed 2014; Rey 2009; Salim 2016).
Gris 2004 compared LDA to LMWH, while Martinelli 2012; Rey
2009; and Schleussner 2015 compared LMWH to no treatment/
standard care. For Martinelli 2012, standard care included LDA
intake and medical surveillance through monthly visits. Women
in the control group in Schleussner 2015 received multivitamins
containing folic acid. Salim 2016 compared an adjusted dose of
LMWH according to anti-factor Xa levels (a measurement of
plasma LMWH), to a fixed dose of 40 mg LMWH a day. All
women in Salim 2016 who had anti-phospholipid antibodies were
also given LDA.
In the three-armed trial reported in Ahmed 2014, LDA and
LMWH were administered as described above. Women in the
placebo arm received intensive pregnancy surveillance alongside a
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matching schedule of placebo tablets. No such placebo injections
were described for the LMWH arm.
Third-party leukocyte immunisation
Christiansen 1994 assessed immunisations with 150 mL leuko-
cyte-enriched blood from erythrocyte-compatible third-party
blood donors. Immunisations were administered on an outpatient
basis and started pre-conception and continued until conception.
The control group received a matching schedule of placebo injec-
tions.
Intravenous IgG
Christiansen 1995 and Christiansen 2002 assessed the use of
Nordimmun, a human IgG preparation administered on an outpa-
tient basis. Doses varied according to pre-pregnancy bodyweight or
gestational age, or both. Infusions were started early in pregnancy
on a weekly-basis and progressed to a fortnightly basis from eight
weeks’ gestation in Christiansen 1995 and from 10 weeks’ gesta-
tion in Christiansen 2002. Infusions ceased at 26 weeks’ gestation
in Christiansen 2002 and at 34 weeks’ gestation in Christiansen
1995. In both trials, the control group received a matching sched-
ule of placebo injections.
Progestogen
Levine 1964 assessed progestogen (Delalutin). Women received a
weekly 500 mg injection from their first visit until the 36th week
of pregnancy or until termination of pregnancy/pregnancy loss.
The control group received a weekly placebo injection.
Outcomes
With the exception of Levine 1964, we obtained all data presented
in our meta-analyses through contacting trialists. We supplied each
trialist with a tailored data-request form seeking the required, pre-
specified outcome data, and any information on trial methods and
procedures that could not be gleaned from the published reports,
or that required clarification. Where they were measured, data for
most of the prespecified review outcomes were made available and
are included in the current analyses.
Data on stillbirths were available for all 10 trials. Data on neonatal
deaths were available for nine of the 10 trials, and data on adverse
perinatal outcomes were available for eight of the 10 trials. Data
on adverse maternal psychological effects were only available from
Martinelli 2012. Most trials measured important secondary out-
comes, including preterm birth, induction of labour, and serious
maternal outcome (death; cardiac arrest; respiratory arrest; admis-
sion to intensive care). No trials measured maternal-fetal attach-
ment, or longer-term outcomes of children, such as psychological
and behavioural problems, anxiety, depression, or neurodevelop-
mental problems. No trials measured economic costs of interven-
tions, nor quality of life for mothers, partners, or children.
Levine 1964 reported individual participant data (from which we
included only data from women who had a previous stillbirth of
20 weeks’ gestation or more). We were unable to retrieve further
information about the trial methodology or about outcomes that
were not reported in the study report. In addition, data from
this trial are reported descriptively only, due to ambiguity in the
data for two of the primary outcomes (stillbirth; adverse perinatal
outcome). Specifically, it was reported that one woman in the
control group had an abortion, but the gestational age at which
the death occurred was unclear (the death occurred after the 10th
weekly progestogen injection, but the time at which injections
began was not reported).
Excluded studies
We excluded 140 trials following full-text review, or after contact-
ing trialists for further information to determine eligibility. Trials
were most commonly excluded based on the women’s previous
pregnancy losses occurring at less than 20 weeks’ gestation (52
trials; 37%). Twenty-two trials (16%) recruited women who had
not experienced a previous pregnancy loss. Of the 90 trialists con-
tacted for further information to determine eligibility, 38 (42%)
did not respond. For 13 trials (14%), the trialists no longer had
access to the trial data and/or did not collect data on the gestational
age of women’s previous pregnancy losses. Ten trialists (11%) were
deceased or could not be traced, and five trialists (6%) declined to
provide data for this review. Reasons for declining to provide data
were: lack of funding/resources to carry out the required subgroup
analyses; trialist illness; concern over the validity of the review
methodology; having already provided data for other reviews; and
reasons unknown.
Risk of bias in included studies
We judged the risk of bias in the trials for methodology and re-
porting to be low to moderate. For a summary of the risks of bias
across the included trials, see Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
With the exception of Levine 1964, which used an alternate alloca-
tion procedure, all trials described an adequate process of random
sequence generation, using computer-generated programmes. We
therefore assessed Levine 1964 to be at high risk for both domains
of selection bias. Insufficient details were available to assess the
adequacy of allocation concealment for Gris 2004. The remaining
trials described adequate methods for allocation concealment, in-
cluding central allocation (Martinelli 2012; Schleussner 2015) and
sealed, opaque, consecutively-labelled envelopes (Ahmed 2014;
Christiansen 1995; Rey 2009).
Blinding
We rated Christiansen 1994, Christiansen 1995, Christiansen
2002, and Levine 1964, all placebo-controlled trials, at low risk
of performance and detection bias. The parallel trials assessing
LMWH therapies (Gris 2004; Martinelli 2012; Rey 2009; Salim
2016; Schleussner 2015) were all unblinded, and we therefore
judged them to be at high risk of performance bias. Adequacy
of blinding procedures for Ahmed 2014 was unclear. Specifically,
while women in the control arm of this trial received placebo
tablets matching those provided in the LDA arm, there did not
appear to be a schedule of placebo injections matching those pro-
vided in the combined LDA and LMWH arm. When consider-
ing objective outcomes only (e.g. stillbirth, neonatal death), we
assessed all trials to be at low risk of performance and detection
bias.
Incomplete outcome data
We considered seven of the 10 trials (Christiansen 1994;
Christiansen 1995; Christiansen 2002; Martinelli 2012; Rey
2009; Salim 2016; Schleussner 2015) to be at low risk of attrition
bias. Risk of attrition bias in Ahmed 2014 and Gris 2004 was
unclear. Loss of follow-up and reasons for loss of follow-up were
reported in both trials, but the groups to which participants had
been allocated was unclear. We rated Levine 1964 at high risk of
attrition bias, due to the high proportion of women (46%) who
were excluded post-randomisation.
Selective reporting
With the exception of Schleussner 2015, we judged the risk of
reporting bias in all trials to be unclear. No trial protocols were
available for Ahmed 2014, Christiansen 1994, Christiansen 1995,
Christiansen 2002, Gris 2004, or Levine 1964, while we noted
only retrospective trial registration for Rey 2009 and Salim 2016.
We judged Martinelli 2012 to have unclear risk of reporting bias,
due to conflicting information about the primary outcome re-
ported in the published report compared to that given in con-
ference reports. Limited details were available in the trial proto-
col for clarification, and one outcome (changes in platelet count
(PLT) or aspartate aminotransferase (AST)/alanine aminotrans-
ferase (ALT)) appeared to be missing from the published report.
All outcomes were reported as prespecified in the trial protocol
for Schleussner 2015, which we considered to be at low risk of
reporting bias.
Other potential sources of bias
We did not identify other sources of bias for seven of the 10 trials
(Christiansen 1994; Christiansen 1995; Christiansen 2002; Gris
2004; Martinelli 2012; Salim 2016; Schleussner 2015). Risk of
other bias was unclear in Rey 2009, where there appeared to be
some baseline imbalance for LDA use and ethnicity. This trial was
stopped early following slow recruitment and favourable interim
analyses. The trialists noted “We are aware that stopping the study
may have led to exaggerated effect sizes” (study report p. 63). The
Martinelli 2012 trial was stopped early due to futility and safety
concerns, following review by the trial Data and Safety Monitor-
ing Board. However, in accordance with the Handbook (Higgins
2011), we considered the influence of early trial cessation as part
of our GRADE assessments of the quality of evidence, and not as
part of our ’Risk of bias’ assessments.
Ahmed 2014 and Levine 1964 provided insufficient methodolog-
ical detail to allow us to determine other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison; Summary
of findings 2
We undertook analyses as follows.
• Comparison 1: LMWH versus no treatment/standard care
(Martinelli 2012; Rey 2009; Schleussner 2015).
• Comparison 2: LDA versus placebo (Ahmed 2014).
• Comparison 3: LDA + LMWH versus LDA alone (Ahmed
2014).
• Comparison 4: LDA + LMWH versus placebo (Ahmed
2014).
• Comparison 5: LMWH versus LDA (Gris 2004).
• Comparison 6: LMWH (dose adjusted according to anti-
factor Xa levels) versus LMWH (fixed dose) (Salim 2016).
• Comparison 7: Third-party leukocyte immunisation versus
placebo (Christiansen 1994).
• Comparison 8: Intravenous IgG versus placebo
(Christiansen 1995; Christiansen 2002).
• Comparison 9: Progestogen versus placebo (Levine 1964).
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We conducted assessment of the quality of evidence for compar-
isons 1 and 2, and judged them to be very low to low, in accor-
dance with the GRADE approach (see Summary of findings for
the main comparison and Summary of findings 2). All but one of
the comparisons (comparison 1) were based on data from only one
or two trials, all with extremely small sample sizes. Very serious
imprecision in the data was evident for all comparisons, including
comparison 1. It was therefore largely uncertain whether there was
any benefit or harm across the interventions assessed in this review
(regardless of GRADE assessments).
Comparison 1: LMWH versus no treatment/standard
care
Three trials contributed to the comparison of LMWH versus no
treatment/standard care (Martinelli 2012; Rey 2009; Schleussner
2015).
A total of 123 women and their infants were included, depending
on the outcome. The numbers of trials and participants by out-
come are provided below.
Primary outcomes
Due largely to the imprecision in the data available, it was uncer-
tain whether LMWH reduced the risk of stillbirth (risk ratio (RR)
2.58, 95% confidence interval (CI) 0.40 to 16.62; 3 trials; 122
participants; Analysis 1.1; low-quality evidence), adverse perinatal
outcome (RR 0.81, 95% CI 0.20 to 3.32; 2 trials; 77 participants;
Analysis 1.3; low-quality evidence), or adverse maternal psycho-
logical effects (RR 1.00, 95% CI 0.07 to 14.90; 1 trial; 40 partic-
ipants; Analysis 1.4; very low-quality evidence), when compared
to no treatment/standard care. No neonatal deaths were reported.
Secondary outcomes
The effect of LMWH on the risk of perinatal mortality (RR 2.58,
95% CI 0.40 to 16.62; 3 trials; 122 participants; Analysis 1.5;
low-quality evidence) and any preterm birth < 37 weeks (RR 1.01,
0.58 to 1.74; 3 trials; 114 participants; Analysis 1.8; low-quality
evidence) was also uncertain.
There was no clear evidence of a difference between the groups
on the remaining secondary outcomes: very preterm birth (28 to
< 32 weeks) (RR 0.94, 95% CI 0.31 to 2.82; 3 trials; 114 partic-
ipants; Analysis 1.6); late preterm birth (32 to < 37 weeks) (RR
0.78, 95% CI 0.36 to 1.66; 3 trials; 114 participants; Analysis
1.7); birthweight (mean difference (MD) −225.26 g, 95% CI
−546.36 to 95.84 g; 3 trials; 109 participants; Analysis 1.9); low
birthweight (RR 1.00, 95% CI 0.45 to 2.21; 2 trials; 85 partic-
ipants; Analysis 1.10); small-for-gestational age (RR 1.32, 95%
CI 0.57 to 3.08; 3 trials; 115 participants; Analysis 1.11); Apgar
score less than seven at five minutes (RR 3.33, 95% CI 0.58 to
19.29; 2 trials; 69 participants; Analysis 1.12); adherence to the
intervention (RR 1.03, 95% CI 0.88 to 1.22; 2 trials; 85 partici-
pants; Analysis 1.15); caesarean birth (elective) (RR 2.05, 95% CI
0.83 to 5.07; 3 trials; 115 participants; Analysis 1.16); caesarean
birth (emergency) (RR 0.88, 95% CI 0.39 to 1.99; 3 trials; 115
participants; Analysis 1.17); induction of labour (RR 0.64, 95%
CI 0.33 to 1.22; 2 trials; 85 participants; Analysis 1.18); Instru-
mental vaginal birth (RR 3.00, 95% CI 0.13 to 69.52; 1 trial; 40
participants; Analysis 1.19); placental abruption (RR 0.32, 95%
CI 0.04 to 2.91; 3 trials; 115 participants; Analysis 1.20); pre-
eclampsia (RR 0.40, 95% CI 0.04 to 4.10; 3 trials; 115 partici-
pants; Analysis 1.21); gestational diabetes (RR 1.28, 95% CI 0.50
to 3.25; 2 trials; 85 participants; Analysis 1.22); chorioamnionitis
(RR 1.60, 95% CI 0.33 to 7.86; 2 trials; 85 participants; Analysis
1.23); postpartum haemorrhage (RR 1.59, 95% CI 0.27 to 9.45;
2 trials; 70 participants; Analysis 1.24); serious maternal outcome
(RR 0.27, 95% CI 0.01 to 6.27; 3 trials; 123 participants; Analysis
1.25); maternal antenatal admission (RR 0.60, 95% CI 0.15 to
2.38; 1 trial; 45 participants; Analysis 1.26); duration of maternal
hospital stay (MD −0.02 days, 95% CI −2.01 to 1.97 days; 1
trial; 45 participants; Analysis 1.27); duration of neonatal hospital
stay (MD 1.70 days, 95% CI −8.70 to 12.10 days; 1 trial; 45
participants; Analysis 1.28); admission to the neonatal intensive
care unit (RR 0.80, 95% CI 0.27 to 2.38; 1 trial; 45 participants;
Analysis 1.29); or duration of neonatal intensive care unit stay
(MD 4.20 days, 95% CI −25.13 to 33.53 days; 1 trial; 10 partic-
ipants; Analysis 1.30).
There were no reported instances of respiratory distress syndrome
(1 trial; 40 participants) or neonatal jaundice (1 trial; 40 partici-
pants).
Heterogeneity
Adverse perinatal outcome: We chose to use a fixed-effect model
for this analysis. In our Methods, we stated that we would use a
random-effects model if heterogeneity was evident. We specified
that we would regard heterogeneity to be present if the I2 was
greater than 30% and either the Tau2 was greater than zero, or there
was a low P value (less than 0.10) in the Chi2 test for heterogeneity.
However, in this analysis (Analysis 1.3), although the I2 value was
just above 30%, (31%), there were no differences in the results
between a fixed- or a random-effects model. The P value was also
high (P = 0.23). We therefore retained a fixed-effect model.
Any preterm birth < 37 weeks: We chose to use a fixed-effect
model for this analysis. In our Methods, we stated that we would
use a random-effects model if heterogeneity was evident. We spec-
ified that we would regard heterogeneity to be present if the I2
was greater than 30% and either the Tau2 was greater than zero,
or there was a low P value (less than 0.10) in the Chi2 test for
heterogeneity. However, in this analysis (Analysis 1.8), although
the I2 value was just above 30%, (35%), there were no differences
in the results between a fixed- or a random-effects model. The P
value was also high (P = 0.21). We therefore retained a fixed-effect
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model.
Comparison 2: LDA versus placebo
One trial (Ahmed 2014) contributed to the comparison of LDA
versus placebo. The trial also assessed combined LDA and LMWH
as part of a three-armed design, including a total of 40 women. We
included all arms of the trial as separate, independent comparisons
(comparisons 2, 3, and 4). The comparison of LDA versus placebo
included 24 women and 24 infants.
In all outcomes presented below, there was one trial and 24 par-
ticipants, unless otherwise stated.
Primary outcomes
It was uncertain whether LDA reduced the risk of stillbirth (RR
0.85, 95% CI 0.06 to 12.01; Analysis 2.1), neonatal death (RR
0.29, 95% CI 0.01 to 6.38; Analysis 2.2), or adverse perinatal
outcome (RR 0.28, 95% CI 0.03 to 2.34; Analysis 2.3) (all very
low-quality evidence), when compared to placebo. No data were
available for adverse maternal psychological effects.
Secondary outcomes
LDA appeared to be associated with an increase in birthweight
when compared to placebo (MD 790.00 g, 95% CI 295.03 to
1284.97 g; Analysis 2.8). Whether LDA had any effect on the
following secondary outcomes was uncertain: perinatal mortality
(RR 0.42, 95% CI 0.04 to 4.06; Analysis 2.4) and any preterm
birth < 37 weeks (RR 0.42, 95% CI 0.04 to 4.06; Analysis 2.7),
both very low-quality evidence; very preterm birth (28 to < 32
weeks) (RR 0.29, 95% CI 0.01 to 6.38; Analysis 2.5); late preterm
birth (32 to < 37 weeks) (RR 0.85, 95% CI 0.06 to 12.01; Analysis
2.6); low birthweight (RR 0.28, 95% CI 0.03 to 2.34; Analysis
2.9); small-for-gestational age (RR 0.29, 95% CI 0.01 to 6.38;
Analysis 2.10); respiratory distress syndrome (RR 0.29, 95% CI
0.01 to 6.38; Analysis 2.11); adherence to the intervention (RR
1.00, 95% CI 0.86 to 1.17; Analysis 2.12); caesarean birth (elec-
tive) (RR 0.63, 95% CI 0.18 to 2.24; Analysis 2.13); caesarean
birth (emergency) (RR 1.69, 95% CI 0.38 to 7.55; Analysis 2.14);
induction of labour (RR 1.69, 95% CI 0.38 to 7.55; Analysis
2.15); instrumental vaginal birth (RR 2.57, 95% CI 0.12 to 57.44;
Analysis 2.16); placental abruption (RR 2.57, 95% CI 0.12 to
57.44; Analysis 2.17); pre-eclampsia (RR 0.85, 95% CI 0.14 to
5.06; Analysis 2.18); gestational diabetes (RR 0.42, 95% CI 0.04
to 4.06; Analysis 2.19); postpartum haemorrhage (RR 0.29, 95%
CI 0.01 to 6.38; Analysis 2.20); antenatal care attendance (RR
1.00, 95% CI 0.86 to 1.17; Analysis 2.22); duration of mater-
nal hospital stay (MD 0.00 days, 95% CI −2.41 to 2.41 days;
Analysis 2.23); duration of neonatal hospital stay (MD −2.00
days, 95% CI −4.41 to 0.41 days; Analysis 2.24); admission to
the neonatal intensive care unit (RR 1.48, 95% CI 0.58 to 3.75;
Analysis 2.25); and duration of neonatal intensive care unit stay
(MD −2.00 days, 95% CI −5.29 to 1.29 days; 1 trial; 11 partic-
ipants; Analysis 2.26).
There were no reported instances of serious maternal outcome.
Comparison 3: LDA + LMWH versus LDA alone
Arm two of the Ahmed 2014 trial assessed LDA + LMWH versus
LDA alone among 29 women and 29 infants.
In all outcomes presented below, there was one trial and 29 par-
ticipants, unless otherwise stated.
Primary outcome
It was uncertain whether LDA + LMWH reduced the risk of still-
birth (RR 0.27, 95% CI 0.01 to 6.23; Analysis 3.1) or adverse
perinatal outcome (RR 2.44, 95% CI 0.29 to 20.75; Analysis 3.3),
when compared to LDA alone. No neonatal deaths were reported
and no data were available for adverse maternal psychological ef-
fects.
Secondary outcomes
LDA appeared to be associated with an increase in birthweight
when compared to LDA + LMWH (MD −650.00 g, 95% CI
−1210.33 to −89.67 g; Analysis 3.8). Whether there were any
differences between the groups on the following secondary out-
comes was uncertain: perinatal mortality (RR 0.27, 95% CI 0.01
to 6.23; Analysis 3.4); very preterm birth (28 to < 32 weeks) (RR
2.47, 95% CI 0.11 to 56.03; Analysis 3.5); late preterm birth
(32 to < 37 weeks) (RR 0.81, 95% CI 0.06 to 11.77; Analysis
3.6); any preterm birth (< 27 weeks) (RR 3.25, 95% CI 0.41 to
25.64; Analysis 3.7); low birthweight (RR 1.63, 95% CI 0.17 to
15.99; Analysis 3.9); small-for-gestational age (RR 2.47, 95% CI
0.11 to 56.03; Analysis 3.10); respiratory distress syndrome (RR
2.47, 95% CI 0.11 to 56.03; Analysis 3.11); adherence to the in-
tervention (RR 1.00, 95% CI 0.88 to 1.14; Analysis 3.12); cae-
sarean birth (elective) (RR 1.35, 95% CI 0.40 to 4.63; Analysis
3.13); caesarean birth (emergency) (RR 0.20, 95% CI 0.03 to
1.60; Analysis 3.14); induction of labour (RR 0.61, 95% CI 0.17
to 2.25; Analysis 3.15); instrumental vaginal birth (RR 0.81, 95%
CI 0.06 to 11.77; Analysis 3.16); placental abruption (RR 0.81,
95% CI 0.06 to 11.77; Analysis 3.17); pre-eclampsia (RR 0.41,
95% CI 0.04 to 4.00; Analysis 3.18); gestational diabetes (RR
0.27, 95% CI 0.01 to 6.23; Analysis 3.19); postpartum haem-
orrhage (RR 2.47, 95% CI 0.11 to 56.03; Analysis 3.20); ante-
natal care attendance (RR 1.00, 95% CI 0.88 to 1.14; Analysis
3.22); duration of maternal hospital stay (MD 0.00 days, 95% CI
−2.55 to 2.55 days; Analysis 3.23); duration of neonatal hospital
stay (MD 2.00 days, 95% CI −0.55 to 4.55 days; Analysis 3.24);
admission to the neonatal intensive care unit (RR 1.16, 95% CI
0.62 to 2.18; Analysis 3.25); and duration of neonatal intensive
care unit stay (MD 2.00 days, 95% CI −0.38 to 4.38 days; 1 trial;
17 participants; Analysis 3.26).
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There were no reported instances of serious maternal outcome.
Comparison 4: LDA + LMWH versus placebo
Arm three of the Ahmed 2014 trial assessed LDA + LMWH versus
placebo among 27 women and 27 infants.
In all outcomes presented below, there was one trial and 27 par-
ticipants, unless otherwise stated.
Primary outcomes
It was uncertain whether LDA + LMWH reduced the risk of
stillbirth or neonatal death (both RR 0.24, 95% CI 0.01 to 5.30;
Analysis 4.1 and Analysis 4.2), or adverse perinatal outcome (RR
0.69, 95% CI 0.17 to 2.80; Analysis 4.3), when compared to
placebo. No data were available for adverse maternal psychological
effects.
Secondary outcomes
Whether LDA + LMWH had any effect on the following sec-
ondary outcomes was also uncertain: perinatal mortality (RR 0.14,
95% CI 0.01 to 2.68; Analysis 4.4); very preterm birth (28 to
< 32 weeks) and late preterm birth (32 to < 37 weeks) (both
RR 0.69, 95% CI 0.05 to 9.86; Analysis 4.5 and Analysis 4.6);
any preterm birth (< 37 weeks) (RR 1.38, 95% CI 0.30 to 6.25;
Analysis 4.7); birthweight (MD 140.00 g, 95% CI −501.26 to
781.26 g; Analysis 4.8); low birthweight (RR 0.46, 95% CI 0.09
to 2.31; Analysis 4.9); small-for-gestational age and respiratory
distress syndrome (both RR 0.69, 95% CI 0.05 to 9.86; Analysis
4.10 and Analysis 4.11); adherence to the intervention (RR 1.00,
95% CI 0.87 to 1.16; Analysis 4.12); caesarean birth (elective)
(RR 0.86, 95% CI 0.30 to 2.50; Analysis 4.13); caesarean birth
(emergency) (RR 0.34, 95% CI 0.04 to 3.34; Analysis 4.14);
induction of labour (RR 1.03, 95% CI 0.20 to 5.19; Analysis
4.15); instrumental vaginal birth (RR 2.12, 95% CI 0.09 to 47.68;
Analysis 4.16); placental abruption (RR 2.12, 95% CI 0.09 to
47.68; Analysis 4.17); pre-eclampsia (RR 0.34, 95% CI 0.04 to
3.34; Analysis 4.18); gestational diabetes (RR 0.14, 95% CI 0.01
to 2.68; Analysis 4.19); postpartum haemorrhage (RR 0.69, 95%
CI 0.05 to 9.86; Analysis 4.20); antenatal care attendance (RR
1.00, 95% CI 0.87 to 1.16; Analysis 4.22); duration of maternal
hospital stay (MD 0.00 days, 95% CI −2.64 to 2.64 days; Analysis
4.23); duration of neonatal hospital stay (MD 0.00 days, 95%
CI −2.64 to 2.64 days; Analysis 4.24); admission to the neona-
tal intensive care unit (RR 1.72, 95% CI 0.72 to 4.10; Analysis
4.25); and duration of neonatal intensive care unit stay (MD 0.00
days, 95% CI −3.48 to 3.48 days; 1 trial; 14 participants; Analysis
4.26).
There were no reported instances of serious maternal outcome.
Comparison 5: LMWH versus LDA
One trial (Gris 2004), including 22 women and 22 infants, con-
tributed to the comparison of LMWH versus LDA.
In all outcomes presented below, there was one trial and 22 par-
ticipants, unless otherwise stated.
Primary outcomes
It was uncertain whether LMWH reduced the risk of stillbirth
or adverse perinatal outcome (both RR 3.55, 95% CI 0.16 to
78.56; Analysis 5.1 and Analysis 5.3), when compared to LDA.
No neonatal deaths occurred. No data were available for adverse
maternal psychological effects.
Secondary outcomes
Whether there were any differences between the groups on the
following secondary outcomes was also uncertain: perinatal mor-
tality (RR 3.55, 95% CI 0.16 to 78.56; Analysis 5.4); late preterm
birth (32 to < 27 weeks) (RR 1.20, 95% CI 0.09 to 16.84; Analysis
5.6); any preterm birth (< 37 weeks) (RR 0.60, 95% CI 0.06 to
5.69; Analysis 5.7); birthweight (MD 75.00 g, 95% CI -151.69 to
301.69 g; Analysis 5.8); low birthweight (RR 0.60, 95% CI 0.06
to 5.69; Analysis 5.9); small-for-gestational age (RR 0.60, 95%
CI 0.06 to 5.69; Analysis 5.10); Apgar score less than seven at five
minutes (RR 0.80, 95% CI 0.16 to 3.88; Analysis 5.11); respira-
tory distress syndrome (RR 1.20, 95% CI 0.09 to 16.84; Analysis
5.12); neonatal jaundice (RR 0.90, 95% CI 0.47 to 1.72; Analysis
5.13); caesarean birth (elective) (RR 1.20, 95% CI 0.20 to 7.05;
Analysis 5.14); caesarean birth (emergency) (RR 0.60, 95% CI
0.06 to 5.69; Analysis 5.15); induction of labour (RR 8.27, 95%
CI 0.48 to 143.35; Analysis 5.16); pre-eclampsia (RR 0.60, 95%
CI 0.06 to 5.69; Analysis 5.19); breastfeeding (RR 0.96, 95% CI
0.35 to 2.64; Analysis 5.23); maternal antenatal admission (RR
0.60, 95% CI 0.06 to 5.69; Analysis 5.24); duration of maternal
hospital stay (MD 0.00 days, 95% CI −0.19 to 0.19 days; Analysis
5.25); duration of neonatal hospital stay (MD 0.00 days, 95% CI
−0.30 to 0.30 days; Analysis 5.26); admission to the neonatal in-
tensive care unit (RR 1.20, 95% CI 0.09 to 16.84; Analysis 5.27);
and duration of neonatal intensive care unit stay (MD 0.22 days,
95% CI −8.52 to 8.96 days; 1 trial; 2 participants; Analysis 5.28).
There were no reported instances of very preterm birth; instrumen-
tal vaginal birth; placental abruption; gestational diabetes; post-
partum haemorrhage; or serious maternal outcome.
Comparison 6: LMWH (dose adjusted according to
anti-factor Xa levels) versus LMWH (fixed dose)
One trial (Salim 2016) assessed LMWH with doses adjusted ac-
cording to anti-factor Xa levels against a fixed dose of LMWH.
Data from 13 women and 13 infants are included.
In all outcomes presented below, there was one trial and 13 par-
ticipants.
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Primary outcomes
There were no reported stillbirths. No data were available for
neonatal deaths, adverse perinatal outcome, or adverse maternal
psychological effects.
Secondary outcomes
It was uncertain whether an adjusted dose of LMWH compared
to a fixed dose had any effect on very preterm birth (28 to < 32
weeks) (RR 0.58, 95% CI 0.07 to 4.95; Analysis 6.2); late preterm
birth (32 to < 37 weeks) (RR 0.23, 95% CI 0.01 to 4.00; Analysis
6.3); any preterm birth (< 37 weeks) (RR 0.29, 95% CI 0.04 to
1.95; Analysis 6.4); birthweight (MD 812.00 g, 95% CI −257.81
to 1881.81 g; Analysis 6.5); low birthweight (RR 0.39, 95% CI
0.05 to 2.83; Analysis 6.6); small-for-gestational age (RR 1.17,
95% CI 0.09 to 14.92; Analysis 6.7); adherence to the interven-
tion (RR 1.00, 95% CI 0.76 to 1.31; Analysis 6.9); caesarean
birth (elective) (RR 1.17, 95% CI 0.09 to 14.92; Analysis 6.10);
caesarean birth (emergency) (RR 0.58, 95% CI 0.07 to 4.95;
Analysis 6.11); induction of labour (RR 0.70, 95% CI 0.28 to
1.77; Analysis 6.12); placental abruption (RR 0.38, 95% CI 0.02
to 7.93; Analysis 6.14); pre-eclampsia (RR 0.38, 95% CI 0.02 to
7.93; Analysis 6.15); gestational diabetes (RR 0.38, 95% CI 0.02
to 7.93; Analysis 6.16); postpartum haemorrhage (RR 0.16, 95%
CI 0.01 to 2.64; Analysis 6.18); and admission to neonatal inten-
sive care unit (RR 0.58, 95% CI 0.07 to 4.95; Analysis 6.20).
There were no reported instances of Apgar score less than seven
at five minutes; instrumental vaginal birth; chorioamnionitis; or
serious maternal outcome.
Comparison 7: Leukocyte immunisation versus
placebo
One trial (Christiansen 1994) assessed third-party leukocyte im-
munisation against placebo. Data from four women and four in-
fants are included.
In all outcomes presented below, there was one trial and four
participants.
Primary outcomes
There were no instances of stillbirth, neonatal death, or adverse
perinatal outcome. No data were available for adverse maternal
psychological effects.
Secondary outcomes
Leukocyte immunisation appeared to be associated with an in-
crease in infant birthweight among the two women who received
this intervention when compared to placebo (MD 1195.00 g, 95%
CI 273.35 to 2116.65 g; Analysis 7.8). Whether leukocyte immu-
nisation had any effect on the following secondary outcomes was
uncertain: late preterm birth (32 to < 37 weeks) (RR 0.33, 95%
CI 0.02 to 5.33; Analysis 7.6); any preterm birth (< 37 weeks) (RR
0.33, 95% CI 0.02 to 5.33; Analysis 7.7); low birthweight (RR
0.33, 95% CI 0.02 to 5.33; Analysis 7.9); adherence to the inter-
vention (RR 1.00, 95% CI 0.49 to 2.05; Analysis 7.12); and cae-
sarean birth (emergency) (RR 0.33, 95% CI 0.02 to 5.33; Analysis
7.14).
There were no reported instances of perinatal mortality; very
preterm birth; small-for-gestational age; Apgar score less than
seven at five minutes; caesarean birth (elective); induction of
labour; instrumental vaginal birth; placental abruption; pre-
eclampsia; gestational diabetes; chorioamnionitis; or serious ma-
ternal outcome.
Comparison 8: Intravenous IgG versus placebo
Two trials (Christiansen 1995; Christiansen 2002) assessed intra-
venous IgG against placebo.
A total of 13 women and their infants were included, depending
on the outcome. The numbers of trials and participants for each
outcome are provided below.
Primary outcomes
It was uncertain whether intravenous IgG reduced the risk of still-
birth (RR 0.74, 95% CI 0.16 to 3.40; 2 trials; 7 participants;
Analysis 8.1) or adverse perinatal outcome (RR 0.74, 95% CI 0.16
to 3.40; 2 trials; 7 participants; Analysis 8.3). No neonatal deaths
were reported and no data were available for adverse maternal psy-
chological effects.
Secondary outcomes
Both trials reported individual birthweights among the neonates
assessed. For Christiansen 1995, birthweight data were available
for one liveborn neonate in the intervention group (2390 g) and
two liveborn neonates in the placebo group (2650 and 2530 g).
For Christiansen 2002, one liveborn infant in the intervention
group weighed 2950 g.
Whether intravenous IgG had any effect on the following sec-
ondary outcomes was uncertain: perinatal mortality (RR 0.74,
95% CI 0.16 to 3.40; 2 trials; 7 participants; Analysis 8.4); late
preterm birth (32 to < 37 weeks) (RR 0.44, 95% CI 0.03 to 7.52; 2
trials; 7 participants; Analysis 8.6); any preterm birth (< 37 weeks)
(RR 0.44, 95% CI 0.03 to 7.52; 2 trials; 7 participants; Analysis
8.7); low birthweight (RR 4.00, 95% CI 0.24 to 67.71; 2 trials;
7 participants; Analysis 8.8); adherence to the intervention (RR
1.00, 95% CI 0.69 to 1.44; 2 trials; 13 participants; Analysis 8.13);
caesarean birth (elective) (RR 1.50, 95% CI 0.18 to 12.46; 2 trials;
7 participants; Analysis 8.14); induction of labour (RR 3.00, 95%
CI 0.24 to 37.67; 2 trials; 7 participants; Analysis 8.16); and in-
strumental vaginal birth (RR 1.16, 95% CI 0.21 to 6.35; 2 trials;
7 participants; Analysis 8.17).
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There were no reported instances of very preterm birth (2 trials; 7
participants); small-for-gestational age (1 trial; 2 participants); Ap-
gar score less than seven at five minutes (2 trials; 7 participants); res-
piratory distress syndrome (1 trial; 2 participants); neonatal jaun-
dice (1 trial; 2 participants); caesarean birth (emergency) (2 trials;
7 participants); placental abruption (2 trials; 7 participants); pre-
eclampsia (2 trials; 7 participants); gestational diabetes (2 trials; 7
participants); chorioamnionitis (2 trials; 7 participants); postpar-
tum haemorrhage (1 trial; 2 participants); serious maternal out-
come (2 trials; 7 participants); admission to the neonatal intensive
care unit (1 trial; 2 participants).
Comparison 9: Progestogen versus placebo
One trial (Levine 1964) assessed progestogen against placebo. We
include data from a total of seven women and five infants in this
review. We report the data descriptively only, due to ambiguity in
the data for two of the primary outcomes (see above).
Primary outcomes
There were no stillbirths, neonatal deaths, or adverse perinatal out-
comes in the intervention group among the four women included.
Three women were assessed in the control group, of which one
woman miscarried. Another woman experienced an ’abortion’ but
the gestational age at which the death occurred was unclear. It is
possible that this death was a stillbirth according to our definition.
Adverse maternal psychological effects were not reported.
Secondary outcomes
Two women in the intervention group and one woman in the
control group experienced a late preterm birth (32 to < 37 weeks).
There were no reported instances of very preterm birth (28 to
< 32 weeks). Birthweights were reported for all four infants in
the intervention group. Birthweights were provided in pounds
and ounces, which we converted to kilograms before calculating
a mean figure, equalling 1978 g. Birthweight was available for
one infant in the control group, reported as 4 lb 11 oz (2126 g).
Data pertaining to low birthweight was not provided in the study
report. Applying the WHO definition (< 2500 g), all infants in
the trial were of low birthweight.
There appeared to be 100% adherence to the intervention, ac-
cording to the study report: “The injections were discontinued
only when patients proved not to be pregnant or failed to return
regularly for their weekly administration” (study report p. 31). As
reported, “No untoward reactions were encountered” (study re-
port p. 31).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Low-dose aspirin compared to placebo for improving outcomes in subsequent pregnancies following stillbirth
Patient or population: women with a previous st illbirth of > 20 weeks’ gestat ion who are pregnant or considering a subsequent pregnancy
Setting: tert iary referral obstetric hospital, Pakistan
Intervention: low-dose aspirin
Comparison: placebo








Risk with placebo Risk with low-dose as-
pirin







91 per 1000 77 per 1000
(5 to 1000)






















273 per 1000 76 per 1000
(8 to 638)
Adverse maternal psy-
chological ef fects (anx-
iety, depression or com-
plicated grief ) - not
measured
- - - - - Outcome was not mea-


























































































































182 per 1000 76 per 1000
(7 to 738)
Any preterm birth (birth
< 37 weeks)







182 per 1000 76 per 1000
(7 to 738)
Maternal-infant attach-
ment - not measured
- - - - - Outcome was not mea-
sured in this trial
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High certainty: this research provides a very good indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erentd is low
Moderate certainty: this research provides a good indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erentd is moderate.
Low certainty: this research provides some indicat ion of the likely ef fect. However, the likelihood that it will be substant ially dif f erentd is high.
Very low certainty: this research does not provide a reliable indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erentd is very high.
a (-1) Downgraded for ’serious’ trial lim itat ions: unclear attrit ion bias and select ive report ing. Details on blinding of part icipants
and personnel unclear for the enoxaparin arm (three-armed trial - not downgraded for this as possible lack of blinding for
enoxaparin does not af fect the current comparison; outcome is object ive).
bOnly one trial included, so inconsistency cannot be assessed.
c(-2) Downgraded for ’very serious’ imprecision: single, small t rial with wide CIs crossing the line of no ef fect, and few events.



















































































































D I S C U S S I O N
Summary of main results
This review set out to assess the effects of different interventions
or models of care prior to and during subsequent pregnancies fol-
lowing stillbirth on maternal, fetal, neonatal and family health
outcomes, and health service utilisation. We included 10 trials at
low to moderate risk of bias, assessing low-dose aspirin (LDA) or
low-molecular-weight heparin (LMWH), or both (Ahmed 2014;
Gris 2004; Martinelli 2012; Rey 2009; Salim 2016; Schleussner
2015); third-party leukocyte immunisation (Christiansen 1994);
intravenous IgG (Christiansen 1995; Christiansen 2002); and
progestogen (Levine 1964). The review includes data from 222
women and their infants. We assessed the trials under nine com-
parisons. All but one of the comparisons were based on data from
only one or two trials, all with extremely small sample sizes. As
a result, the analyses were not sufficiently powered to detect dif-
ferences in most of the outcomes assessed. Based on the GRADE
approach, the quality of the evidence assessed in this review was
very low to low.
Among the primary outcomes, it was uncertain whether the inter-
ventions assessed had any effect on stillbirth, neonatal death, or ad-
verse perinatal outcome. There appeared to be a minor trend across
these outcomes in favour of LDA when compared to placebo, al-
though serious imprecision in the data limits any meaningful in-
terpretation of these findings. Data on adverse maternal psycho-
logical effects were available from one trial only, assessing LMWH
against no treatment (Martinelli 2012), and results were uncertain:
among the 40 women included, there were two reported events,
one in each trial arm (very low-quality evidence).
For secondary outcomes, we observed a possible increase in birth-
weight associated with LDA and third-party leukocyte immunisa-
tion. However, the reliability of these findings is limited substan-
tially due to the extremely low number of participants included in
the associated analyses, each of which included only one trial. The
clinical significance of these findings is also limited, given the lack
of accompanying differences in the outcomes of low birthweight
or small-for-gestational age.
For the remaining secondary outcomes, there was no clear evidence
of benefit or harm across the interventions, although these results
were largely uncertain due to insufficient data.
Overall completeness and applicability of
evidence
The evidence around interventions to improve outcomes in sub-
sequent pregnancies following stillbirth is sparse. Our review set
out to capture a broad range of medical and psychosocial inter-
ventions addressing this research question, including outcomes of
mothers and partners, and longer-term outcomes of children. Our
review also set out to capture interventions spanning pre-concep-
tion through to birth. However, the 10 eligible trials were focused
on medical interventions among mothers (most commonly LDA
and LMWH), administered largely during pregnancy. Other po-
tentially beneficial interventions were not assessed, including in-
formation and decision-making support on interpregnancy inter-
val and pre-conception health, early or regular ultrasound surveil-
lance, elective induction of labour or elective early caesarean birth,
and intrapartum monitoring. None of the trials assessed partner or
(longer-term) childhood outcomes. Psychosocial outcomes were
rarely measured, and in no trials was psychosocial well-being a
component of, or adjunctive to, the given medical interventions.
It should be acknowledged, however, that non-randomised, qual-
itative methodologies are generally more likely to be adopted for
such psychosocial interventions, and therefore by design would
not have been captured in this review.
This review is also unable to offer information on the relative cost
effectiveness of the interventions assessed, due to unavailability of
data. Further, the trials included in this review typically focused on
women who had a history of unexplained pregnancy loss. With the
exception of thrombophilia disorders, no trials targeted women
with (other) specific risk factors for stillbirth that may have ex-
plained or contributed to their previous pregnancy losses; such as
diabetes, hypertensive disorders, obesity, smoking, or alcohol use.
With regard to the data that were available for this review, we
found only a small number of trials, many of which had relatively
few participants (only Schleussner 2015 included more than 200
women). Sample sizes for our meta-analyses were further reduced
by restricting our data extraction to women who had experienced
a previous stillbirth of 20 weeks’ gestation or more, in accordance
with the review’s inclusion criteria. As a result, the analyses were
not sufficiently powered to detect differences in most of the out-
comes assessed. We are therefore unable to draw firm conclusions
about the potential effectiveness of the specified interventions for
improving outcomes in subsequent pregnancies following still-
birth.
The overall completeness and applicability of evidence was also
limited by variation in the characteristics of the women included
in the trials. Most of the trials focused on recurrent pregnancy
loss, but recurrent pregnancy loss was variably defined (e.g. the
number of previous deaths, their gestational age cut-off points,
and whether the deaths were consecutive). Although we extracted
outcome data exclusively from women who had a previous still-
birth of 20 weeks’ gestation or more, as stated in our review proto-
col, the broader trial populations from which these women were
recruited remained somewhat heterogeneous. Variation in the pri-
mary objectives of trials, and therefore their inclusion and exclu-
sion criteria, was also evident. Most trials focused on the preven-
tion of recurrent pregnancy loss and reported livebirth rates as
primary outcomes, but three of the trials (Martinelli 2012; Rey
2009; Salim 2016) focused directly on the prevention of recur-
rent placenta-mediated complications such as pre-eclampsia, and
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measured stillbirth as part of a composite outcome. The impact
of these variations has been mitigated somewhat by the separation
of comparisons according to interventions and comparators, but
should be highlighted nonetheless.
The trials in this review recruited women who had a history of
pregnancy loss more broadly, rather than a history specifically of
stillbirth. The women had therefore experienced previous preg-
nancy losses at varying stages of pregnancy. Again, while we only
extracted data from the population of women relevant to this re-
view (women who had a previous stillbirth of 20 weeks’ gestation
or more), it is important to consider the broader context in which
the trials were conducted, given the widely varying pathophysi-
ology of deaths according to gestational age (Silver 2011). This
emphasises the urgent need for trials that specifically address ther-
apeutic or management strategies in pregnancies after stillbirth,
as opposed to other forms of pregnancy loss. Importantly, future
trials should adequately describe and consider the cause of the pre-
vious stillbirth in the study population, as this will affect both the
choice of intervention and its potential effect size. For example,
LDA may be beneficial in women with maternal vascular malper-
fusion, but it would not be expected to have a beneficial effect in
women who had stillbirth secondary to preterm prelabour rupture
of membranes.
Finally, all but one of the trials (Ahmed 2014) were conducted
in high-income countries. Of the interventions considered in this
review, while aspirin is a simple and relatively inexpensive medical
therapy that is feasible to implement in low-resource settings, it
would be considerably more difficult to implement expensive im-
munotherapies such as third-party leukocyte immunisation and
intravenous IgG in these settings (Wong 2014). Additionally, such
interventions may have limited relevance in LMICs, where still-
births appear to be caused far more often by infections, antepartum
haemorrhage, pre-eclampsia/eclampsia, and intrapartum compli-
cations (Goldenberg 2016; McClure 2018), than by maternal im-
munological disturbances that affect largely the earlier develop-
mental stages of pregnancy.
Quality of the evidence
The risk of bias in the trials in terms of their methodology and
reporting was low to moderate. Most of the trials described ad-
equate methods of random sequence generation, allocation con-
cealment, and blinding of outcome assessment. For most trials
there appeared to be low risk of attrition bias. However, the trials
assessing LMWH (Ahmed 2014; Gris 2004; Martinelli 2012; Rey
2009; Salim 2016; Schleussner 2015) were at high or unclear risk
of performance bias, due to a lack (or possible lack) of blinding
of participants. The risk of reporting bias was unclear in most
trials, due to unavailability of study protocols. The trials of the
highest quality were those assessing third-party leukocyte immu-
nisation (Christiansen 1994) and intravenous IgG (Christiansen
1995; Christiansen 2002). Limited methodological details were
available for the trial assessing progestogen (Levine 1964), which
we judged to be of the lowest quality.
We used the GRADE methodology to assess the quality of evi-
dence provided for the two main comparisons, on the outcomes
of stillbirth, neonatal death, adverse perinatal outcome, adverse
maternal psychological effects, perinatal mortality, preterm birth
(< 37 weeks), and maternal-infant attachment. The ’Summary of
findings’ tables (see Summary of findings for the main comparison;
Summary of findings 2) show the quality of evidence across these
critical outcomes to be very low to low. As outlined already, we
downgraded evidence predominantly due to serious imprecision
in the effect estimates; specifically, wide confidence intervals cross-
ing the line of no effect, small sample sizes, and low event rates.
We also downgraded some outcomes due to design shortcomings
in the associated trials.
Potential biases in the review process
We conducted our review in accordance with recommendations
provided in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). We aimed to reduce bias wherever pos-
sible by having two review authors independently assess trial eli-
gibility, perform data extraction, and carry out ’Risk of bias’ eval-
uations and GRADE assessments of evidence.
We aimed to reduce bias in trial selection by comprehensive
searches of available data. We conducted the original search for
trials in this area using Cochrane Pregnancy and Childbirth’s Trials
Register, and included trials directly addressing stillbirth/late fetal
loss. We subsequently determined that, given varying nomencla-
ture in the literature and varying definitions of stillbirth in terms
of gestational age, it was necessary to expand this search. We liaised
with the Cochrane Pregnancy and Childbirth Group’s Informa-
tion Specialist to carry out a second search, ensuring the capture
of trials dealing with pregnancy loss/miscarriage/abortion in ad-
dition to stillbirth/fetal death, as these trials potentially included
women who had experienced a previous stillbirth according to our
definition (a death of 20 weeks’ gestation or more). Our addi-
tional searches for ongoing trials within ClinicalTrials.gov and the
WHO International Clinical Trials Registry Platform ( ICTRP)
also followed this principle.
While our searches were exhaustive, we have not included data
from a number of potentially relevant trials. Specifically, our as-
sessments of the eligibility of trials necessitated contacting the au-
thors of 90 trials, as many of the yielded search results used terms
such as previous ’pregnancy loss’, ’miscarriage’, ’abortion’, and ’fe-
tal death’ without defining these by gestational age, rendering it
unclear whether these trials would be eligible for inclusion. In ad-
dition, some of the trials captured in our searches included women
who had experienced a previous stillbirth of 20 weeks’ gestation
or more alongside women who had experienced a previous earlier
pregnancy loss, necessitating a disaggregation of data in order for
the trial to be eligible for inclusion. Of the 90 potentially eligible
30Care prior to and during subsequent pregnancies following stillbirth for improving outcomes (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
trials, 11 were confirmed to include only women who had a pre-
vious pregnancy loss of less than 20 weeks’ gestation, and we can
therefore be confident of the non-applicability of these trials to the
current review. However, we excluded 66 trials for other reasons
(see Study Flow Diagram: Figure 1). The evidence presented in this
review is therefore potentially biased towards trials for which the
trialists were contactable, and willing and able to assist with the
necessary data extraction.
We were unable to explore the potential for publication bias sta-
tistically, due to insufficient numbers of trials within each meta-
analysis.
Agreements and disagreements with other
studies or reviews
It is difficult to compare the results of this review against those
of existing reviews, due to inconsistencies in review characteristics
and objectives and, particularly, in trial populations. The limited
data available for this review, alongside variation across existing
reviews in adopted nomenclature and the definitions of terms such
as ’miscarriage’, ’abortion’, and ’fetal death’, limit our capacity to
make meaningful contrasts in this regard. There are no existing
Cochrane Reviews of interventions specific to the population of
parents who have experienced, or are at risk of, a recurrent stillbirth
of 20 weeks’ gestation or more.
Nonetheless, a Cochrane Review of immunotherapy for recurrent
miscarriage (Wong 2014), including three trials assessing third-
party leukocyte immunisations and eight assessing intravenous
IgG, found that neither intervention increased rates of livebirth
when compared to placebo (the same was shown for the other im-
munotherapies assessed; i.e. paternal white cell immunisation and
trophoblast membrane immunisation). The review methods did
not define recurrent miscarriage in terms of gestational age, but
women who had a previous stillbirth of 20 weeks’ gestation or more
appeared to be among the trials included (and their data analysed
together with women who had previous pregnancy losses at earlier
gestational ages). The review concluded that such immunothera-
pies were ineffective in improving rates of livebirth among women
with unexplained recurrent miscarriage and should therefore be
abandoned, particularly given the financial cost and potentially
harmful side effects of these therapies (as noted in the Christiansen
1994 trial).
A Cochrane Review of progestogens for preventing recurrent mis-
carriage has also been conducted (Haas 2018). The review evalu-
ated the effects of progestogen treatment during the first trimester
of pregnancy, among women who had a history of miscarriage,
which was usually defined as pregnancy loss at less than 20 weeks’
gestation, and was typically of unknown aetiology. Data from
11 trials assessing progestogens against placebo or no treatment
among 2359 women showed a probable reduction in miscarriage
for the intervention group, which appeared more pronounced for
women who had a history of three or more miscarriages, com-
pared to women who had a history of two or more miscarriages.
Meta-analyses of three included trials and 1199 women showed a
possible reduction in stillbirth (measured as a secondary outcome
and defined in accordance with this review), although the authors
urged a high degree of caution in interpreting this finding, as the
outcome was driven largely by one trial with a potentially dispro-
portionate rate of miscarriage (Haas 2018). Elsewhere, a meta-
analysis of 10 RCTs, including 1586 women with unexplained
recurrent pregnancy loss (up to 24 weeks’ gestation) found that
progestogens initiated in the first trimester were associated with
higher livebirth rates when compared to placebo or no treatment
(Saccone 2017). Importantly, the beneficial effects of therapy were
evident only among the eight trials assessing progestins (synthetic
progesterone), not in those assessing natural progesterone. The au-
thors called for further research to identify the most effective prepa-
rations, doses, and routes of administration of such progestins for
preventing recurrent unexplained pregnancy loss (Saccone 2017).
A growing body of evidence for the use of anticoagulants (aspirin
or heparin, or both) during pregnancy is available. A Cochrane
Review of nine trials including 1228 women with unexplained
recurrent miscarriage, with or without inherited thrombophilia,
found that evidence of a beneficial effect of anticoagulants on rates
of livebirth among this population was lacking, regardless of the
type and combinations of anticoagulants administered (De Jong
2014). The review, which included women who had two or more
previous miscarriages up to 24 weeks’ gestation, also showed no
evidence of benefit of anticoagulants for secondary outcomes, in-
cluding preterm delivery, pre-eclampsia, and intrauterine growth
restriction. Side effects including bleeding and skin irritation were
not consistently reported across the trials, but appeared more fre-
quent among the women receiving LMWH in one study. Given
the low number of included trials and their varying methodolog-
ical quality, the authors called for further trials addressing this
research question. A Cochrane Review of aspirin or heparin (or
both) for improving pregnancy outcomes in women with persis-
tent antiphospholipid antibodies and recurrent pregnancy loss is
currently underway (Scheres 2017).
More recent evidence for the use of heparin varies. An individual-
patient-data (IPD) meta-analysis (Rodger 2016) of 963 women
across eight trials found no benefit of LMWH on placenta-me-
diated complications, except among women who had a previous
placental abruption. It is possible that unfractionated heparin has
a therapeutic effect on placenta-mediated complications within
the sub-population of women exhibiting antiphospholipid anti-
bodies, but further research is required (Duffett 2015). A meta-
analysis of eight trials including 483 women who had inherited
thrombophilia (Skeith 2016) found no benefit of LMWH for pre-
venting recurrent late pregnancy loss (> 10 weeks) in this sub-
population.
The largest body of evidence promulgating the use of LDA dur-
ing pregnancy centres on the prevention of pre-eclampsia and its
sequelae. A Cochrane Review of 37,560 women at risk of pre-
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eclampsia across 59 trials found antiplatelet agents (predominantly
LDA) reduced the risk of pre-eclampsia by 17% when compared
to placebo or no treatment, alongside reductions in preterm birth
and small-for-gestational age (Duley 2007). No reduction specifi-
cally in stillbirth was shown. However, when analysed as a compos-
ite outcome together with neonatal and infant death, antiplatelet
agents reduced the risk of death by 14%. Analogous results were
shown in an IPD meta-analysis of 32,217 women across 31 trials
(Askie 2007). Of note, subgroup analyses in the Askie 2007 re-
port suggested antiplatelet agents (mainly LDA) reduced the risk
of stillbirth among women in their second or subsequent preg-
nancy who had a history of hypertensive disorder, when compared
to women in their second or subsequent pregnancy with no such
history of hypertensive disorder, although the authors advised dis-
cretion in interpreting this finding due to the role of chance when
performing multiple comparisons.
More recent systematic reviews have further reinforced the bene-
fits of LDA among populations of women at risk of pre-eclampsia,
particularly when therapy is started early in pregnancy. As shown
by Bujold 2010, among the included trials in which LDA was
started within the first 16 weeks of pregnancy, a reduction in pre-
eclampsia and intrauterine growth restriction was evident. LDA
also reduced the risk of severe pre-eclampsia, gestational hyper-
tension, and preterm birth within this sub-population of trials.
No such benefits of LDA were shown among the trials in which
LDA was started after 16 weeks. A further systematic review in-
cluding 27,222 women across 42 trials found that LDA started
within the first 16 weeks of pregnancy reduced the risk of perinatal
death when compared to control (Roberge 2013), suggesting that
interventions to improve placental perfusion need to begin early
in pregnancy to positively affect placental development.
Our review is unable to offer any information about psychoso-
cial support interventions. However, a recent systematic review of
RCTs (San Lazaro 2017) assessing interventions to reduce stress,
anxiety, or depression among women in pregnancies after miscar-
riage (defined as pregnancy loss from conception until 24 weeks’
gestation), found no eligible trials.
We have not addressed other interventions in this review, includ-
ing information and decision-making support on interpregnancy
interval and pre-conception health, early or regular ultrasound
surveillance, elective induction of labour, elective early caesarean
birth, and intrapartum monitoring, due to a lack of eligible trials.
To our knowledge, there are no systematic reviews or individual
RCTs assessing these interventions in the context of prevention of
recurrent stillbirth.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence in this review to inform clinical
practice about the effectiveness of interventions to improve care
prior to and during subsequent pregnancies following stillbirth.
The scarcity of eligible trials, the limited amount of data available,
and the imprecision in the data presented in this review do not
permit the formulation of any clear conclusions or implications
for practice.
Implications for research
This review highlights the urgent need for well-designed trials eval-
uating the effect of interventions for improving outcomes among
parents entering or considering a subsequent pregnancy following
stillbirth. Such trials should target this specific population of par-
ents, and define clear and consistent objectives, inclusion criteria,
and outcomes related to the intervention assessed. Such trials also
need to be sufficiently powered to detect differences in statistically
rare but important outcomes, such as stillbirth and neonatal death.
To detect a 30% reduction in stillbirth in a subsequent pregnancy
(from 2.5% to 1.75%) with 80% power requires almost 6000
participants in each arm. Achieving adequate statistical power is
therefore unlikely to be feasible in single-centre RCTs, but may
be feasible by conducting pragmatic, multicentre, possibly inter-
national RCTs, that enable data collection from the requisite large
sample sizes.
Future trials of LDA specifically for the prevention of stillbirth and
recurrent stillbirth appear warranted. Given the simplicity and low
financial costs of this medical therapy, such trials would be feasible
to conduct across diverse settings, including LMICs. However, we
must acknowledge the challenges in undertaking trials adopting
a randomised design in this context. There are scarce data on the
contemporary feasibility of RCTs comparing a specific interven-
tion to placebo in this population. As one potential barrier, women
who have had a previous stillbirth secondary to placental malper-
fusion, which has a considerable recurrence risk (Monari 2016),
may not be willing to be randomised to a placebo arm in a subse-
quent pregnancy. Furthermore, their treating clinicians may not
endorse such a trial, given its potential lack of clinical equipoise.
Consequently, data are needed to determine the most appropriate
methodologies to evaluate such therapies. Stepped-wedge cluster-
RCTs provide (all) participants with the given intervention in a
stepwise fashion, and therefore may overcome some of the ethical
and logistical difficulties associated with traditional RCTs in this
context (Hussey 2007; Mdege 2011). The APPLE feasibility trial
(Rodger 2017), estimated for completion in 2020, may shed light
on the specific reasons for non-consent into RCTs addressing re-
current pregnancy loss.
This review has also highlighted many challenges in compiling ev-
idence addressing the current and related review questions within
the pregnancy and childbirth context. Consistency in the defini-
tion of key outcomes, such as stillbirth, alongside consistency in
data collection and presentation, will considerably aid the mean-
ingful interpretation of evidence within this space. Future trials
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(including those that report data from non-randomised/observa-
tional studies) may benefit from a core outcomes data set for still-
birth research, which may promote consistency in nomenclature,
and facilitate the collection of data across well-defined populations
and outcome measures. Such a core outcomes data set should in-
clude short- and longer-term psychosocial outcomes for families,
as well as economic outcomes, both of which were largely absent
from measurement in the trials in this review.
As the bulk of evidence available to inform clinical practice for care
in subsequent pregnancies following a stillbirth, at least in RCTs,
appears focused heavily on medical aspects of care, psychosocial
interventions addressing maternal-fetal attachment and parental
anxiety and depression are particularly called for. Ensuring clinical
equipoise, these trials could randomise parents to different forms
of support to determine which interventions yield the greatest
benefit for parents and families, with the least economic cost.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahmed 2014
Methods Randomised controlled trial (3-armed)
Participants 172 women were randomised. Data from 40 eligible women were included in this review
Setting: Fatima Memorial Hospital, Pakistan, tertiary referral obstetric hospital with
advanced obstetric and gynaecology care and neonatology care
Women with a diagnosis of idiopathic recurrent miscarriage (defined as 2 consecutive
miscarriages, loss < 24 weeks’ gestation, with urine for pregnancy test positive along with
clinical manifestation of miscarriage or ultrasonographic evidence of histopathological
evidence of products of conception)
Dates of recruitment: not stated
Inclusion criteria: previous idiopathic recurrent miscarriage (2 or more consecutive
losses < 24 weeks’ gestation after exclusion of all known causes of recurrent miscarriage)
Exclusion criteria: not stated
Interventions Aspirin: 75 mg oral aspirin daily from 6 weeks onward (fetal cardiac activity positive)
until 36 weeks
Number randomised unclear (see notes), data from 54 women were analysed
Combined aspirin and enoxaparin (heparin): 40 mg enoxaparin (LMWH) subcuta-
neous injection daily from 6 weeks onward (fetal cardiac activity positive) until start of
labour. Aspirin as above
Number randomised unclear (see notes), data from 56 women were analysed
Placebo: intensive pregnancy surveillance with placebo in similar packs to aspirin, orally
daily from 6 weeks onward until 36 weeks
Number randomised unclear (see notes), data from 50 women were analysed
Outcomes Primary outcome: livebirth rate.
Secondary outcomes: serious adverse events during pregnancy (miscarriage, intrauterine
fetal death (fetal death > 24 weeks)), SGA, preterm birth, APH and PPH
Funding source(s) Not reported in abstract; trialists confirmed there was no funding for the trial
Declarations of interest Not reported in abstract; trialists confirmed there were no conflicts of interests
Information source(s) Primary publication (published as abstract only) and completed data request form
Notes Assessment of trial methodology and risk of bias was carried out based on the trial abstract
only (and additional information provided by the trialists)
12 women were excluded post-randomisation, though unclear to which group these
women had been assigned (2 participants did not want to continue Clexane after 24
weeks’ gestation. A further 7 participants were lost to follow-up and 3 did not adhere to
treatment)
Risk of bias
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Ahmed 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “An online computer program was
used to generate the random sequence. We as-
sumed the number of patients to be booked
during the study period (2007-2013) to be
400 (though the actual number enrolled was
172) and created 3 arms, placebo, aspirin
alone and aspirin with Clexane [heparin]. We
followed the random sequence as generated by
the program as the patients were booked/en-
rolled in the study” (information provided by
trialists)
Allocation concealment (selection bias) Low risk Sealed, opaque, consecutively-labelled en-
velopes which were taken in order as the
women were booked/enrolled in the study (in-
formation provided by trialists)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk While it was reported that the aspirin and
placebo tablets were provided in similar packs,
there did not appear to be a placebo for the
heparin (enoxaparin)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Lack of blinding unlikely to influence objec-
tive outcomes
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk No detail was provided as to whether outcome
assessors were blinded for subjective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 participants did not want to continue Clex-
ane after 24 weeks’ gestation. A further 7 par-
ticipants were lost to follow-up and 3 did not
adhere to treatment, but it is not clear to which
group these participants were assigned
Selective reporting (reporting bias) Unclear risk Not possible to confidently assess selective
outcome reporting with no access to published
trial protocol; trial published in abstract form
only
Other bias Unclear risk Insufficient methodological detail provided in
abstract to determine other potential sources
of bias
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Christiansen 1994
Methods Randomised controlled trial
Participants 75 women were randomised. Data from 4 eligible women were included in this review
Setting: Aalborg Hospital, Denmark
Dates of recruitment: appeared to commence from October 1987, end date not stated
Inclusion criteria: women with recurrent unexplained miscarriage who had suffered
at least 3 consecutive miscarriages; with no abnormalities in the non-immunological
investigation programme; with a maximum of 1 pregnancy loss after 14 weeks’ gestation;
who were not consanguineous with spouse; who were negative for lymphocytotoxic
antibodies; who were negative for lupus anticoagulant; who did not have antinuclear
antibodies titres > 80 or anti-DNA levels > 8.0 mg/L
Exclusion criteria: auto-antibodies including lupus anticoagulant, anticardiolipin an-
tibodies, antinuclear antibodies, anti-double-stranded deoxyribonucleic-acid (NB: anti-
cardiolipin antibodies in the absence of lupus anticoagulant were not excluded)
Interventions Third-party leukocytes: women were immunised with intravenous infusions with buffy
coat (leukocyte enriched blood) from erythrocyte-compatible third-party blood donors.
Women received the initial immunisations twice prior to conception 1 month apart.
Before the immunisations, 200 mL of blood was drawn from each woman; after 1 hour
women were infused intravenously with 150 mL of buffy coat from 2 third-party donors.
Women received 1 repeated infusion of buffy coat from 2 third-party donors every 5th
month until conception had occurred. Infusions were carried out on an outpatient basis
Total number randomised: n = 49 (43 analysed)
Placebo: women were immunised with intravenous infusions of their own autologous
blood, with the regimen as described above
Total number randomised: n = 26 (23 analysed)
Outcomes Study report: livebirth; miscarriage; ectopic pregnancy; time from last immunisation to
pregnancy; birthweight; preterm birth; Apgar score ≤ 7 at 5 minutes; malformations;
admission to hospital in first year (and causes for admission); immunological parameters
(lymphocyte subsets: levels of CD2+, CD4+, CD8+ and CD16+ cells (%) lymphocyte
antibodies: positive (%))
Funding source(s) Research Fund of Aalborg Voluntary Blood Donors, the Research Fund of the County
of North Jutland and Aalborg Stifts Julelotteri (local diocese Christmas lottery)
Declarations of interest Not in study report; trialists confirmed there were no conflicts of interests
Information source(s) Primary publication and completed data request form
Notes There were no significant different in livebirths between the groups, but subgroup anal-
yses of women with primary recurrent miscarriages (no previous livebirths) suggested
benefit of immunisation, as did subgroup analyses of women with primary recurrent
miscarriage and no pregnancies progressing beyond 14 weeks’ gestation.
A 2:1 allocation ratio was adopted to make participation more appealing and because
a third allocation group involving immunisation with husbands’ lymphocytes had been
planned, but was later abandoned due to unacceptable side-effects, including dizziness
and formation of red cell antibodies.
Severe reactions were noted in both women and children that could have been attributed
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The leading consultant at the Department allocated par-
ticipants by drawing lots
Allocation concealment (selection bias) Low risk The leading consultant at the Department performed al-
location by drawing lots each time a new patient had
signed the informed consent for participation. The con-
sultant had not been in contact or known the reproduc-
tive history of the women. When allocation was done
before pregnancy, a message was given to the blood bank
to prepare allogenous or autologous buffy coat for the
first transfusion within a few days
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Neither the couple nor the women’s obstetricians
knew whether active treatment or placebo was provided”
(study report p. 262)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Trialists confirmed that doctors involved in outcome as-
sessment were blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Women (who completed questionnaires 1 year after
birth) and doctors were reported to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 75 women were randomised; 9 (12%) were excluded
from analyses, 6/49 (12%) from the intervention group,
and 3/26 (12%) from the control group; all except one
of the exclusions were due to women not being pregnant
during the trial period
Selective reporting (reporting bias) Unclear risk Not possible to confidently assess selective outcome re-
porting with no access to published trial protocol
Other bias Low risk No other obvious sources of bias identified
Christiansen 1995
Methods Randomised controlled trial
Participants 34 women were randomised. Data from 5 eligible women were included in this review
Setting: Aalborg Hospital, Denmark.
Dates of recruitment: not stated
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Christiansen 1995 (Continued)
Inclusion criteria: women with 3 or more consecutive pregnancy losses (defined as
spontaneous abortion or the unexplained intrauterine death of the fetus before 28 weeks’
gestation), who either 1) had a history of secondary recurrent spontaneous abortion (3
or more spontaneous abortions subsequent to a birth) or 2) had at least 1 pregnancy
loss after the 14th gestational week; for all women these previous pregnancy losses were
unexplained (following hysterosalpingography or hysteroscopy, karyotyping and mea-
surement of the mid-luteal serum progesterone concentration). Women were identified
preconception, and randomised once pregnancy was confirmed
Exclusion criteria: systemic lupus erythematosus or IgA deficiency
Interventions Intravenous IgG: women received Nordimmun, a human IgG, given in a solution also
containing human albumin and saccharose. Doses ranged from 25 - 35 g depending on
pre-pregnancy bodyweight. Doses were administered weekly from 5 - 8 weeks’ gestation,
then fortnightly from 8 - 34 weeks’ gestation
Total number randomised: n = 17 (17 analysed)
Placebo: women receive a placebo - a solution containing only human albumin and
saccharose. Women received the placebo according to the same regimen detailed above
Total number randomised: n = 17 (17 analysed)
Outcomes Study report: successful pregnancies; surviving infants; birthweight; preterm birth; Apgar
10 after 5 minutes; congenital malformations; pregnancy complications; immunological
parameters (APTT concentrations; antinuclear factor, anti-ds-DNA, rheumatoid factor,
anticardiolipin, all autoantibodies; plasma C3 neodeterminants; total serum IgG; main
lymphocyte subpopulations; ALAT concentrations); side effects/symptoms
Funding source(s) Novo-Nordisk A/S, Denmark (commercial global health company), and Aalborg Stift-
stidendes Julelotteri (local newspaper lottery)
Declarations of interest Not in study report; trialists confirmed there were no conflicts of interests
Information source(s) Primary publication and completed data request form
Notes The study report notes that no significant differences between the groups were evident
at baseline on clinical and demographic characteristics
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Low risk Quote: “The sealed envelope method” was used (study
report p. 2,691)
Envelopes were stored at the Department of Clinical Im-
munology, Aalborg Hospital and at the Nordisk Gen-
tofte company, Copenhagen and reported to be opaque
by trialists
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Christiansen 1995 (Continued)
Quote: “The list assigned the pregnant patient the next
free consecutive allocation number” (additional informa-
tion provided by trialists)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial.
Quote: “The packages of Nordimmun/placebo could not
be distinguished between, and the codes were blinded
for both the patients and hospital staff, including the
authors” (study report p. 2,691). The study treatments
were packaged in identical bottles at the Nordisk Gen-
tofte pharmaceutical company; the bottles could only be
distinguished by allocation number (additional informa-
tion provided by trialists)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Doctors involved in outcome assessment were reported
to be blind by trialists
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Doctors involved in outcome assessment were reported
to be blind by trialists
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary outcomes assessed using ITT, 100% compliance
with treatment and no exclusions from the analyses
Selective reporting (reporting bias) Unclear risk Not possible to confidently assess selective outcome re-
porting with no access to published trial protocol
Other bias Low risk No other obvious sources of bias identified, although the
number of previous pregnancy losses “was accidentally
biased at allocation” (study report p. 2,692) with women
in the intervention group having a higher number (4.6
vs. 3.9; P < 0.10 “NS”)
Christiansen 2002
Methods Randomised controlled trial
Participants 58 women were randomised. Data from 8 eligible women were included in this review
Setting: Aalborg Hospital, Aalborg, Denmark
Dates of recruitment: June 1994 to June 1999
Inclusion criteria: women with (i) a history of 4 or more confirmed unexplained mis-
carriages before the end of the 26th gestational week, of which the last 3 had been con-
secutive; (ii) no uterine or parental chromosomal abnormality; (iii) regular menstrua-
tions with cycle length between 21 and 35 days; (iv) written informed consent; and (v)
a positive pregnancy test carried out at the hospital
All miscarriages stated by the women were confirmed by searching hospital records or by
contacting the practitioners. All women had normal findings by hysterosalpingography
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or hysteroscopy, and all couples had normal chromosomes by ordinary G-band technique
Exclusion criteria: (i) total IgA deficiency; (ii) autoimmune rheumatic disease; (iii) in-
sulin-dependent diabetes mellitus; (iv) pregnancy obtained by IVF or controlled ovarian
stimulation; and (v) application to participate in the trial later than 7 days after the
expected menstruation
Interventions Intravenous IgG: Nordimmun human IgG preparation, containing 4.6% human IgG,
1.5% human albumin, 4.6% sucrose and 0.15 mol/l sodium. Women received their first
infusion immediately after randomisation; at each intravenous infusion until 20 weeks’
gestation, 0.8 g of study drug per kg bodyweight was administered; from 20 to 26 weeks’
gestation 1.0 g of study drug per kg bodyweight was given. Women received infusions
weekly from gestational weeks 5 - 10, then fortnightly until 26 weeks (total 14 infusions
in successful pregnancies). All infusions were given on an outpatient basis
Total number randomised: n = 29 (29 analysed)
Placebo: women received a placebo drug containing 1.5% human albumin, 4.6% sucrose
and 0.15 mol/l sodium Placebo given according to regimen described above
Total number randomised: n = 29 (29 analysed)
Outcomes Study report: live births; pregnancy losses/miscarriages; GA at birth; birthweight; Apgar
score ≤ 7 at 5 minutes; caesarean section; neonatal disorders; maternal safety parameters
(clinical symptoms; hepatitis and HIV transmission; signs of hepatic and renal affection)
; fetal safety parameter (health and development of child at 3 and 12 months after birth)
Funding source(s) HemaSure AS of Gentofte, Denmark (pharmaceutical company)
Declarations of interest Not in study report; trialists confirmed there were no conflicts of interest
Information source(s) Primary publication and completed data request form
Notes The study report notes that no significant differences between groups were evident at
baseline on clinical and demographic characteristics
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list.
Quote: “Allocation to the treatment arms was made
according to a computer-generated randomization list
which was retained by HemaSure A/S, Copenhagen, dur-
ing conduct of the trial” (study report p. 810)
Allocation concealment (selection bias) Low risk As above and
Quote: “The randomization code was blinded to the pa-
tients and hospital staff (including the authors) until af-
ter the last included patient had given birth and all data
had been entered into a computer database in April 2000
by an independent clinical research organization (Ecron
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Christiansen 2002 (Continued)
Wiedey GmbH, Konstanz, Germany)” (study report p.
810)
Trialists confirmed patients were allocated to the next
free consecutive number of randomisation from a list
kept at the Department of Clinical Immunology, which
gave no information on treatment group (the computer-
generated randomisation list, linking allocation numbers
to treatment group was retained by HemaSure A/S during
the trial); the drugs were packaged in identical bottles
at HemaSure A/S, and were only distinguished by the
allocation number (additional information provided by
trialists)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial
Quote: “The placebo drug could not be distinguished
visually from the active drug. Bottles containing either
Nordimmun or placebo were marked with their alloca-
tion numbers, but otherwise were identical” (study re-
port p. 810)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Trialists confirmed that all doctors and nurses treating the
patients involved in outcome assessment were blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Trialists confirmed that all doctors and nurses treating the
patients involved in outcome assessment were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary outcomes assessed using ITT, no participants
were lost to follow-up or discontinued infusions
Selective reporting (reporting bias) Unclear risk Not possible to confidently assess selective outcome re-
porting with no access to published trial protocol
Other bias Low risk No other obvious sources of bias identified
Gris 2004
Methods Randomised controlled trial
Participants 174 women were randomised. Data from 22 eligible women were included in this review
Setting: Mediterranean Abnormal Pregnancy Study Program; patients referred across
the Southern French Region Languedoc-Roussillon.
Dates of recruitment: not stated
Inclusion criteria: women with 1 single unexplained pregnancy loss from the 10th
week of amenorrhoea with no unexplained pregnancy losses before the beginning of the
10th week of amenorrhoea and no explained pregnancy losses associated with a factor
V Leiden mutation, a factor II G20210A mutation (all heterozygous), or a protein S
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Gris 2004 (Continued)
deficiency
Exclusion criteria: presumptive aetiologic factor (hysterosalpingogram, karyotype in
both parents, glucose tolerance test, toxoplasmosis serology, thyroid function, serum
prolactin levels, normal luteal phase of at least 12 days and plasma progesterone above
25 ng/mL, absence of antinuclear factor, or antiphospholipid/antiprotein antibodies (lu-
pus anticoagulant, anticardiolipin, anti-beta2-glycoprotein I, anti-annexinV, anti-phos-
phatidylethanolamine, IgG, and IgM), absence of antithrombin or protein C deficiency,
fasting plasma total homocysteine lower than 15 µM/L; any antecedent of venous or
arterial thrombosis; any pregnancy loss before the beginning of the 10th week of amenor-
rhoea; any lethal fetal defect; fetal haemorrhage; pregnancy-induced hypertension with
its complications; any infectious disease during pregnancy; known erythroblastosis fe-
talis, immune thrombocytopenic purpura, or fetomaternal alloimmune thrombocytope-
nia; trauma during pregnancy; diabetes mellitus; tobacco consumption at least equal to
10 cigarettes a days
Interventions Enoxaparin (heparin): 40 mg LMWH enoxaparin, daily subcutaneous injection self-
administered percutaneously in the abdomen at 8 pm. Treatment began at the 8th week
of amenorrhoea after a positive pregnancy test
Number randomised unclear (see notes), data from 80 women were analysed
Aspirin: 100 mg low-dose aspirin, taken daily at 8 pm
Number randomised unclear (see notes), data from 80 women were analysed
Outcomes Outcomes reported in study report: live births; pregnancy losses from the beginning of the
8th week; preterm birth; pre-eclampsia; caesarean birth; vaginal birth; birthweight; SGA;
heparin-induced thrombocytopenia, abnormal skin reactions, clinical manifestation of
spontaneous bone pain; digestive intolerance; haemorrhages
Funding source(s) “Supported by grants from Diagnostica Stago, Biopep S.A., and Baxter Healthcare Cor-
poration” (study report p 3,695). Institutional funding also received
Declarations of interest Not reported in study report; trialists confirmed there were no conflicts of interest
Information source(s) Primary publication and completed data request form
Notes 14 women were excluded post-randomisation, though unclear to which group these
women had been assigned
All women took 5 mg daily folic acid from 1 month preconception and throughout
pregnancy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation was performed blindly and at random by an
independent statistician using a computer random-num-
ber generator to ensure equal distribution of women with
specific thrombophilia disorders among the groups (e.
g. half of women with Protein S deficiency allocated to
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Gris 2004 (Continued)
each arm, half with Factor V Leiden mutation allocated
to each arm)
Allocation concealment (selection bias) Unclear risk Quote: “Sealed opaque envelopes sent by an independent
statistician” (additional information provided by trialists)
. Whether envelopes were consecutively numbered was
not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Patients and physicians were aware of the treat-
ment being taken” (study report p. 3698)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Trialists confirmed outcome assessment was blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Trialists confirmed outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Appeared that 174 women were randomised, and 14
(8%) were excluded from analyses with 160 analysed. 12
women had an early pregnancy loss and were excluded;
unclear why additional 2 women were excluded. Not
clearly reported from which groups these women were
excluded
Selective reporting (reporting bias) Unclear risk Not possible to confidently assess selective outcome re-
porting with no access to published trial protocol
Other bias Low risk No other obvious sources of bias identified
Levine 1964
Methods Quasi-randomised controlled trial
Participants 56 women were randomised. Data from 7 eligible women were included in this review
Setting: Chicago Board of Health Prenatal Clinics, Canada
Dates of recruitment: not stated
Inclusion criteria: women with 3 consecutive spontaneous abortions prior to the present
pregnancy, 16 weeks’ gestation or less at study enrolment, with no symptoms of threat-
ened abortion, with voluntary agreement to the conditions of the study, with no obvious
physical defects
Exclusion criteria: as above; no other exclusions reported
Interventions Progestogen/progestational agent (Delalutin): 500 mg injection of 17a-hydroxypro-
gesterone caproate weekly, started at first visit, continued until the 36th week of preg-
nancy or termination, whichever occurred first
Number randomised unclear (see notes), data from 15 women were analysed
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Levine 1964 (Continued)
Placebo: weekly placebo injection, as above
Number randomised unclear (see notes), data from 15 women were analysed
Outcomes “Salvaged” pregnancies (live babies); abortions; complications of treatment; “significant
undesirable manifestations” for women; discontinuation of injections; “hormonal effects”
for infants
Funding source(s) “Delalutin and placebo were supplied through the generosity of Dr. E. C. Reinfenstin,
Jr., Squibb Institute for Medical Research, New Brunswick, New Jersey” (study report
p. 31)
Declarations of interest Not reported in study report
Information source(s) Primary publication only
Notes 26 women were excluded post-randomisation, though unclear to which group these
women had been assigned
Trialist now deceased; no further information sought. Results are reported descriptively
only due to problems with data reporting
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Trial was quasi-randomised:
Quote: “As patients were accepted into the study
they were alternately placed into Group A or Group
B” (study report p. 31)
Allocation concealment (selection bias) High risk As above, trial was quasi-randomised
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The investigation was designed as a con-
trolled double-blind study - i.e., neither physician
nor patient knew if actual drug or placebo was
given” (study report p. 31)
Specific detail regarding similarity of intervention
and placebo was not provided, but considered likely
that this could have been achieved successfully
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Lack of blinding unlikely to influence objective
outcomes
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk No detail provided as to whether outcome assessors
were blinded for subjective outcomes, but compli-
cations of treatment were likely assessed by physi-
cians/patients (who were blinded)
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Levine 1964 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 56 women were randomised; 26 (46%) were ex-
cluded post-randomisation (16: found not to be
pregnant; 10: did not return for injections, and
thus not followed up)
Selective reporting (reporting bias) Unclear risk Not possible to confidently assess selective outcome
reporting with no access to published trial protocol
Other bias Unclear risk Insufficient methodological detail provided to de-
termine other potential sources of bias
Martinelli 2012
Methods Randomised controlled trial
Participants 135 women were randomised. Data from 40 eligible women were included in this review
Setting: 8 obstetric units in Italy
Dates of recruitment: April 2007 to April 2010
Inclusion criteria: pregnant women referred to a participating centre at a GA < 12
weeks, who provided written informed consent, with any of the following events com-
plicating previous pregnancies: (1) mild pre-eclampsia, defined by blood pressure higher
than 140/90 mmHg on 2 or more occasions after the 20th gestational week plus pro-
teinuria ≥ 0.3 g/24 hours or > 2+ on dipstick testing; severe pre-eclampsia, defined by
blood pressure higher than 160/100 mmHg plus proteinuria more than or equal to 0.
5 g/24 hours or 3+ on dipstick testing, or concomitant placental abruption, FGR, or
fetal loss; eclampsia, defined by the occurrence of new-onset seizures in a pre-eclamptic
woman; (2) HELLP syndrome, defined by the concomitant presence of signs of haemol-
ysis (lactate dehydrogenase > 600 IU/L or serum bilirubin > 1.2 mg/dL or presence of
schistocytes in the peripheral blood), serum aspartate transaminase more than 70 IU/L
and thrombocytopenia (platelet count < 100,000/mm3); (3) spontaneous fetal loss after
the 15th gestational week; (4) FGR, defined by birthweight below the 10th percentile
for GA together with a percentile reduction from the growth curve of the abdominal
circumference more than 40% by ultrasound; and (5) placental abruption, defined by
vaginal bleeding with or without uterine tenderness and fetal distress followed by emer-
gency delivery after 24 gestational weeks
Exclusion criteria: women with the above previous pregnancy complications most likely
explained by anatomic, chromosomal, endocrine, immunologic abnormalities or inter-
current traumatic or infectious events or who, at the time of screening evaluation, re-
ported previous venous or arterial thrombotic events or were found to have a multiple
pregnancy, diabetes mellitus, immunologic disorders, abnormal placental insertion, alco-
hol or drug abuse, < 50,000 platelets/mm3, renal impairment, or any medical condition
requiring continued anticoagulant or antiplatelet treatment, including low-dose aspirin,
during pregnancy
“Antiphospholipid antibodies were tested in fresh unfrozen plasma within 24 hours since
blood sampling, and their results were promptly communicated to the participating
centers; women who tested positive were excluded from the study” (study report p. 3270)
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Martinelli 2012 (Continued)
Interventions Nadroparin (heparin): 3800 IU/40 mg LMWH (nadroparin), daily subcutaneous in-
jection combined with medical surveillance (monthly visits and controls of maternal
weight, blood pressure, aspirin intake, abdominal growth, and ultrasound evaluation of
fetal biometry) and were actively followed up to delivery or to complete resolution of
any intercurrent adverse event, or both. Mean GA at randomisation was 11 weeks
Total number randomised: n = 67 (63 analysed)
No treatment: medical surveillance alone (monthly visits and controls of maternal
weight, blood pressure, aspirin intake, abdominal growth, and ultrasound evaluation of
fetal biometry)
Total number randomised: n = 68 (65 analysed)
Outcomes Composite endpoint of pre-eclampsia, eclampsia, HELLP syndrome, intrauterine fetal
death, FGR, or placental abruption;
Pregnancy complications: miscarriage; termination; gestational diabetes; gestational
hypertension; cholestasis; premature rupture of membranes; oligohydramnios; placental
praevia; risk of preterm delivery; abnormal uterine artery velocimetry; others;
Other maternal adverse events: bleeding; thrombocytopenia; others;
Fetal/neonatal adverse events: chromosomal or congenital abnormalities; abnormal
cardiotocography; others;Other outcomes: abnormal uterine artery velocimetry; GA
at birth; delivery after 38th week; delivery at or before 38th week (before 35th week;
before 31st week); caesarean section; birthweight < 10th centile; birthweight 10th to
49th centile; birthweight 50th to 89th centile; birthweight > 90th centile; birthweight;
Apgar score < 7
Funding source(s) Trial supported by the Italian Drug Agency (Agenzia Italiana del Farmaco) of the Ministry
of Health (grant for independent research; trial registration: EudraCT 2006-004205-
26). The study report notes “No pharmaceutical company was involved in any phases of
the trial, including protocol design, study conduction, co-ordination and monitoring,
data handling and analysis, and manuscript writing” (study report p. 3270)
Declarations of interest “The authors declare no competing financial interests” (study report p. 3275)
Information source(s) Primary publication; Abstract/interim analyses: Martinelli I. LMWH in pregnant women
with previous obstetrical complications. A multicenter, randomised trial. Pathophysiol-
ogy of Haemostasis and Thrombosis 2010;37 Suppl 1:A3; HAPPY study protocol CRF
(supplied by trialists) and completed data request form
The trial was registered at ricerca-clinica.agenziafarmaco.it as EudraCT 2006-004205-
26
Notes Study ceased after first planned interim analyses due to futility and for safety considera-
tions. The trial Data and Safety Monitoring Board concluded at this time that LMWH
prophylaxis was ineffective in the prevention of late pregnancy complications
Risk of bias
Bias Authors’ judgement Support for judgement
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Martinelli 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “A computer randomization list was generated
by the Laboratory of Biostatistics of the Mario Negri
Institute (Ranica, Italy)” (study report p. 3270)
Allocation concealment (selection bias) Low risk Quote: “Patient randomisation numbers and study arm
were requested by phone or fax and centrally assigned
by the treatment secretariat at the Mario Negri Institute”
(study report p. 3270)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Participants and care providers were not blind
to study treatments” (study report p. 3270)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “The primary outcome was a composite end
point of pre-eclampsia, eclampsia, HELLP syndrome,
intrauterine fetal death, FGR, or placental abruption.
These outcomes were allocated on the basis of the same
criteria used at screening evaluation by an independent
adjudicator (P.R.) who was blinded to treatment alloca-
tion” (study report p. 3270); further, lack of blinding not
considered likely to impact objective outcomes
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: “Assessed by an independent adjudicator (P.R.)
who was blinded to treatment allocation” (study report
p. 3270)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analyses employed. Of 135 women randomised, 7
(5%) were excluded from primary outcome analyses (4
in heparin group, 3 in medical surveillance group)
Selective reporting (reporting bias) Unclear risk Published study reports: “The primary outcome was
a composite end-point of pre-eclampsia, eclampsia,
HELLP syndrome, intrauterine fetal death, FGR, or pla-
cental abruption” (study report p. 3270), although pub-
lished conference abstract reports: “The primary out-
come was the live-birth rate.” Trial protocol was available,
but limited detail provided in protocol regarding nature
of prespecified outcomes; 1 such outcome “changes in
platelet count (PLT) or aspartate aminotransferase (AST)
/alanine aminotransferase (ALT)” was not reported in
study report
Other bias Low risk No other obvious sources of bias identified
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Rey 2009
Methods Randomised controlled trial
Participants 114 women were randomised. Data from 45 eligible women were included in this review
Setting: 6 high-risk pregnancy referral centres in Canada
Dates of recruitment: August 2000 to June 2007
Inclusion criteria: GA < 17 weeks at randomisation; normal thrombophilia screen
(absence of heterozygous or homozygous factor (F)V Leiden or prothrombin 20210A
mutations; negative testing for lupus anticoagulant and absence of moderate or high
levels of anticardiolipin antibodies; normal levels of antithrombin, protein C, protein
S and normal level of homocysteine or absence of the homozygous MTHFR C677T
mutation) and; 1 or more of the following complications in the immediate previous
pregnancy: severe PET resulting in delivery before 34 6/7 weeks; unexplained newborn
weight less than the 5th percentile; abruptio placenta resulting in delivery before 34 6/7
weeks or in fetal death after 19 6/7 weeks; 1 or more episodes of unexplained intrauterine
death after 19 6/7 weeks or 2 episodes of unexplained fetal death between 12 and 19 6/
7 weeks
Exclusion criteria: any of the following in the previous or the current pregnancy: mul-
tiple gestation, alcohol or illicit drug use, underlying metabolic disease other than hy-
pertension which could promote SGA or stillbirth (such as diabetes, hyperthyroidism
and renal disease), uterine malformation, placental or cord pathologies, cytomegalovirus
or toxoplasmosis infection, known fetal malformation or chromosomal anomaly at ran-
domisation; a previous venous or arterial thrombotic event, known allergy to heparin
or LMWH, contraindication to dalteparin or an absolute indication for anticoagulant
therapy
Interventions Dalteparin (heparin): subcutaneous self-injection of dalteparin administered daily at
4000 IU daily for women weighing < 60 kg, 5000 IU for women weighing 60 - 90 kg
and 6000 IU for women weighing > 90 kg (weights as at randomisation). Injections
were stopped at 36 weeks’ gestation or birth (whichever came first). A complete blood
count was performed twice in the first 2 weeks and thereafter, at the discretion of the
participating centre
Total number randomised: n = 57 (55 analysed)
No treatment
Total number randomised: n = 57 (55 analysed)
Outcomes Primary outcome: composite of severe pre-eclampsia, birthweight > 5th percentile,
major abruptio placentae resulting in delivery < 34 weeks’ gestation or fetal death > 20
weeks’ gestation
Secondary outcomes: non-severe pre-eclampsia; newborn weight between the 6th and
10th percentile; GA at delivery
Other outcomes reported: fetal loss < 20 weeks; fetal loss > 20 weeks; use of antihy-
pertensive agents; gestational diabetes; haemoglobin at birth; antenatal hospitalisation
for hypertension/fetal indications; preterm prelabour rupture of membranes; preterm
labour; induction of labour; induction for hypertension/fetal indications; vaginal birth;
magnesium sulphate; preterm birth (< 37 weeks, < 34 weeks, < 30 weeks); delivery
for pre-eclampsia/fetal indications (< 37 weeks, < 34 weeks, < 30 weeks); birthweight;
birthweight percentile; birthweight < 2500 g; newborn intensive care unit admission;
safety: skin reaction; heparin-induced thrombocytopenia or haemorrhage (other than
local bruising at injection site)
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Rey 2009 (Continued)
Funding source(s) Trial financially supported by the Canadian Foundation for Women’s Health, Pharmacia
& Upjohn Inc and Pfizer Canada. The study report notes the funders were not involved
in the study design, data collection, analyses, interpretation or writing of the manuscript
Declarations of interest “S.R. Kahn and M. Rodger have received speaker’s honoraria and investigator-initiated
grants-in-aid from various manufacturers of LMWH. The other authors state that they
have no conflict of interest” (study report p. 63)
Information source(s) Primary publication and completed data request form. Trial registration at
www.isrctn.com/ISRCTN78732833 (retrospectively registered in 2008)
Notes Clinical trials identifier: ISRCTN78732833
Study was stopped early due to slow recruitment and following interim analyses demon-
strating a decrease in the primary outcome at P < 0.005. Trialists noted: “We are aware
that stopping the study may have led to exaggerated effect sizes” (study report p. 63)
Most of the participants (78.4%) were recruited at 1 hospital (CHU Sainte-Justine)
Women with spontaneous abortion < 12 weeks’ gestation were censored a posteriori
from the analyses as they could not develop primary or secondary outcomes
Low birthweight defined as weight < 2500 g
SGA defined by percentile < 10th percentile
Prematurity and neonatal intensive care stay was taken as the proxy for neonatal morbidity
Adherence defined by observance of treatment. 1 woman switched from control to
intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Women were randomized in a 1:1 ratio to dal-
teparin vs. no dalteparin (open-label control) groups, us-
ing a computer generated random numbers table (blocks
of six)” (study report p. 59)
Allocation concealment (selection bias) Low risk Quote: “Each generated number was linked to a sealed,
opaque envelope containing the name of the group to
which the woman was randomized” (study report p. 59)
. Envelopes were sequentially numbered and taken in
order (information provided by trialist)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded trial
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Two adjudicators blinded to treatment assign-
ment and not involved in the study reviewed all the pa-
tient report forms” (study report p. 59)
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Rey 2009 (Continued)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: “Two adjudicators blinded to treatment assign-
ment and not involved in the study reviewed all the pa-
tient report forms” (study report p. 59)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analyses employed. Minimal and equal attrition be-
tween groups
Selective reporting (reporting bias) Unclear risk Not possible to confidently assess selective outcome re-
porting. Retrospective trial registration
Other bias Unclear risk Although the statistical significance of differences was not
reported, there appeared to be some baseline imbalance
for aspirin use and ethnicity; trialists report results of
adjusted analyses
Salim 2016
Methods Randomised controlled trial
Participants 144 women were randomised. Data from 13 eligible women were included in this review
Setting: University teaching hospital and 3 specialised community clinics focusing on
high-risk pregnancies in Israel
Dates of recruitment: October 2009 to January 2015
Inclusion criteria: singleton pregnancy at 14 weeks’ gestation or less at enrolment and
prior placenta-mediated pregnancy complications or a lower-leg thrombotic event along-
side any diagnosed thrombophilia (details provided in study report). Prior placenta-
mediated pregnancy complications included prior severe pre-eclampsia, prior SGA with
placenta-related antepartum signs, prior placental abruption, or prior unexplained preg-
nancy loss (3 losses before 13 weeks, 2 losses between 14 and 22 weeks’ gestation, or any
loss after 23 weeks’ gestation)
Exclusion criteria: women with pre-gestational diabetes or women with prior need for
therapeutic dosages of LMWH or contraindication to LMWH, plus women who had
previous pregnancy complications that could be attributed to multiple gestations, major
congenital or chromosomal abnormalities, fetal infection, or hydrops fetalis
Interventions Enoxaparin (heparin; adjusted dose): daily by subcutaneous self-injection of 40 mg
initially, then adjusted by fractions of 20 mg according to anti-factor Xa levels. Injections
continued from enrolment to birth. Targeted prophylactic level was determined at 0.2
IU/mL or more 3½ to 4 hours post-injection by blood sample. Results were computerised
and dose adjusted accordingly in the next visit. Women attended follow-up visits every
3 - 4 weeks. Women with anti-phospholipid antibodies were also given LDA
From birth to 42 days, all women were prescribed daily enoxaparin 40 mg by subcuta-
neous injection. Otherwise, standard antepartum and peripartum care given
Total number randomised: n = 74 (74 analysed)
Enoxaparin (heparin; fixed dose): daily by subcutaneous self-injection of 40 mg re-
gardless of anti-factor Xa levels. Injections continued from enrolment to birth. Anti-
factor Xa levels were examined approximately every 8 - 10 weeks for all women. Women
with anti-phospholipid antibodies were also given LDA
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Salim 2016 (Continued)
Total number randomised: n = 70 (66 analysed)
From birth to 42 days, all women were prescribed daily enoxaparin 40 mg by subcuta-
neous injection. Otherwise, standard antepartum and peripartum care given
Outcomes Primary outcome: composite of any pregnancy loss after randomisation, pre-eclampsia,
birth of a SGA infant, placental abruption, or objectively documented VTE
Secondary outcomes: GA at birth, preterm birth, mode of delivery, and maternal com-
plications related to enoxaparin use (thrombocytopenia, antepartum bleeding, and symp-
tomatic fracture)
Funding source(s) Not stated in article. Trialists advised that the trial was supported by Emek Medical
Center
Declarations of interest None declared
Information source(s) Primary publication and completed data request. Trial registration at
www.clinicaltrials.gov/ct2/show/NCT01068795 (registered during the trial in 2010)
Notes Cross-over of 1 woman from the fixed- to the adjusted-dose group (ITT analyses carried
out)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation sequence generation pro-
gramme with 1:1 ratio
Allocation concealment (selection bias) Low risk Quote: “The randomisation sequence results were kept
in the delivery ward in a closed study box. The site in-
vestigator enrolled participants after confirming eligibil-
ity. The sequence was concealed until intervention was
assigned (and after obtaining a signed informed consent)
” (study report p. 3)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded trial
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Lack of blinding unlikely to influence objective outcomes
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Assessments were undertaken by the research team and
the participating women, none of whom were blinded
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Salim 2016 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analyses employed. 4 women excluded post-ran-
domisation from the control group with reasons given (2
women delivered at another institution; 1 discontinued
intervention due side-effects and 1 discontinued due to
ineligibility)
Selective reporting (reporting bias) Unclear risk All outcomes specified in Methods are reported. Retro-
spective trial registration
Other bias Low risk No other obvious sources of bias identified
Schleussner 2015
Methods Randomised controlled trial
Participants 449 women were randomised. Data from 38 eligible women were included in this review
Setting: 14 outpatient clinics specialising in recurrent pregnancy loss in Austria and
Germany; 9 were university hospitals, 3 were general women’s hospitals, and 2 were
centres for reproductive medicine
Dates of recruitment: December 2006 to August 2012
Inclusion criteria: women aged over 18 years with at least 2 consecutive early miscar-
riages (< 12 weeks’ gestation) or 1 late miscarriage (≥ 12 weeks’ gestation) and a viable
singleton pregnancy of 5 to 8 weeks’ gestation as detected by ultrasonography. No other
trial participation in 30 days prior to enrolment
Exclusion criteria: previous miscarriages due to chromosomal, uterine, or fetal struc-
tural anomalies or infection; current diabetes mellitus; known nicotine, drug, or alcohol
use; HIV infection; anticipated poor adherence (as judged by investigators); clinical need
for heparin therapy according to the criteria from the ETHIG I trial or any contraindi-
cation to LMWH; homozygous factor V Leiden mutations, homozygous prothrombin
mutations, antiphospholipid antibody syndrome
Interventions Dalteparin (heparin): 5000 IU dalteparin-sodium self-administered daily as a subcu-
taneous injection until 24 weeks’ gestation. Women received 30 syringes at each study
visit and self-administered daily
Total number randomised: n = 226 (220 analysed)
No treatment: no placebo injections. Both groups received multivitamins containing
folic acid
Total number randomised: n = 223 (214 analysed)
Outcomes Primary outcome: ongoing pregnancy rate up to and including the 24th week of gesta-
tion as recorded in the final study visit
Secondary outcomes: live-birth rate/stillbirth; mean duration of gestation at miscar-
riage; preterm birth (34 to 36 weeks, 28 to 33 weeks, < 38 weeks); intrauterine growth
restriction < 5th percentile; pre-eclampsia or HELLP syndrome; placental abruption; sa-
fety outcomes: maternal death; withdrawals due to serious adverse events; serious adverse
events (vaginal haemorrhage; other haemorrhage; cervical incompetence/preterm labour
without birth; GI problems; infection; other); adverse events that were not serious ad-
verse events (vaginal haemorrhage; other haemorrhage; cervical incompetence/preterm
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Schleussner 2015 (Continued)
labour without birth; GI problems; infection; other); complications during birth; fetal
structural abnormalities; thrombocytopenia, osteoporosis
Other: use of concomitant medication; adherence
Funding source(s) “The ETHIG II trial received an unrestricted grant from Pfizer Pharma and was given
the multivitamin supplements free of charge from Merck Selbstmedikation. The funding
sources played no role in the design, conduct, analysis, reporting, or interpretation of
results or the decision to submit the manuscript for publication” (study report p. 603)
Declarations of interest Conflicts provided at: www.acponline.org/authors/icmje/ConflictOfInterestForms.do?
msNum=M14-2062
Dr Bauersachs reports personal fees from Leo, personal fees from Pfizer, during the
conduct of the study; personal fees from LEO, personal fees from Pfizer, personal fees
from Sanofi-Aventis, outside the submitted work
Dr Schleussner reports grants from Pfizer Pharma GmbH Germany, non-financial sup-
port from Merck Selbstmedikation GmbH Germany, during the conduct of the study
Dr Toth reports other from Pfizer (company), during the conduct of the study
Dr Bohlmann reports other from Pfizer, during the conduct of the study
All other authors report nothing to disclose
Information source(s) Primary publication and its web appendices; Abstracts: Schleussner E, Bohlmann M.
Kamin G. et al. Low-molecular-weight heparin for the prevention of habitual abortion
- introduction of the multicentre study ETHIG 2 and discussion of the current data.
Archives of Gynecology and Obstetrics 2012;286(Suppl 1):S220 and Schleussner E,
Kamin G. Seeliger G. Rogenhofer N. Toth B. Low-molecular-weight heparin in recurrent
pregnancy loss-Results of the ETHIG II study. Thrombosis Research 2013;131(Suppl
1):S73
clinicaltrials.gov/ct2/show/NCT00400387
Completed data request form
Notes Trial registration number: NCT00400387
Women from both groups received multivitamins containing folic acid (Femibion 800
Metafolin [Merck]) from allocation up to 24 weeks’ gestation. Women returned for
study visits at 9, 12, 16, 20, and 24 weeks’ gestation. The trial protocol stipulated that
acetylsalicylic acid (ASA) may not be used
The primary focus of the study was prevention of miscarriage. Therefore, while trial
protocol did not foresee the use of LMWH after 24 weeks’ gestation, use of LMWH
beyond this was permitted
Number analysed for the primary outcome was further reduced from 220 to 215 in the
intervention group and from 214 to 211 in the control group; only these women were
included in some secondary outcomes
At least 39 women in the intervention group continued LMWH after 24 weeks and at
least 15 women in the control group began use of LMWH after 24 weeks. These women
continued LMWH to 35 weeks on average
Women who investigators judged would have poor adherence were also excluded
Risk of bias
Bias Authors’ judgement Support for judgement
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Schleussner 2015 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was stratified by week of ges-
tation, trial site, and inherited thrombophilia using the
minimization method described by Pocock and Simon
(14). Using weights of 1 for the stratification factors, 0.
01 for the overall group balance (1:1 ratio), and a ran-
dom component, we chose the group that would mini-
mize differences in the stratification factors between the
groups with 80% probability. The trial statistician pre-
pared the allocation algorithm, which was implemented
at the clinical trial center. Physicians provided the patient
information to the center, where a data manager gener-
ated the group allocation” (study report p. 602)
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Placebo injections were not used, and neither
trial staff nor patients were blinded” (study report p. 601)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Lack of blinding unlikely to influence objective outcomes
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Assessed by local gynaecologists who were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 449 women were randomised; 15 (3%) were excluded
post-randomisation from primary outcome analysis, and
a total of 23 (5%) from birth (secondary) outcome anal-
yses. Numbers and reasons for exclusion similar across
groups
Selective reporting (reporting bias) Low risk Trial protocol provided with published trial report; out-
comes reported as prespecified;
Quote: “No important changes were made to the out-
comes after commencement of the trial” (study report p.
602)
We noted the protocol listed a composite outcome of
late pregnancy complications which was not reported as
such (reported instead as individual outcomes only), but
judged this as low risk of bias
Other bias Low risk No other obvious sources of bias identified
ALAT: alanine aminotransferase; Apgar: appearance, pulse, grimace, activity, respiration; APH: antepartum haemorrhage; APTT: acti-
vated partial thromboplastin time; DNA: deoxyribonucleic acid; FGR: fetal growth restriction; GA: gestational age; HELLP: haemol-
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ysis, elevated liver enzymes, low platelet count; HIV: human immunodeficiency virus; IgA: immunoglobulin A; IgG: Immunoglob-
ulin G; ITT: intention-to-treat; IU: international units; IVF: in vitro fertilisation; kg: kilogram; LMWH: low-molecular-weight
heparin; mg: milligram; MTHFR: methylene-tetrahydrofolate reductase; NICU: neonatal intensive care unit; NS: non-significant;
PET: pre-eclamptic toxaemia; PPH: postpartum haemorrhage; SGA: small-for-gestational age; VTE: venous thromboembolism
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelhafez 2014 No response from trialists
Ahmadi 2017 No response from trialists
Alalaf 2012 Previous loss < 20 weeks’ gestation
Aoki 1993 Previous loss < 20 weeks’ gestation
Baber 1988 No previous loss
Badawy 2008 Previous loss < 20 weeks’ gestation
Bao 2017 No response from trialists
Berle 1980 Authors deceased or unable to be located
Blomqvist 2017 Previous loss < 20 weeks’ gestation
Blumenfeld 1992 Previous loss < 20 weeks’ gestation
Branch 2000 No access to data or GA of previous losses unknown
Brenner 2005 No response from trialists
Carta 2005 Previous loss < 20 weeks’ gestation
Cauchi 1991 Previous loss < 20 weeks’ gestation
Chakravarty 2012 No response from trialists
Check 1995 No response from trialists
Christiansen 1992 No access to data or GA of previous losses unknown
Christiansen 2015 Previous loss < 20 weeks’ gestation
Clark 2010 No access to data or GA of previous losses unknown
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Cohen 1996 No response from trialists
Coomarasamy 2015 Previous loss < 20 weeks’ gestation
Cote-Arsenault 2014 No response from trialists
Coulam 1995 Previous loss < 20 weeks’ gestation
Cowchock 1992 No access to data or GA of previous losses unknown
Cowchock 1995 Previous loss < 20 weeks’ gestation
Cowchock 1997 No access to data or GA of previous losses unknown
Dal Canto 2012 No response from trialists
Dendrinos 2007 Previous loss < 20 weeks’ gestation
DeVeciana 2001 No previous loss
Dolitzky 2006 Data not supplied
El-Zibdeh 2005 Previous loss < 20 weeks’ gestation
Elmahashi 2014 Previous loss < 20 weeks’ gestation
Epperson 2011 No response from trialists
Famina 2015 No previous loss
Farquharson 2002 No access to data or GA of previous losses unknown
Fawzy 2008 No response from trialists
Fuchs 1966 Authors deceased or unable to be located
Gao 2015 No response from trialists
Gatenby 1993 Previous loss < 20 weeks’ gestation
Gerhard 1987 No previous loss
German RSA/IVIG Group 1994 Previous loss < 20 weeks’ gestation
Geva 1998 No previous loss
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Giancotti 2012 No response from trialists
Goel 2006 No response from trialists
Goldzieher 1964 Authors deceased or unable to be located
Gomaa 2014 Previous loss < 20 weeks’ gestation
Gris 1995 Previous loss < 20 weeks’ gestation
Gris 2010 No previous loss
Gris 2011 No previous loss
Harrison 1992 Previous loss < 20 weeks’ gestation
Ho 1991 Previous loss < 20 weeks’ gestation
Illeni 1994 Previous loss < 20 weeks’ gestation
Ismail 2016 Data not supplied
Ismail 2018 No response from trialists
Jablonowska 1999 Previous loss < 20 weeks’ gestation
Johnson 1975 Authors deceased or unable to be located
Johnson 1991 Previous loss < 20 weeks’ gestation
Kaaja 1993 No previous loss
Kaandorp 2010 Previous loss < 20 weeks’ gestation
Kayatas 2013 No response from trialists
Khan 2017 Previous loss < 20 weeks’ gestation
Kilpatrick 1993 No access to data or GA of previous losses unknown
Kim 1997 No response from trialists
Kim 2012 No response from trialists
Klopper 1965 Authors deceased or unable to be located
Kumar 2014 Previous loss < 20 weeks’ gestation
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Kutteh 1996 Data not supplied
Kwon 2012 No previous loss
Laskin 1997 No access to data or GA of previous losses unknown
Laskin 2009 No access to data or GA of previous losses unknown
Lazzarin 2009 Previous loss < 20 weeks’ gestation
Li 1998 No response from trialists
MacDonald 1972 Authors deceased or unable to be located
Maged 2016 Previous loss < 20 weeks’ gestation
Mahmoud 2004 No response from trialists
Malathi 2011 No response from trialists
Malinowski 2003 No response from trialists
Mankuta 1999 No access to data or GA of previous losses unknown
Meng 2016 Previous loss < 20 weeks’ gestation
Mohamed 2014 No response from trialists
Moller 1965 No previous loss
Mowbray 1985 Authors deceased or unable to be located
Nagpal 2001 Authors deceased or unable to be located
Navidian 2018 No previous loss
Nazari 2015 No response from trialists
Noble 2005 Previous loss < 20 weeks’ gestation
Norman 2006 No previous loss
Norman 2016 Data not supplied
Ober 1999 No response from trialists
Pandey 2004 Previous loss < 20 weeks’ gestation
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Pasquier 2015 Previous loss < 20 weeks’ gestation
Pattison 2000 No access to data or GA of previous losses unknown
Perino 1997 Previous loss < 20 weeks’ gestation
Prietl 1992 No previous loss
Quenby 1992 Previous loss < 20 weeks’ gestation
Quenby 1994 Previous loss < 20 weeks’ gestation
Quenby 2007 Previous loss < 20 weeks’ gestation
Qureshi 2005 No previous loss
Raddatz 2005 Previous loss < 20 weeks’ gestation
Rafiee 2015 Previous loss < 20 weeks’ gestation
Rai 1997 No response from trialists
Rai 2005 No response from trialists
Rajan 1993 No access to data or GA of previous losses unknown
Reijnders 1988 No response from trialists
Reznikoff-Etievant 1994 Authors deceased or unable to be located
Rodger 2014 Data not supplied
Saad 2014 No response from trialists
Salman 2012 No response from trialists
Samantha 2013 No previous loss
Scarpellini 2009 Previous loss < 20 weeks’ gestation
Scarpellini 2017 No response from trialists
Schisterman 2014 Previous loss < 20 weeks’ gestation
Scott 1996 No access to data or GA of previous losses unknown
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Shaaban 2017 Previous loss < 20 weeks’ gestation
Sharifi Saki 2015 No response from trialists
Shearman 1963 Authors deceased or unable to be located
Shefras 1995 No previous loss
Shu 2002 Previous loss < 20 weeks’ gestation
Silver 1993 No response from trialists
Smitz 1992 No previous loss
Sondergaard 1985 No previous loss
Stephenson 2004 No previous loss
Stephenson 2010 Previous loss < 20 weeks’ gestation
Stray-Pedersen 1996 Previous loss < 20 weeks’ gestation
Sun 2010 No response from trialists
Svigos 1982 Previous loss < 20 weeks’ gestation
Swyer 1953 Previous loss < 20 weeks’ gestation
Tang 2013 Previous loss < 20 weeks’ gestation
Tognoni 1980 No previous loss
Triolo 2003 Previous loss < 20 weeks’ gestation
Tulppala 1997 No response from trialists
Turner 1966 No previous loss
Vahid Dastjerdi 1999 No response from trialists
Van Hoorn 2016 No previous loss
Vaquero 2001 Previous loss < 20 weeks’ gestation
Visser 2011 No response from trialists
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Walch 2005 Previous loss < 20 weeks’ gestation
Xiao 2013 Previous loss < 20 weeks’ gestation
Zafardoust 2017 Previous loss < 20 weeks’ gestation
Zolghadri 2010 No response from trialists
GA: gestational age
Characteristics of ongoing studies [ordered by study ID]
Alves 2014
Trial name or title The BRAzil MAGnesium (BRAMAG) trial: a randomised clinical trial of oral magnesium supplementation
in pregnancy for the prevention of preterm birth and perinatal and maternal morbidity
Methods Randomised controlled trial
Participants Inclusion criteria: women aged 18 - 45 years, 12 weeks 1 day to 20 weeks 6 days gestation, with accurate
estimated date of confinement (based on last menstrual period among women with a regular menstrual cycle,
or by a first trimester pregnancy dating ultrasound), with a singleton pregnancy, currently residing within
Recife or Petrolina, with 1 or more of the following risk factors, related to:
• a prior pregnancy: preterm delivery at 24 weeks 1 day to < 36 weeks 6 days gestation, stillbirth at
more than 20 weeks 1 day gestation, placental abruption, pre-eclampsia or eclampsia, a live born infant
small-for-gestational age (< 10th percentile), or a live-born infant with birthweight < 2500 g;
• the current pregnancy: nulliparity, chronic hypertension, type 1 or 2 diabetes mellitus, aged > 35
years, obesity (BMI > 30 kg/m2), smoking cigarettes currently.
Exclusion criteria: women with known uncontrolled hyperthyroidism, known active parathyroid disease of
any kind, chronic kidney disease (defined by an estimated glomerular filtration rate < 60 mg/min/1.73 m2,
with chronic diarrhoeal disease, with high serum magnesium concentration > 9.5 mmol/dL
Interventions Oral magnesium: magnesium citrate capsules (150 mg elemental Mg2+ citrate per capsule), manufactured
by IMIP’s Department of Pharmacology; 1 capsule twice daily starting at 12 to 20 weeks’ gestation and
continued until birth
Note: discrepancy between trial registration (160 mg) and published trial protocol (150 mg)
Placebo: matched placebo capsules, manufactured by IMIP’s Department of Pharmacology, and identical
in colour and shape; 1 capsule twice daily
Outcomes Composite perinatal outcome: preterm birth before 37 weeks’ gestation; stillbirth after 20 weeks’ gestation;
neonatal death before 28 days after birth; or small-for-gestational-age birthweight under the 3rd percentile
Composite maternal outcome: pre-eclampsia or eclampsia arising before 37 weeks’ gestation; severe non-
proteinuric hypertension arising before 37 weeks’ gestation; placental abruption; maternal stroke during
pregnancy or ≤ 7 days after delivery; or maternal death during pregnancy or ≤ 7 days after delivery
Note: trial registration reports preterm birth as the primary outcome of interest, and gestational diabetes
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mellitus, pre-eclampsia, and low birthweight as secondary outcomes of interest
Starting date March 2014
Contact information Dr Joao G Alves: joaoguilherme@imip.org.br
Instituto de Medicina Integral Prof Fernando Figueira, Recife, Pernambuco, Brazil
Information source(s) Published protocol: Alves JG, et al. The BRAzil MAGnesium (BRAMAG) trial: a randomised clinical trial
of oral magnesium supplementation in pregnancy for the prevention of preterm birth and perinatal and
maternal morbidity. BMC Pregnancy and Childbirth 2014;14:222
Trial registration: clinicaltrials.gov/show/NCT02032186
Notes Clinical trials identifier: NCT02032186
Estimated enrolment: 3000
Recruitment status at submission of this review: the official recruitment status of this trial is unknown.
Correspondence with the trialists indicated that the trial was disrupted by the Zika virus. The trial had been
completed but analyses of the data have yet to begin
De Jong 2015
Trial name or title ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited throm-
bophilia
Methods Randomised controlled trial
Participants Inclusion criteria: women aged 18 to 42 years, with recurrent miscarriage and/or intra-uterine fetal deaths
(that is ≥ 2 miscarriages or intra-uterine fetal deaths, irrespective of gestational age) (not necessarily con-
secutive), with confirmed inherited thrombophilia (factor V Leiden mutation; prothrombin gene mutation
(G20210A); protein S deficiency; protein C deficiency; antithrombin deficiency), with pregnancy confirmed
by urine pregnancy test, willing and able to give informed consent
Exclusion criteria: duration of current pregnancy ≥ 7 weeks, based on first day of last menstruation;
indication for anticoagulant treatment during pregnancy (e.g. prosthetic heart valves, a history of venous
thromboembolism or antiphospholipid syndrome); contraindications to LMWH (previous heparin-induced
thrombocytopenia, active bleeding or renal insufficiency with creatinine clearance of < 30 mL/minute);
known allergy to at least 3 different LMWH preparations; previous inclusion in the ALIFE2 study (for
another pregnancy)
Interventions Low-molecular-weight heparin: LMWH in addition to standard pregnancy surveillance. Women will im-
mediately begin injecting themselves once daily in either the upper leg or abdomen with Clexane (enoxa-
parin, Sanofi-Aventis Netherlands B.V., Kampenringweg 45 E, 2803 PE GOUDA, the Netherlands) 40
mg LMWH, 100 mg/mL, 0.4 mL syringe. If the recommended intervention is unavailable another type of
LMWH in a dosage equivalent to enoxaparin 40 mg may be chosen (see published protocol). Women will
continue the treatment until the first signs of labour, or in the case of planned delivery, according to local
policy (at least 12 hours prior to caesarean section/neuraxial anaesthesia). Women will be randomised upon
confirmation of pregnancy and treatment will continue until start of labour
Standard care: women in the control group will receive standard pregnancy surveillance
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Outcomes Primary: live birth
Secondary:
Efficacy: ongoing pregnancy beyond 12 weeks’ gestation; pre-eclampsia; HELLP syndrome; intrauterine
growth restriction; placental abruption; premature birth; intra-uterine fetal death; major congenital anoma-
lies; composite of confirmed deep vein thrombosis and confirmed pulmonary embolism;
Safety: clinically-relevant bleeding; postpartum bleeding and severe postpartum bleeding; major bleeding;
clinically relevant non-major bleeding; minor bleeding, including increased tendency to bruising not fulfilling
the criteria for clinically relevant non-major bleeding; heparin-induced thrombocytopenia (defined according
to ACCP criteria); allergic reactions (redness or itching) localised at the injection site of LMWH; type 1
allergy: e.g. generalised symptoms including anaphylaxis
Starting date Planned starting date: 1 September 2012
Start of recruitment: December 2012
Contact information Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
Scientific queries: Dr S Middeldorp
Phone: +31 20 5665976
Email: alife@amc.uva.nl
General queries: Dr Luuk Scheres, MD
Phone: +31 20 5667516
Email: l.j.scheres@amc.uva.nl
Information source(s) Published protocol: De Jong PG et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent
miscarriage and inherited thrombophilia-study protocol for a randomised controlled trial. Trials 2015;16:
208.
Trial website: www.studies-obsgyn.nl/ALIFE2/page.asp?page id=1344
Notes Clinical trials identifier: NTR3361
Target sample size: 399
Recruitment status at submission of this review: recruiting
El-refaie 2016
Trial name or title Vaginal progesterone versus cervical cerclage for pregnant women with sonographic short cervix and history
of preterm labour and/or midtrimester miscarriage
Methods Randomised controlled trial
Participants Inclusion criteria: women aged 20 - 35 years, with a singleton pregnancy, a history of preterm labour and/
or mid-trimester miscarriage in a previous pregnancy, and cervical length of 15 - 25 mm by transvaginal
sonography at 16 - 25 weeks’ gestation
Exclusion criteria: women aged < 20 or > 35 years, with congenital uterine malformations, multi-fetal
pregnancies, known major fetal structural or chromosomal abnormality, known allergy or contraindication
(relative or absolute) to progesterone therapy, presence of contraindication to cervical cerclage, medical
conditions complicating pregnancy, vaginal bleeding
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Interventions Progesterone: vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United
Kingdom) 400 mg/day
Cervical cerclage: cervical cerclage by transvaginal placement of purse-string stitch suture at the cervicov-
aginal junction, without mobilisation of the urinary bladder (McDonald cervical cerclage)
Outcomes Primary: preterm labour before 35 weeks
Secondary: delivery before 37 weeks; low birthweight (< 2500 g); neonatal respiratory distress syndrome;
early neonatal death
Starting date February 2016
Contact information Dr Waleed El-refaie: wrefaie@yahoo.com
Obstetrics and Gynecology Department in Mansoura University Hospital Recruiting, Mansoura, Dakahlia,
Egypt, 35111
Information source(s) Trial registration: clinicaltrials.gov/ct2/show/NCT02673359
Correspondence with investigators
Notes Clinical trials identifier: NCT02673359
Estimated enrolment: 220
Estimated study completion date: June 2019
Final data collection date for primary outcome measure: May 2019
Recruitment status at submission of this review: recruiting
Hezelgrave 2016
Trial name or title Rationale and design of SuPPoRT: a multi-centre randomised controlled trial to compare 3 treatments:
cervical cerclage, cervical pessary and vaginal progesterone, for the prevention of preterm birth in women
who develop a short cervix
Methods Randomised controlled trial (3-armed)
Participants Women aged 18 - 50 with a singleton pregnancy and a short cervix (< 25 mm on transvaginal ultrasound),
between 14 and 23 + 6 weeks’ gestation and 1 or more of the following risk factors: previous preterm premature
rupture of the fetal membranes; previous preterm birth/second trimester loss; any cervical procedure to treat
abnormal smears; or Incidental finding of a short cervix on ultrasound scan
Interventions Cervical cerclage: performed within 7 days of recruitment
Vaginal progesterone: 200 mg pessary self-inserted once daily from recruitment until 34 weeks’ gestation
or delivery (whichever occurs first)
Cervical pessary: pessary inserted by clinician within 7 days of recruitment and removed by clinician at
37 weeks’ gestation (or in the event of established labour). Rescue pessary inserted if cervix shortens and
membranes become visible prior to 24 weeks’ gestation
Outcomes Primary: preterm birth prior to 37 weeks
Secondary: adverse perinatal outcome (composite of stillbirth and neonatal death prior to discharge or 1
(or more) of intraventricular haemorrhage, periventricular leukomalacia, hypoxic ischaemic encephalopathy,
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necrotising enterocolitis, bronchopulmonary dysplasia and sepsis); delivery < 30 and 34 completed weeks’
gestation; gestation at delivery; time between intervention and delivery; requirement for rescue cerclage;
other maternal and fetal outcomes: clinical course, therapies administered, maternal and fetal morbidity and
mortality data until discharge or 28 days postnatal (whichever soonest); participant and clinician’s perceptions
of treatment; health costs at 28 days post-natal; biochemical endpoints
Starting date July 2015
Contact information Dr Natasha Hezelgrave
natasha.hezelgrave@kcl.ac.uk
King’s College London & St Thomas’s Hospital, London, United Kingdom
Information source(s) Published protocol: Hezelgrave NL, Watson HA, Ridout A, Diab F, Seed PT, Chin-Smith E, et al. Rationale
and design of SuPPoRT: a multi-centre randomised controlled trial to compare 3 treatments: cervical cerclage,
cervical pessary and vaginal progesterone, for the prevention of preterm birth in women who develop a short
cervix. BMC Pregnancy and Childbirth 2016;16(1):358
Trial registration: doi.org/10.1186/ISRCTN13364447
Notes EudraCT identifier: 2015-000456-15
Estimated enrolment: 540
Estimated study completion date: July 2018
Recruitment status at submission of this review: no longer recruiting. Reporting of results anticipated
April - July 2019
McLindon 2011
Trial name or title Public title: Does using progesterone reduce the miscarriage rate in high risk pregnancies?
Scientific title: In pregnant women with previous subfertility, does progesterone supplementation decrease
the likelihood of miscarriage?
Methods Randomised controlled trial
Participants Inclusion criteria: women aged > 18 years with previous diagnosis of subfertility (no pregnancy after 12
months random unprotected intercourse, a history of 3 or more miscarriages, failing to achieve an ongoing
pregnancy after 12 months of random unprotected intercourse); pregnancy less than 7 weeks + 0 days
Exclusion criteria: pregnancy following Assisted Reproductive Technologies
Interventions Progesterone: 400 mg progesterone (pessary), nightly from 7 - 12 weeks
Placebo: placebo pessary, carrier compound of the intervention pessary, identical in appearance
Outcomes Primary: miscarriage (pregnancy loss < 20 weeks’ gestation)
Secondary: antepartum haemorrhage; presentation with bleeding after 20 weeks’ gestation and volume of
blood lost; birthweight; congenital anomaly; gestation at birth; livebirth; threatened miscarriage; presentation
with bleeding or pain or both prior to 20 weeks
Starting date January 2012
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Contact information Dr Luke McLindon: lucas.mclindon@mater.org.au
Mater Mothers’ Hospital, Raymond Terrace, South Brisbane, Queensland 4101 Australia




Notes Clinical trials identifier: ACTRN12611000401954
Anticipated sample size: 344
Estimated study completion date: December 2017
Recruitment status at submission of this review: recruiting
Rodger 2017
Trial name or title Antiphospholipid syndrome low-molecular-weight heparin pregnancy loss evaluation: The pilot study (AP-
PLE)
Methods Randomised controlled trial (feasibility trial)
Participants Women aged 18 years or more with confirmed pregnancy and antiphospholipid syndrome, plus 2 or more
unexplained pregnancy losses before 10 weeks’ gestation, and/or 1 or more unexplained pregnancy losses at
or after 10 weeks’ gestation
Interventions Low-dose aspirin: daily 81 mg oral LDA from randomisation until delivery
Low-molecular-weight heparin: and low-dose aspirin: LMWH and daily LDA (LMWH dosages at dis-
cretion of attending physician) until 37 weeks’ gestation. Suggested regimen: daily 4500 IU tinzaparin by
subcutaneous injection until 20 weeks’ gestation, followed by 4500 IU by subcutaneous injection twice daily
until 37 weeks’ gestation
Outcomes Primary: feasibility (mean recruitment rate per centre per month)
Secondary: essential documents (proportion of sites requiring > 18 months to obtain all approvals/autho-
risations; eligibility (proportion among those screened); consent (among those eligible); withdrawals/loss to
follow-up; cross-over rate; drug compliance; non-consent and reasons
Starting date November 2017
Contact information Marc Rodger, MD
mrodger@toh.ca
Ottawa Hospital Research Institute, Canada
Information source(s) Trial registration: clinicaltrials.gov/ct2/show/NCT03100123
Notes Clinical trials identifier: NCT03100123
Estimated enrolment: 24 (feasibility trial)
Estimated primary completion date: November 2019
Estimated study completion date: January 2020
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Recruitment status at submission of this review: recruiting
Schreiber 2017
Trial name or title HYPATIA: A study of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospho-
lipid Antibodies
Methods Randomised controlled trial
Participants Women with known persistent antiphospholipid antibodies who are planning pregnancy
Interventions Hydroxychloroquine (HCQ): 200 mg film-coated tablet taken orally
Placebo: placebo tablet taken orally
Outcomes Primary: composite of 3 principal aPL-related adverse pregnancy outcomes: 1 or more pregnancy loss(es)
(either < 10 weeks’ gestation or beyond 10 weeks’ gestation of a morphologically normal fetus documented by
ultrasound or by direct examination of the fetus) and premature birth of a morphologically normal neonate
before 34 weeks due to any of: pre-eclampsia, eclampsia, recognised features of placental insufficiency
Secondary: individual components of the composite primary outcomes, plus: gestational age at delivery;
birthweight; caesarean birth; Apgar score < 7 at 5 minutes; neonatal morbidity (bleeding or thrombotic
complications, infections, congenital abnormalities); days to hospital discharge following delivery (mother
and child); thrombotic events in the mother during pregnancy and 6 weeks postpartum; days of neonate in
special care; safety and tolerability of hydroxychloroquine in the mother and neonate
Starting date March 2018
Contact information Prof Beverley J Hunt
beverley.hunt@gstt.nhs.uk
Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
Information source(s) Published protocol: Schreiber K, Breen K, Robinson SE, Hunt BJ, Jacobsen S, Cohen H, et al. Hydroxy-
chloroquine to improve pregnancy outcome in women with antiphospholipid antibodies (HYPATIA) pro-
tocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to stan-
dard treatment in pregnant women with antiphospholipid syndrome or antibodies. Seminars in Thrombosis
and Hemostasis 2017;43(6):562-571
Trial registration: www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002256-25
Notes EudraCT Number: 2016-002256-25
Target sample size: 328
Recruitment status at submission of this review: ongoing
ACCP: American College of Chest Physicians; APL: antiphospholipid antibodies; BMI: body mass index; g: gram; HELLP: haemolysis,
elevated liver enzymes, low platelet count; IU: international units; kg: kilogram; LDA: low-dose aspirin; LMWH: low-molecular-
weight heparin; mg: milligram; mL: millilitre; mm: millimetre
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D A T A A N D A N A L Y S E S
Comparison 1. LMWH vs no treatment/standard care




participants Statistical method Effect size
1 Stillbirth 3 122 Risk Ratio (M-H, Fixed, 95% CI) 2.58 [0.40, 16.62]
2 Neonatal death 3 122 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse perinatal outcome
(composite outcome including
stillbirth, neonatal death, and
major neonatal morbidity)
2 77 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.20, 3.32]
4 Adverse maternal psychological
effects (anxiety, depression or
complicated grief )
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.90]
5 Perinatal mortality 3 122 Risk Ratio (M-H, Fixed, 95% CI) 2.58 [0.40, 16.62]
6 Very preterm birth (28 to < 32
weeks)
3 114 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.31, 2.82]
7 Late preterm birth (32 to < 37
weeks)
3 114 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.36, 1.66]
8 Any preterm birth (birth < 37
weeks)
3 114 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.58, 1.74]
9 Birthweight 3 109 Mean Difference (IV, Fixed, 95% CI) -225.26 [-546.36,
95.84]
10 Low birthweight 2 85 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.45, 2.21]
11 Small-for-gestational age 3 115 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.57, 3.08]
12 Apgar score less than seven at
five minutes
2 69 Risk Ratio (M-H, Fixed, 95% CI) 3.33 [0.58, 19.29]
13 Respiratory distress syndrome 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Neonatal jaundice 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Adherence to the intervention 2 85 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.88, 1.22]
16 Caesarean birth (elective) 3 115 Risk Ratio (M-H, Fixed, 95% CI) 2.05 [0.83, 5.07]
17 Caesarean birth (emergency) 3 115 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.39, 1.99]
18 Induction of labour 2 85 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.33, 1.22]
19 Instrumental vaginal birth 1 40 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.52]
20 Placental abruption 3 115 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.04, 2.91]
21 Pre-eclampsia 3 115 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.04, 4.10]
22 Gestational diabetes 2 85 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.50, 3.25]
23 Chorioamnionitis 2 85 Risk Ratio (M-H, Fixed, 95% CI) 1.6 [0.33, 7.86]
24 Postpartum haemorrhage 2 70 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.27, 9.45]
25 Serious maternal outcome
(death; cardiac arrest;
respiratory arrest; admission to
intensive care)
3 123 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 6.27]
26 Maternal antenatal admission 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.15, 2.38]
27 Duration of maternal hospital
stay
1 45 Mean Difference (IV, Fixed, 95% CI) -0.02 [-2.01, 1.97]
28 Duration of neonatal hospital
stay
1 45 Mean Difference (IV, Fixed, 95% CI) 1.70 [-8.70, 12.10]
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29 Admission to the neonatal
intensive care unit
1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.27, 2.38]
30 Duration of neonatal intensive
care unit stay
1 10 Mean Difference (IV, Fixed, 95% CI) 4.20 [-25.13, 33.53]
Comparison 2. LDA vs placebo




participants Statistical method Effect size
1 Stillbirth 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.06, 12.01]
2 Neonatal death 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 6.38]
3 Adverse perinatal outcome
(composite outcome including
stillbirth, neonatal death, and
major neonatal morbidity)
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.03, 2.34]
4 Perinatal mortality 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.04, 4.06]
5 Very preterm birth (28 to < 32
weeks)
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 6.38]
6 Late preterm birth (32 to < 37
weeks)
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.06, 12.01]
7 Any preterm birth (birth < 37
weeks)
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.04, 4.06]
8 Birthweight 1 24 Mean Difference (IV, Fixed, 95% CI) 790.0 [295.03,
1284.97]
9 Low birthweight 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.03, 2.34]
10 Small-for-gestational age 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 6.38]
11 Respiratory distress syndrome 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 6.38]
12 Adherence to the intervention 1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.86, 1.17]
13 Caesarean birth (elective) 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.18, 2.24]
14 Caesarean birth (emergency) 1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.38, 7.55]
15 Induction of labour 1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.38, 7.55]
16 Instrumental vaginal birth 1 24 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.12, 57.44]
17 Placental abruption 1 24 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.12, 57.44]
18 Pre-eclampsia 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.14, 5.06]
19 Gestational diabetes 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.04, 4.06]
20 Postpartum haemorrhage 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 6.38]
21 Serious maternal outcome
(death; cardiac arrest;
respiratory arrest; admission to
intensive care)
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Antenatal care attendance 1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.86, 1.17]
23 Duration of maternal hospital
stay
1 24 Mean Difference (IV, Fixed, 95% CI) 0.0 [-2.41, 2.41]
24 Duration of neonatal hospital
stay
1 24 Mean Difference (IV, Fixed, 95% CI) -2.0 [-4.41, 0.41]
25 Admission to the neonatal
intensive care unit
1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.58, 3.75]
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26 Duration of neonatal intensive
care unit stay
1 11 Mean Difference (IV, Fixed, 95% CI) -2.0 [-5.29, 1.29]
Comparison 3. LDA + LMWH vs LDA alone




participants Statistical method Effect size
1 Stillbirth 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 6.23]
2 Neonatal death 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse perinatal outcome
(composite outcome including
stillbirth, neonatal death, and
major neonatal morbidity)
1 29 Risk Ratio (M-H, Fixed, 95% CI) 2.44 [0.29, 20.75]
4 Perinatal mortality 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 6.23]
5 Very preterm birth (28 to < 32
weeks)
1 29 Risk Ratio (M-H, Fixed, 95% CI) 2.47 [0.11, 56.03]
6 Late preterm birth (32 to < 37
weeks)
1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.06, 11.77]
7 Any preterm birth (birth < 37
weeks)
1 29 Risk Ratio (M-H, Fixed, 95% CI) 3.25 [0.41, 25.64]
8 Birthweight 1 29 Mean Difference (IV, Fixed, 95% CI) -650.0 [-1210.33, -
89.67]
9 Low birthweight 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.17, 15.99]
10 Small-for-gestational age 1 29 Risk Ratio (M-H, Fixed, 95% CI) 2.47 [0.11, 56.03]
11 Respiratory distress syndrome 1 29 Risk Ratio (M-H, Fixed, 95% CI) 2.47 [0.11, 56.03]
12 Adherence to the intervention 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.88, 1.14]
13 Caesarean birth (elective) 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.40, 4.63]
14 Caesarean birth (emergency) 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.03, 1.60]
15 Induction of labour 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.17, 2.25]
16 Instrumental vaginal birth 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.06, 11.77]
17 Placental abruption 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.06, 11.77]
18 Pre-eclampsia 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.04, 4.00]
19 Gestational diabetes 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 6.23]
20 Postpartum haemorrhage 1 29 Risk Ratio (M-H, Fixed, 95% CI) 2.47 [0.11, 56.03]
21 Serious maternal outcome
(death; cardiac arrest;
respiratory arrest; admission to
intensive care)
1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Antenatal care attendance 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.88, 1.14]
23 Duration of maternal hospital
stay
1 29 Mean Difference (IV, Fixed, 95% CI) 0.0 [-2.55, 2.55]
24 Duration of neonatal hospital
stay
1 29 Mean Difference (IV, Fixed, 95% CI) 2.0 [-0.55, 4.55]
25 Admission to the neonatal
intensive care unit
1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.62, 2.18]
26 Duration of neonatal intensive
care unit stay
1 17 Mean Difference (IV, Fixed, 95% CI) 2.0 [-0.38, 4.38]
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participants Statistical method Effect size
1 Stillbirth 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.01, 5.30]
2 Neonatal death 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.01, 5.30]
3 Adverse perinatal outcome
(composite outcome including
stillbirth, neonatal death, and
major neonatal morbidity)
1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.17, 2.80]
4 Perinatal mortality 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.68]
5 Very preterm birth (28 to < 32
weeks)
1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.05, 9.86]
6 Late preterm birth (32 to < 37
weeks)
1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.05, 9.86]
7 Any preterm birth (birth < 37
weeks)
1 27 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.30, 6.25]
8 Birthweight 1 27 Mean Difference (IV, Fixed, 95% CI) 140.0 [-501.26, 781.
26]
9 Low birthweight 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.09, 2.31]
10 Small-for-gestational age 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.05, 9.86]
11 Respiratory distress syndrome 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.05, 9.86]
12 Adherence to the intervention 1 27 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.87, 1.16]
13 Caesarean birth (elective) 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.30, 2.50]
14 Caesarean birth (emergency) 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.04, 3.34]
15 Induction of labour 1 27 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.20, 5.19]
16 Instrumental vaginal birth 1 27 Risk Ratio (M-H, Fixed, 95% CI) 2.12 [0.09, 47.68]
17 Placental abruption 1 27 Risk Ratio (M-H, Fixed, 95% CI) 2.12 [0.09, 47.68]
18 Pre-eclampsia 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.04, 3.34]
19 Gestational diabetes 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.68]
20 Postpartum haemorrhage 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.05, 9.86]
21 Serious maternal outcome
(death; cardiac arrest;
respiratory arrest; admission to
intensive care)
1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Antenatal care attendance 1 27 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.87, 1.16]
23 Duration of maternal hospital
stay
1 27 Mean Difference (IV, Fixed, 95% CI) 0.0 [-2.64, 2.64]
24 Duration of neonatal hospital
stay
1 27 Mean Difference (IV, Fixed, 95% CI) 0.0 [-2.64, 2.64]
25 Admission to the neonatal
intensive care unit
1 27 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.72, 4.10]
26 Duration of neonatal intensive
care unit stay
1 14 Mean Difference (IV, Fixed, 95% CI) 0.0 [-3.48, 3.48]
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Comparison 5. LMWH vs LDA




participants Statistical method Effect size
1 Stillbirth 1 22 Risk Ratio (M-H, Fixed, 95% CI) 3.55 [0.16, 78.56]
2 Neonatal death 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse perinatal outcome
(composite outcome including
stillbirth, neonatal death, and
major neonatal morbidity)
1 22 Risk Ratio (M-H, Fixed, 95% CI) 3.55 [0.16, 78.56]
4 Perinatal mortality 1 22 Risk Ratio (M-H, Fixed, 95% CI) 3.55 [0.16, 78.56]
5 Very preterm birth (28 to < 32
weeks)
1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Late preterm birth (32 to < 37
weeks)
1 22 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.09, 16.84]
7 Any preterm birth (birth < 37
weeks)
1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.06, 5.69]
8 Birthweight 1 22 Mean Difference (IV, Fixed, 95% CI) 75.0 [-151.69, 301.
69]
9 Low birthweight 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.06, 5.69]
10 Small-for-gestational age 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.06, 5.69]
11 Apgar score less than seven at
five minutes
1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.16, 3.88]
12 Respiratory distress syndrome 1 22 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.09, 16.84]
13 Neonatal jaundice 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.47, 1.72]
14 Caesarean birth (elective) 1 22 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.20, 7.05]
15 Caesarean birth (emergency) 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.06, 5.69]
16 Induction of labour 1 22 Risk Ratio (M-H, Fixed, 95% CI) 8.27 [0.48, 143.35]
17 Instrumental vaginal birth 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Placental abruption 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Pre-eclampsia 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.06, 5.69]
20 Gestational diabetes 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Postpartum haemorrhage 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Serious maternal outcome
(death; cardiac arrest;
respiratory arrest; admission to
intensive care)
1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Breastfeeding 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.35, 2.64]
24 Maternal antenatal admission 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.06, 5.69]
25 Duration of maternal hospital
stay
1 22 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.19, 0.19]
26 Duration of neonatal hospital
stay
1 22 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.30, 0.30]
27 Admission to the neonatal
intensive care unit
1 22 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.09, 16.84]
28 Duration of neonatal intensive
care unit stay
1 2 Mean Difference (IV, Fixed, 95% CI) 0.22 [-8.52, 8.96]
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Comparison 6. LMWH (adjusted dose) vs LMWH (fixed dose)




participants Statistical method Effect size
1 Stillbirth 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Very preterm birth (28 to < 32
weeks)
1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.07, 4.95]
3 Late preterm birth (32 to < 37
weeks)
1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.01, 4.00]
4 Any preterm birth (birth <
37weeks)
1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.04, 1.95]
5 Birthweight 1 13 Mean Difference (IV, Fixed, 95% CI) 812.0 [-257.81,
1881.81]
6 Low birthweight 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.05, 2.83]
7 Small-for-gestational age 1 13 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.09, 14.92]
8 Apgar score less than seven at
five minutes
1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Adherence to the intervention 1 13 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.76, 1.31]
10 Caesarean birth (elective) 1 13 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.09, 14.92]
11 Caesarean birth (emergency) 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.07, 4.95]
12 Induction of labour 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.7 [0.28, 1.77]
13 Instrumental vaginal birth 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Placental abruption 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 7.93]
15 Pre-eclampsia 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 7.93]
16 Gestational diabetes 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 7.93]
17 Chorioamnionitis 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Postpartum haemorrhage 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.01, 2.64]
19 Serious maternal outcome
(death, cardiac arrest,
respiratory arrest, admission to
intensive care)
1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Admission to neonatal intensive
care unit
1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.07, 4.95]
Comparison 7. Leukocyte immunisation vs placebo




participants Statistical method Effect size
1 Stillbirth 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Neonatal death 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse perinatal outcome
(composite outcome including
stillbirth, neonatal death, and
major neonatal morbidity)
1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Perinatal mortality 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5 Very preterm birth (28 to < 32
weeks)
1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Late preterm birth (32 to < 37
weeks)
1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 5.33]
7 Any preterm birth (birth < 37
weeks)
1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 5.33]
8 Birthweight 1 4 Mean Difference (IV, Fixed, 95% CI) 1195.0 [273.35,
2116.65]
9 Low birthweight 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 5.33]
10 Small-for-gestational age 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Apgar score less than seven at
five minutes
1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Adherence to the intervention 1 4 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.49, 2.05]
13 Caesarean birth (elective) 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Caesarean birth (emergency) 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 5.33]
15 Induction of labour 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Instrumental vaginal birth 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Placental abruption 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Pre-eclampsia 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Gestational diabetes 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Chorioamnionitis 1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Serious maternal outcome
(death; cardiac arrest;
respiratory arrest; admission to
intensive care)
1 4 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 8. Intravenous IgG vs placebo




participants Statistical method Effect size
1 Stillbirth 2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.16, 3.40]
2 Neonatal death 2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse perinatal outcome
(composite outcome including
stillbirth, neonatal death, and
major neonatal morbidity)
2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.16, 3.40]
4 Perinatal mortality 2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.16, 3.40]
5 Very preterm birth (28 to < 32
weeks)
2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Late preterm birth (32 to < 37
weeks)
2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.03, 7.52]
7 Any preterm birth (birth < 37
weeks)
2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.03, 7.52]
8 Low birthweight 2 7 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.24, 67.71]
9 Small-for-gestational age 1 2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Apgar score less than seven at
five minutes
2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Respiratory distress syndrome 1 2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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12 Neonatal jaundice 1 2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Adherence to the intervention 2 13 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.69, 1.44]
14 Caesarean birth (elective) 2 7 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.18, 12.46]
15 Caesarean birth (emergency) 2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Induction of labour 2 7 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.24, 37.67]
17 Instrumental vaginal birth 2 7 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.21, 6.35]
18 Placental abruption 2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Pre-eclampsia 2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Gestational diabetes 2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Chorioamnionitis 2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Postpartum haemorrhage 1 2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Serious maternal outcome
(death; cardiac arrest;
respiratory arrest; admission to
intensive care)
2 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
24 Admission to the neonatal
intensive care unit
1 2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 LMWH vs no treatment/standard care, Outcome 1 Stillbirth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 1 Stillbirth
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 1/20 0/20 35.2 % 3.00 [ 0.13, 69.52 ]
Rey 2009 0/25 0/20 Not estimable
Schleussner 2015 2/17 1/20 64.8 % 2.35 [ 0.23, 23.75 ]
Total (95% CI) 62 60 100.0 % 2.58 [ 0.40, 16.62 ]
Total events: 3 (LMWH), 1 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
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Analysis 1.2. Comparison 1 LMWH vs no treatment/standard care, Outcome 2 Neonatal death.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 2 Neonatal death
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 0/20 0/20 Not estimable
Rey 2009 0/25 0/20 Not estimable
Schleussner 2015 0/17 0/20 Not estimable
Total (95% CI) 62 60 Not estimable
Total events: 0 (LMWH), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
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Analysis 1.3. Comparison 1 LMWH vs no treatment/standard care, Outcome 3 Adverse perinatal outcome
(composite outcome including stillbirth, neonatal death, and major neonatal morbidity).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 3 Adverse perinatal outcome (composite outcome including stillbirth, neonatal death, and major neonatal morbidity)
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 1/20 3/20 76.6 % 0.33 [ 0.04, 2.94 ]
Schleussner 2015 2/17 1/20 23.4 % 2.35 [ 0.23, 23.75 ]
Total (95% CI) 37 40 100.0 % 0.81 [ 0.20, 3.32 ]
Total events: 3 (LMWH), 4 (Placebo or no treatment)
Heterogeneity: Chi2 = 1.46, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
Analysis 1.4. Comparison 1 LMWH vs no treatment/standard care, Outcome 4 Adverse maternal
psychological effects (anxiety, depression or complicated grief).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 4 Adverse maternal psychological effects (anxiety, depression or complicated grief)
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 1/20 1/20 100.0 % 1.00 [ 0.07, 14.90 ]
Total (95% CI) 20 20 100.0 % 1.00 [ 0.07, 14.90 ]
Total events: 1 (LMWH), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
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Analysis 1.5. Comparison 1 LMWH vs no treatment/standard care, Outcome 5 Perinatal mortality.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 5 Perinatal mortality
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 1/20 0/20 35.2 % 3.00 [ 0.13, 69.52 ]
Rey 2009 0/25 0/20 Not estimable
Schleussner 2015 2/17 1/20 64.8 % 2.35 [ 0.23, 23.75 ]
Total (95% CI) 62 60 100.0 % 2.58 [ 0.40, 16.62 ]
Total events: 3 (LMWH), 1 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
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Analysis 1.6. Comparison 1 LMWH vs no treatment/standard care, Outcome 6 Very preterm birth (28 to <
32 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 6 Very preterm birth (28 to < 32 weeks)
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 2/20 2/20 34.6 % 1.00 [ 0.16, 6.42 ]
Rey 2009 2/25 3/20 57.6 % 0.53 [ 0.10, 2.89 ]
Schleussner 2015 1/13 0/16 7.8 % 3.64 [ 0.16, 82.62 ]
Total (95% CI) 58 56 100.0 % 0.94 [ 0.31, 2.82 ]
Total events: 5 (LMWH), 5 (Placebo or no treatment)
Heterogeneity: Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
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Analysis 1.7. Comparison 1 LMWH vs no treatment/standard care, Outcome 7 Late preterm birth (32 to <
37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 7 Late preterm birth (32 to < 37 weeks)
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 2/20 4/20 32.7 % 0.50 [ 0.10, 2.43 ]
Rey 2009 6/25 5/20 45.4 % 0.96 [ 0.34, 2.69 ]
Schleussner 2015 2/13 3/16 22.0 % 0.82 [ 0.16, 4.20 ]
Total (95% CI) 58 56 100.0 % 0.78 [ 0.36, 1.66 ]
Total events: 10 (LMWH), 12 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.46, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
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Analysis 1.8. Comparison 1 LMWH vs no treatment/standard care, Outcome 8 Any preterm birth (birth <
37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 8 Any preterm birth (birth < 37 weeks)
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 4/20 6/20 34.1 % 0.67 [ 0.22, 2.01 ]
Rey 2009 8/25 8/20 50.6 % 0.80 [ 0.37, 1.75 ]
Schleussner 2015 6/13 3/16 15.3 % 2.46 [ 0.76, 7.99 ]
Total (95% CI) 58 56 100.0 % 1.01 [ 0.58, 1.74 ]
Total events: 18 (LMWH), 17 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.08, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
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Analysis 1.9. Comparison 1 LMWH vs no treatment/standard care, Outcome 9 Birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 9 Birthweight








N Mean(SD)[g] N Mean(SD)[g] IV,Fixed,95% CI IV,Fixed,95% CI
Martinelli 2012 17 2690.9 (831.4) 17 2866.8 (642.4) 41.3 % -175.90 [ -675.35, 323.55 ]
Rey 2009 25 2845 (832.62) 20 2909.5 (861.81) 41.4 % -64.50 [ -563.68, 434.68 ]
Schleussner 2015 14 2612 (1399) 16 3340 (497) 17.3 % -728.00 [ -1500.23, 44.23 ]
Total (95% CI) 56 53 100.0 % -225.26 [ -546.36, 95.84 ]
Heterogeneity: Chi2 = 2.06, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Favours placebo/no treat Favours LMWH
Analysis 1.10. Comparison 1 LMWH vs no treatment/standard care, Outcome 10 Low birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 10 Low birthweight
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 5/20 5/20 52.9 % 1.00 [ 0.34, 2.93 ]
Rey 2009 5/25 4/20 47.1 % 1.00 [ 0.31, 3.24 ]
Total (95% CI) 45 40 100.0 % 1.00 [ 0.45, 2.21 ]
Total events: 10 (LMWH), 9 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
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Analysis 1.11. Comparison 1 LMWH vs no treatment/standard care, Outcome 11 Small-for-gestational age.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 11 Small-for-gestational age
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 5/20 4/20 51.3 % 1.25 [ 0.39, 3.99 ]
Rey 2009 3/25 3/20 42.7 % 0.80 [ 0.18, 3.54 ]
Schleussner 2015 2/14 0/16 6.0 % 5.67 [ 0.29, 108.91 ]
Total (95% CI) 59 56 100.0 % 1.32 [ 0.57, 3.08 ]
Total events: 10 (LMWH), 7 (Placebo or no treatment)
Heterogeneity: Chi2 = 1.38, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
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Analysis 1.12. Comparison 1 LMWH vs no treatment/standard care, Outcome 12 Apgar score less than
seven at five minutes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 12 Apgar score less than seven at five minutes
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 1/20 1/20 68.9 % 1.00 [ 0.07, 14.90 ]
Schleussner 2015 3/13 0/16 31.1 % 8.50 [ 0.48, 151.05 ]
Total (95% CI) 33 36 100.0 % 3.33 [ 0.58, 19.29 ]
Total events: 4 (LMWH), 1 (Placebo or no treatment)
Heterogeneity: Chi2 = 1.17, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 LMWH vs no treatment/standard care, Outcome 13 Respiratory distress
syndrome.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 13 Respiratory distress syndrome
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 0/20 0/20 Not estimable
Total (95% CI) 20 20 Not estimable
Total events: 0 (LMWH), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 LMWH vs no treatment/standard care, Outcome 14 Neonatal jaundice.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 14 Neonatal jaundice
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 0/20 0/20 Not estimable
Total (95% CI) 20 20 Not estimable
Total events: 0 (LMWH), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 LMWH vs no treatment/standard care, Outcome 15 Adherence to the
intervention.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 15 Adherence to the intervention
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 15/20 15/20 41.0 % 1.00 [ 0.70, 1.43 ]
Rey 2009 25/25 19/20 59.0 % 1.06 [ 0.93, 1.20 ]
Total (95% CI) 45 40 100.0 % 1.03 [ 0.88, 1.22 ]
Total events: 40 (LMWH), 34 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 LMWH vs no treatment/standard care, Outcome 16 Caesarean birth
(elective).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 16 Caesarean birth (elective)
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 3/20 0/20 8.5 % 7.00 [ 0.38, 127.32 ]
Rey 2009 6/25 4/20 75.6 % 1.20 [ 0.39, 3.68 ]
Schleussner 2015 3/14 1/16 15.9 % 3.43 [ 0.40, 29.33 ]
Total (95% CI) 59 56 100.0 % 2.05 [ 0.83, 5.07 ]
Total events: 12 (LMWH), 5 (Placebo or no treatment)
Heterogeneity: Chi2 = 1.79, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 LMWH vs no treatment/standard care, Outcome 17 Caesarean birth
(emergency).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 17 Caesarean birth (emergency)
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 4/20 2/20 19.7 % 2.00 [ 0.41, 9.71 ]
Rey 2009 2/25 4/20 43.7 % 0.40 [ 0.08, 1.97 ]
Schleussner 2015 3/14 4/16 36.7 % 0.86 [ 0.23, 3.19 ]
Total (95% CI) 59 56 100.0 % 0.88 [ 0.39, 1.99 ]
Total events: 9 (LMWH), 10 (Placebo or no treatment)
Heterogeneity: Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 LMWH vs no treatment/standard care, Outcome 18 Induction of labour.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 18 Induction of labour
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 4/20 6/20 37.5 % 0.67 [ 0.22, 2.01 ]
Rey 2009 7/25 9/20 62.5 % 0.62 [ 0.28, 1.38 ]
Total (95% CI) 45 40 100.0 % 0.64 [ 0.33, 1.22 ]
Total events: 11 (LMWH), 15 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 LMWH vs no treatment/standard care, Outcome 19 Instrumental vaginal
birth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 19 Instrumental vaginal birth
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 1/20 0/20 100.0 % 3.00 [ 0.13, 69.52 ]
Total (95% CI) 20 20 100.0 % 3.00 [ 0.13, 69.52 ]
Total events: 1 (LMWH), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 LMWH vs no treatment/standard care, Outcome 20 Placental abruption.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 20 Placental abruption
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 0/20 0/20 Not estimable
Rey 2009 0/25 1/20 54.1 % 0.27 [ 0.01, 6.27 ]
Schleussner 2015 0/14 1/16 45.9 % 0.38 [ 0.02, 8.59 ]
Total (95% CI) 59 56 100.0 % 0.32 [ 0.04, 2.91 ]
Total events: 0 (LMWH), 2 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 LMWH vs no treatment/standard care, Outcome 21 Pre-eclampsia.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 21 Pre-eclampsia
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 0/20 0/20 Not estimable
Rey 2009 1/25 2/20 100.0 % 0.40 [ 0.04, 4.10 ]
Schleussner 2015 0/14 0/16 Not estimable
Total (95% CI) 59 56 100.0 % 0.40 [ 0.04, 4.10 ]
Total events: 1 (LMWH), 2 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 LMWH vs no treatment/standard care, Outcome 22 Gestational diabetes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 22 Gestational diabetes
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 1/20 0/20 8.3 % 3.00 [ 0.13, 69.52 ]
Rey 2009 7/25 5/20 91.7 % 1.12 [ 0.42, 3.00 ]
Total (95% CI) 45 40 100.0 % 1.28 [ 0.50, 3.25 ]
Total events: 8 (LMWH), 5 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 LMWH vs no treatment/standard care, Outcome 23 Chorioamnionitis.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 23 Chorioamnionitis
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 0/20 0/20 Not estimable
Rey 2009 4/25 2/20 100.0 % 1.60 [ 0.33, 7.86 ]
Total (95% CI) 45 40 100.0 % 1.60 [ 0.33, 7.86 ]
Total events: 4 (LMWH), 2 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 1.24. Comparison 1 LMWH vs no treatment/standard care, Outcome 24 Postpartum
haemorrhage.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 24 Postpartum haemorrhage
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 2/20 0/20 26.2 % 5.00 [ 0.26, 98.00 ]
Schleussner 2015 0/14 1/16 73.8 % 0.38 [ 0.02, 8.59 ]
Total (95% CI) 34 36 100.0 % 1.59 [ 0.27, 9.45 ]
Total events: 2 (LMWH), 1 (Placebo or no treatment)
Heterogeneity: Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 LMWH vs no treatment/standard care, Outcome 25 Serious maternal
outcome (death; cardiac arrest; respiratory arrest; admission to intensive care).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 25 Serious maternal outcome (death; cardiac arrest; respiratory arrest; admission to intensive care)
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinelli 2012 0/20 0/20 Not estimable
Rey 2009 0/25 1/20 100.0 % 0.27 [ 0.01, 6.27 ]
Schleussner 2015 0/18 0/20 Not estimable
Total (95% CI) 63 60 100.0 % 0.27 [ 0.01, 6.27 ]
Total events: 0 (LMWH), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours placebo/no treat
105Care prior to and during subsequent pregnancies following stillbirth for improving outcomes (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.26. Comparison 1 LMWH vs no treatment/standard care, Outcome 26 Maternal antenatal
admission.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 26 Maternal antenatal admission
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rey 2009 3/25 4/20 100.0 % 0.60 [ 0.15, 2.38 ]
Total (95% CI) 25 20 100.0 % 0.60 [ 0.15, 2.38 ]
Total events: 3 (LMWH), 4 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 1.27. Comparison 1 LMWH vs no treatment/standard care, Outcome 27 Duration of maternal
hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 27 Duration of maternal hospital stay








N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Rey 2009 25 4.28 (2.78) 20 4.3 (3.81) 100.0 % -0.02 [ -2.01, 1.97 ]
Total (95% CI) 25 20 100.0 % -0.02 [ -2.01, 1.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 LMWH vs no treatment/standard care, Outcome 28 Duration of neonatal
hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 28 Duration of neonatal hospital stay








N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Rey 2009 25 11 (20.83) 20 9.3 (14.7) 100.0 % 1.70 [ -8.70, 12.10 ]
Total (95% CI) 25 20 100.0 % 1.70 [ -8.70, 12.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 1.29. Comparison 1 LMWH vs no treatment/standard care, Outcome 29 Admission to the
neonatal intensive care unit.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 29 Admission to the neonatal intensive care unit
Study or subgroup LMWH
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rey 2009 5/25 5/20 100.0 % 0.80 [ 0.27, 2.38 ]
Total (95% CI) 25 20 100.0 % 0.80 [ 0.27, 2.38 ]
Total events: 5 (LMWH), 5 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.30. Comparison 1 LMWH vs no treatment/standard care, Outcome 30 Duration of neonatal
intensive care unit stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 1 LMWH vs no treatment/standard care
Outcome: 30 Duration of neonatal intensive care unit stay








N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Rey 2009 5 21.2 (29.85) 5 17 (15.12) 100.0 % 4.20 [ -25.13, 33.53 ]
Total (95% CI) 5 5 100.0 % 4.20 [ -25.13, 33.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 LDA vs placebo, Outcome 1 Stillbirth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 1 Stillbirth
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/13 1/11 100.0 % 0.85 [ 0.06, 12.01 ]
Total (95% CI) 13 11 100.0 % 0.85 [ 0.06, 12.01 ]
Total events: 1 (LDA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 LDA vs placebo, Outcome 2 Neonatal death.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 2 Neonatal death
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/13 1/11 100.0 % 0.29 [ 0.01, 6.38 ]
Total (95% CI) 13 11 100.0 % 0.29 [ 0.01, 6.38 ]
Total events: 0 (LDA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 LDA vs placebo, Outcome 3 Adverse perinatal outcome (composite outcome
including stillbirth, neonatal death, and major neonatal morbidity).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 3 Adverse perinatal outcome (composite outcome including stillbirth, neonatal death, and major neonatal morbidity)
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/13 3/11 100.0 % 0.28 [ 0.03, 2.34 ]
Total (95% CI) 13 11 100.0 % 0.28 [ 0.03, 2.34 ]
Total events: 1 (LDA), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 LDA vs placebo, Outcome 4 Perinatal mortality.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 4 Perinatal mortality
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/13 2/11 100.0 % 0.42 [ 0.04, 4.06 ]
Total (95% CI) 13 11 100.0 % 0.42 [ 0.04, 4.06 ]
Total events: 1 (LDA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 LDA vs placebo, Outcome 5 Very preterm birth (28 to < 32 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 5 Very preterm birth (28 to < 32 weeks)
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/13 1/11 100.0 % 0.29 [ 0.01, 6.38 ]
Total (95% CI) 13 11 100.0 % 0.29 [ 0.01, 6.38 ]
Total events: 0 (LDA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 LDA vs placebo, Outcome 6 Late preterm birth (32 to < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 6 Late preterm birth (32 to < 37 weeks)
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/13 1/11 100.0 % 0.85 [ 0.06, 12.01 ]
Total (95% CI) 13 11 100.0 % 0.85 [ 0.06, 12.01 ]
Total events: 1 (LDA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 LDA vs placebo, Outcome 7 Any preterm birth (birth < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 7 Any preterm birth (birth < 37 weeks)
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/13 2/11 100.0 % 0.42 [ 0.04, 4.06 ]
Total (95% CI) 13 11 100.0 % 0.42 [ 0.04, 4.06 ]
Total events: 1 (LDA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 LDA vs placebo, Outcome 8 Birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 8 Birthweight





N Mean(SD)[g] N Mean(SD)[g] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 13 2620 (500) 11 1830 (700) 100.0 % 790.00 [ 295.03, 1284.97 ]
Total (95% CI) 13 11 100.0 % 790.00 [ 295.03, 1284.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 LDA vs placebo, Outcome 9 Low birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 9 Low birthweight
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/13 3/11 100.0 % 0.28 [ 0.03, 2.34 ]
Total (95% CI) 13 11 100.0 % 0.28 [ 0.03, 2.34 ]
Total events: 1 (LDA), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 LDA vs placebo, Outcome 10 Small-for-gestational age.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 10 Small-for-gestational age
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/13 1/11 100.0 % 0.29 [ 0.01, 6.38 ]
Total (95% CI) 13 11 100.0 % 0.29 [ 0.01, 6.38 ]
Total events: 0 (LDA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 LDA vs placebo, Outcome 11 Respiratory distress syndrome.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 11 Respiratory distress syndrome
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/13 1/11 100.0 % 0.29 [ 0.01, 6.38 ]
Total (95% CI) 13 11 100.0 % 0.29 [ 0.01, 6.38 ]
Total events: 0 (LDA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 LDA vs placebo, Outcome 12 Adherence to the intervention.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 12 Adherence to the intervention
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 13/13 11/11 100.0 % 1.00 [ 0.86, 1.17 ]
Total (95% CI) 13 11 100.0 % 1.00 [ 0.86, 1.17 ]
Total events: 13 (LDA), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 LDA vs placebo, Outcome 13 Caesarean birth (elective).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 13 Caesarean birth (elective)
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 3/13 4/11 100.0 % 0.63 [ 0.18, 2.24 ]
Total (95% CI) 13 11 100.0 % 0.63 [ 0.18, 2.24 ]
Total events: 3 (LDA), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 LDA vs placebo, Outcome 14 Caesarean birth (emergency).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 14 Caesarean birth (emergency)
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 4/13 2/11 100.0 % 1.69 [ 0.38, 7.55 ]
Total (95% CI) 13 11 100.0 % 1.69 [ 0.38, 7.55 ]
Total events: 4 (LDA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 LDA vs placebo, Outcome 15 Induction of labour.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 15 Induction of labour
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 4/13 2/11 100.0 % 1.69 [ 0.38, 7.55 ]
Total (95% CI) 13 11 100.0 % 1.69 [ 0.38, 7.55 ]
Total events: 4 (LDA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 LDA vs placebo, Outcome 16 Instrumental vaginal birth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 16 Instrumental vaginal birth
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/13 0/11 100.0 % 2.57 [ 0.12, 57.44 ]
Total (95% CI) 13 11 100.0 % 2.57 [ 0.12, 57.44 ]
Total events: 1 (LDA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 2.17. Comparison 2 LDA vs placebo, Outcome 17 Placental abruption.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 17 Placental abruption
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/13 0/11 100.0 % 2.57 [ 0.12, 57.44 ]
Total (95% CI) 13 11 100.0 % 2.57 [ 0.12, 57.44 ]
Total events: 1 (LDA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 LDA vs placebo, Outcome 18 Pre-eclampsia.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 18 Pre-eclampsia
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 2/13 2/11 100.0 % 0.85 [ 0.14, 5.06 ]
Total (95% CI) 13 11 100.0 % 0.85 [ 0.14, 5.06 ]
Total events: 2 (LDA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 LDA vs placebo, Outcome 19 Gestational diabetes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 19 Gestational diabetes
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/13 2/11 100.0 % 0.42 [ 0.04, 4.06 ]
Total (95% CI) 13 11 100.0 % 0.42 [ 0.04, 4.06 ]
Total events: 1 (LDA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 LDA vs placebo, Outcome 20 Postpartum haemorrhage.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 20 Postpartum haemorrhage
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/13 1/11 100.0 % 0.29 [ 0.01, 6.38 ]
Total (95% CI) 13 11 100.0 % 0.29 [ 0.01, 6.38 ]
Total events: 0 (LDA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.21. Comparison 2 LDA vs placebo, Outcome 21 Serious maternal outcome (death; cardiac
arrest; respiratory arrest; admission to intensive care).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 21 Serious maternal outcome (death; cardiac arrest; respiratory arrest; admission to intensive care)
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/13 0/11 Not estimable
Total (95% CI) 13 11 Not estimable
Total events: 0 (LDA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 LDA vs placebo, Outcome 22 Antenatal care attendance.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 22 Antenatal care attendance
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 13/13 11/11 100.0 % 1.00 [ 0.86, 1.17 ]
Total (95% CI) 13 11 100.0 % 1.00 [ 0.86, 1.17 ]
Total events: 13 (LDA), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.23. Comparison 2 LDA vs placebo, Outcome 23 Duration of maternal hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 23 Duration of maternal hospital stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 13 2 (3) 11 2 (3) 100.0 % 0.0 [ -2.41, 2.41 ]
Total (95% CI) 13 11 100.0 % 0.0 [ -2.41, 2.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.24. Comparison 2 LDA vs placebo, Outcome 24 Duration of neonatal hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 24 Duration of neonatal hospital stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 13 3 (3) 11 5 (3) 100.0 % -2.00 [ -4.41, 0.41 ]
Total (95% CI) 13 11 100.0 % -2.00 [ -4.41, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 2.25. Comparison 2 LDA vs placebo, Outcome 25 Admission to the neonatal intensive care unit.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 25 Admission to the neonatal intensive care unit
Study or subgroup LDA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 7/13 4/11 100.0 % 1.48 [ 0.58, 3.75 ]
Total (95% CI) 13 11 100.0 % 1.48 [ 0.58, 3.75 ]
Total events: 7 (LDA), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 2.26. Comparison 2 LDA vs placebo, Outcome 26 Duration of neonatal intensive care unit stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 2 LDA vs placebo
Outcome: 26 Duration of neonatal intensive care unit stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 7 2 (2) 4 4 (3) 100.0 % -2.00 [ -5.29, 1.29 ]
Total (95% CI) 7 4 100.0 % -2.00 [ -5.29, 1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 LDA + LMWH vs LDA alone, Outcome 1 Stillbirth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 1 Stillbirth
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 1/13 100.0 % 0.27 [ 0.01, 6.23 ]
Total (95% CI) 16 13 100.0 % 0.27 [ 0.01, 6.23 ]
Total events: 0 (LDA + LMWH), 1 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 LDA + LMWH vs LDA alone, Outcome 2 Neonatal death.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 2 Neonatal death
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 0/13 Not estimable
Total (95% CI) 16 13 Not estimable
Total events: 0 (LDA + LMWH), 0 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 LDA + LMWH vs LDA alone, Outcome 3 Adverse perinatal outcome
(composite outcome including stillbirth, neonatal death, and major neonatal morbidity).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 3 Adverse perinatal outcome (composite outcome including stillbirth, neonatal death, and major neonatal morbidity)
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 3/16 1/13 100.0 % 2.44 [ 0.29, 20.75 ]
Total (95% CI) 16 13 100.0 % 2.44 [ 0.29, 20.75 ]
Total events: 3 (LDA + LMWH), 1 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 LDA + LMWH vs LDA alone, Outcome 4 Perinatal mortality.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 4 Perinatal mortality
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 1/13 100.0 % 0.27 [ 0.01, 6.23 ]
Total (95% CI) 16 13 100.0 % 0.27 [ 0.01, 6.23 ]
Total events: 0 (LDA + LMWH), 1 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 LDA + LMWH vs LDA alone, Outcome 5 Very preterm birth (28 to < 32 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 5 Very preterm birth (28 to < 32 weeks)
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 0/13 100.0 % 2.47 [ 0.11, 56.03 ]
Total (95% CI) 16 13 100.0 % 2.47 [ 0.11, 56.03 ]
Total events: 1 (LDA + LMWH), 0 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 LDA + LMWH vs LDA alone, Outcome 6 Late preterm birth (32 to < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 6 Late preterm birth (32 to < 37 weeks)
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 1/13 100.0 % 0.81 [ 0.06, 11.77 ]
Total (95% CI) 16 13 100.0 % 0.81 [ 0.06, 11.77 ]
Total events: 1 (LDA + LMWH), 1 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 LDA + LMWH vs LDA alone, Outcome 7 Any preterm birth (birth < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 7 Any preterm birth (birth < 37 weeks)
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 4/16 1/13 100.0 % 3.25 [ 0.41, 25.64 ]
Total (95% CI) 16 13 100.0 % 3.25 [ 0.41, 25.64 ]
Total events: 4 (LDA + LMWH), 1 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 LDA + LMWH vs LDA alone, Outcome 8 Birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 8 Birthweight





N Mean(SD)[g] N Mean(SD)[g] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 16 1970 (1000) 13 2620 (500) 100.0 % -650.00 [ -1210.33, -89.67 ]
Total (95% CI) 16 13 100.0 % -650.00 [ -1210.33, -89.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 LDA + LMWH vs LDA alone, Outcome 9 Low birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 9 Low birthweight
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 2/16 1/13 100.0 % 1.63 [ 0.17, 15.99 ]
Total (95% CI) 16 13 100.0 % 1.63 [ 0.17, 15.99 ]
Total events: 2 (LDA + LMWH), 1 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 LDA + LMWH vs LDA alone, Outcome 10 Small-for-gestational age.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 10 Small-for-gestational age
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 0/13 100.0 % 2.47 [ 0.11, 56.03 ]
Total (95% CI) 16 13 100.0 % 2.47 [ 0.11, 56.03 ]
Total events: 1 (LDA + LMWH), 0 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 LDA + LMWH vs LDA alone, Outcome 11 Respiratory distress syndrome.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 11 Respiratory distress syndrome
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 0/13 100.0 % 2.47 [ 0.11, 56.03 ]
Total (95% CI) 16 13 100.0 % 2.47 [ 0.11, 56.03 ]
Total events: 1 (LDA + LMWH), 0 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 LDA + LMWH vs LDA alone, Outcome 12 Adherence to the intervention.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 12 Adherence to the intervention
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 16/16 13/13 100.0 % 1.00 [ 0.88, 1.14 ]
Total (95% CI) 16 13 100.0 % 1.00 [ 0.88, 1.14 ]
Total events: 16 (LDA + LMWH), 13 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 LDA + LMWH vs LDA alone, Outcome 13 Caesarean birth (elective).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 13 Caesarean birth (elective)
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 5/16 3/13 100.0 % 1.35 [ 0.40, 4.63 ]
Total (95% CI) 16 13 100.0 % 1.35 [ 0.40, 4.63 ]
Total events: 5 (LDA + LMWH), 3 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 3.14. Comparison 3 LDA + LMWH vs LDA alone, Outcome 14 Caesarean birth (emergency).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 14 Caesarean birth (emergency)
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 4/13 100.0 % 0.20 [ 0.03, 1.60 ]
Total (95% CI) 16 13 100.0 % 0.20 [ 0.03, 1.60 ]
Total events: 1 (LDA + LMWH), 4 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 3.15. Comparison 3 LDA + LMWH vs LDA alone, Outcome 15 Induction of labour.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 15 Induction of labour
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 3/16 4/13 100.0 % 0.61 [ 0.17, 2.25 ]
Total (95% CI) 16 13 100.0 % 0.61 [ 0.17, 2.25 ]
Total events: 3 (LDA + LMWH), 4 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 3.16. Comparison 3 LDA + LMWH vs LDA alone, Outcome 16 Instrumental vaginal birth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 16 Instrumental vaginal birth
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 1/13 100.0 % 0.81 [ 0.06, 11.77 ]
Total (95% CI) 16 13 100.0 % 0.81 [ 0.06, 11.77 ]
Total events: 1 (LDA + LMWH), 1 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 3.17. Comparison 3 LDA + LMWH vs LDA alone, Outcome 17 Placental abruption.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 17 Placental abruption
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 1/13 100.0 % 0.81 [ 0.06, 11.77 ]
Total (95% CI) 16 13 100.0 % 0.81 [ 0.06, 11.77 ]
Total events: 1 (LDA + LMWH), 1 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 3.18. Comparison 3 LDA + LMWH vs LDA alone, Outcome 18 Pre-eclampsia.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 18 Pre-eclampsia
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 2/13 100.0 % 0.41 [ 0.04, 4.00 ]
Total (95% CI) 16 13 100.0 % 0.41 [ 0.04, 4.00 ]
Total events: 1 (LDA + LMWH), 2 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 3.19. Comparison 3 LDA + LMWH vs LDA alone, Outcome 19 Gestational diabetes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 19 Gestational diabetes
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 1/13 100.0 % 0.27 [ 0.01, 6.23 ]
Total (95% CI) 16 13 100.0 % 0.27 [ 0.01, 6.23 ]
Total events: 0 (LDA + LMWH), 1 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 3.20. Comparison 3 LDA + LMWH vs LDA alone, Outcome 20 Postpartum haemorrhage.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 20 Postpartum haemorrhage
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 0/13 100.0 % 2.47 [ 0.11, 56.03 ]
Total (95% CI) 16 13 100.0 % 2.47 [ 0.11, 56.03 ]
Total events: 1 (LDA + LMWH), 0 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 3.21. Comparison 3 LDA + LMWH vs LDA alone, Outcome 21 Serious maternal outcome (death;
cardiac arrest; respiratory arrest; admission to intensive care).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 21 Serious maternal outcome (death; cardiac arrest; respiratory arrest; admission to intensive care)
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 0/13 Not estimable
Total (95% CI) 16 13 Not estimable
Total events: 0 (LDA + LMWH), 0 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.22. Comparison 3 LDA + LMWH vs LDA alone, Outcome 22 Antenatal care attendance.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 22 Antenatal care attendance
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 16/16 13/13 100.0 % 1.00 [ 0.88, 1.14 ]
Total (95% CI) 16 13 100.0 % 1.00 [ 0.88, 1.14 ]
Total events: 16 (LDA + LMWH), 13 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.23. Comparison 3 LDA + LMWH vs LDA alone, Outcome 23 Duration of maternal hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 23 Duration of maternal hospital stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 16 2 (4) 13 2 (3) 100.0 % 0.0 [ -2.55, 2.55 ]
Total (95% CI) 16 13 100.0 % 0.0 [ -2.55, 2.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.24. Comparison 3 LDA + LMWH vs LDA alone, Outcome 24 Duration of neonatal hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 24 Duration of neonatal hospital stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 16 5 (4) 13 3 (3) 100.0 % 2.00 [ -0.55, 4.55 ]
Total (95% CI) 16 13 100.0 % 2.00 [ -0.55, 4.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 3.25. Comparison 3 LDA + LMWH vs LDA alone, Outcome 25 Admission to the neonatal intensive
care unit.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 25 Admission to the neonatal intensive care unit
Study or subgroup LDA + LMWH LDA alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 10/16 7/13 100.0 % 1.16 [ 0.62, 2.18 ]
Total (95% CI) 16 13 100.0 % 1.16 [ 0.62, 2.18 ]
Total events: 10 (LDA + LMWH), 7 (LDA alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 3.26. Comparison 3 LDA + LMWH vs LDA alone, Outcome 26 Duration of neonatal intensive care
unit stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 3 LDA + LMWH vs LDA alone
Outcome: 26 Duration of neonatal intensive care unit stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 10 4 (3) 7 2 (2) 100.0 % 2.00 [ -0.38, 4.38 ]
Total (95% CI) 10 7 100.0 % 2.00 [ -0.38, 4.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 LDA + LMWH vs placebo, Outcome 1 Stillbirth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 1 Stillbirth
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 1/11 100.0 % 0.24 [ 0.01, 5.30 ]
Total (95% CI) 16 11 100.0 % 0.24 [ 0.01, 5.30 ]
Total events: 0 (LDA + LMWH), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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134Care prior to and during subsequent pregnancies following stillbirth for improving outcomes (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.2. Comparison 4 LDA + LMWH vs placebo, Outcome 2 Neonatal death.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 2 Neonatal death
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 1/11 100.0 % 0.24 [ 0.01, 5.30 ]
Total (95% CI) 16 11 100.0 % 0.24 [ 0.01, 5.30 ]
Total events: 0 (LDA + LMWH), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 LDA + LMWH vs placebo, Outcome 3 Adverse perinatal outcome (composite
outcome including stillbirth, neonatal death, and major neonatal morbidity).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 3 Adverse perinatal outcome (composite outcome including stillbirth, neonatal death, and major neonatal morbidity)
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 3/16 3/11 100.0 % 0.69 [ 0.17, 2.80 ]
Total (95% CI) 16 11 100.0 % 0.69 [ 0.17, 2.80 ]
Total events: 3 (LDA + LMWH), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 LDA + LMWH vs placebo, Outcome 4 Perinatal mortality.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 4 Perinatal mortality
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 2/11 100.0 % 0.14 [ 0.01, 2.68 ]
Total (95% CI) 16 11 100.0 % 0.14 [ 0.01, 2.68 ]
Total events: 0 (LDA + LMWH), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 LDA + LMWH vs placebo, Outcome 5 Very preterm birth (28 to < 32 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 5 Very preterm birth (28 to < 32 weeks)
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 1/11 100.0 % 0.69 [ 0.05, 9.86 ]
Total (95% CI) 16 11 100.0 % 0.69 [ 0.05, 9.86 ]
Total events: 1 (LDA + LMWH), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 LDA + LMWH vs placebo, Outcome 6 Late preterm birth (32 to < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 6 Late preterm birth (32 to < 37 weeks)
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 1/11 100.0 % 0.69 [ 0.05, 9.86 ]
Total (95% CI) 16 11 100.0 % 0.69 [ 0.05, 9.86 ]
Total events: 1 (LDA + LMWH), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 LDA + LMWH vs placebo, Outcome 7 Any preterm birth (birth < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 7 Any preterm birth (birth < 37 weeks)
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 4/16 2/11 100.0 % 1.38 [ 0.30, 6.25 ]
Total (95% CI) 16 11 100.0 % 1.38 [ 0.30, 6.25 ]
Total events: 4 (LDA + LMWH), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 LDA + LMWH vs placebo, Outcome 8 Birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 8 Birthweight





N Mean(SD)[g] N Mean(SD)[g] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 16 1970 (1000) 11 1830 (700) 100.0 % 140.00 [ -501.26, 781.26 ]
Total (95% CI) 16 11 100.0 % 140.00 [ -501.26, 781.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 LDA + LMWH vs placebo, Outcome 9 Low birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 9 Low birthweight
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 2/16 3/11 100.0 % 0.46 [ 0.09, 2.31 ]
Total (95% CI) 16 11 100.0 % 0.46 [ 0.09, 2.31 ]
Total events: 2 (LDA + LMWH), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 4.10. Comparison 4 LDA + LMWH vs placebo, Outcome 10 Small-for-gestational age.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 10 Small-for-gestational age
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 1/11 100.0 % 0.69 [ 0.05, 9.86 ]
Total (95% CI) 16 11 100.0 % 0.69 [ 0.05, 9.86 ]
Total events: 1 (LDA + LMWH), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LDA + LMWH Favours placebo
Analysis 4.11. Comparison 4 LDA + LMWH vs placebo, Outcome 11 Respiratory distress syndrome.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 11 Respiratory distress syndrome
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 1/11 100.0 % 0.69 [ 0.05, 9.86 ]
Total (95% CI) 16 11 100.0 % 0.69 [ 0.05, 9.86 ]
Total events: 1 (LDA + LMWH), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 4.12. Comparison 4 LDA + LMWH vs placebo, Outcome 12 Adherence to the intervention.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 12 Adherence to the intervention
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 16/16 11/11 100.0 % 1.00 [ 0.87, 1.16 ]
Total (95% CI) 16 11 100.0 % 1.00 [ 0.87, 1.16 ]
Total events: 16 (LDA + LMWH), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.13. Comparison 4 LDA + LMWH vs placebo, Outcome 13 Caesarean birth (elective).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 13 Caesarean birth (elective)
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 5/16 4/11 100.0 % 0.86 [ 0.30, 2.50 ]
Total (95% CI) 16 11 100.0 % 0.86 [ 0.30, 2.50 ]
Total events: 5 (LDA + LMWH), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 4.14. Comparison 4 LDA + LMWH vs placebo, Outcome 14 Caesarean birth (emergency).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 14 Caesarean birth (emergency)
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 2/11 100.0 % 0.34 [ 0.04, 3.34 ]
Total (95% CI) 16 11 100.0 % 0.34 [ 0.04, 3.34 ]
Total events: 1 (LDA + LMWH), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 4.15. Comparison 4 LDA + LMWH vs placebo, Outcome 15 Induction of labour.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 15 Induction of labour
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 3/16 2/11 100.0 % 1.03 [ 0.20, 5.19 ]
Total (95% CI) 16 11 100.0 % 1.03 [ 0.20, 5.19 ]
Total events: 3 (LDA + LMWH), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 4.16. Comparison 4 LDA + LMWH vs placebo, Outcome 16 Instrumental vaginal birth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 16 Instrumental vaginal birth
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 0/11 100.0 % 2.12 [ 0.09, 47.68 ]
Total (95% CI) 16 11 100.0 % 2.12 [ 0.09, 47.68 ]
Total events: 1 (LDA + LMWH), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 4.17. Comparison 4 LDA + LMWH vs placebo, Outcome 17 Placental abruption.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 17 Placental abruption
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 0/11 100.0 % 2.12 [ 0.09, 47.68 ]
Total (95% CI) 16 11 100.0 % 2.12 [ 0.09, 47.68 ]
Total events: 1 (LDA + LMWH), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 4.18. Comparison 4 LDA + LMWH vs placebo, Outcome 18 Pre-eclampsia.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 18 Pre-eclampsia
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 2/11 100.0 % 0.34 [ 0.04, 3.34 ]
Total (95% CI) 16 11 100.0 % 0.34 [ 0.04, 3.34 ]
Total events: 1 (LDA + LMWH), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LDA + LMWH Favours placebo
Analysis 4.19. Comparison 4 LDA + LMWH vs placebo, Outcome 19 Gestational diabetes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 19 Gestational diabetes
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 2/11 100.0 % 0.14 [ 0.01, 2.68 ]
Total (95% CI) 16 11 100.0 % 0.14 [ 0.01, 2.68 ]
Total events: 0 (LDA + LMWH), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 4.20. Comparison 4 LDA + LMWH vs placebo, Outcome 20 Postpartum haemorrhage.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 20 Postpartum haemorrhage
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 1/16 1/11 100.0 % 0.69 [ 0.05, 9.86 ]
Total (95% CI) 16 11 100.0 % 0.69 [ 0.05, 9.86 ]
Total events: 1 (LDA + LMWH), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 4.21. Comparison 4 LDA + LMWH vs placebo, Outcome 21 Serious maternal outcome (death;
cardiac arrest; respiratory arrest; admission to intensive care).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 21 Serious maternal outcome (death; cardiac arrest; respiratory arrest; admission to intensive care)
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 0/16 0/11 Not estimable
Total (95% CI) 16 11 Not estimable
Total events: 0 (LDA + LMWH), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.22. Comparison 4 LDA + LMWH vs placebo, Outcome 22 Antenatal care attendance.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 22 Antenatal care attendance
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 16/16 11/11 100.0 % 1.00 [ 0.87, 1.16 ]
Total (95% CI) 16 11 100.0 % 1.00 [ 0.87, 1.16 ]
Total events: 16 (LDA + LMWH), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.23. Comparison 4 LDA + LMWH vs placebo, Outcome 23 Duration of maternal hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 23 Duration of maternal hospital stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 16 2 (4) 11 2 (3) 100.0 % 0.0 [ -2.64, 2.64 ]
Total (95% CI) 16 11 100.0 % 0.0 [ -2.64, 2.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.24. Comparison 4 LDA + LMWH vs placebo, Outcome 24 Duration of neonatal hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 24 Duration of neonatal hospital stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 16 5 (4) 11 5 (3) 100.0 % 0.0 [ -2.64, 2.64 ]
Total (95% CI) 16 11 100.0 % 0.0 [ -2.64, 2.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.25. Comparison 4 LDA + LMWH vs placebo, Outcome 25 Admission to the neonatal intensive
care unit.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 25 Admission to the neonatal intensive care unit
Study or subgroup LDA + LMWH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmed 2014 10/16 4/11 100.0 % 1.72 [ 0.72, 4.10 ]
Total (95% CI) 16 11 100.0 % 1.72 [ 0.72, 4.10 ]
Total events: 10 (LDA + LMWH), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 4.26. Comparison 4 LDA + LMWH vs placebo, Outcome 26 Duration of neonatal intensive care
unit stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 4 LDA + LMWH vs placebo
Outcome: 26 Duration of neonatal intensive care unit stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Ahmed 2014 10 4 (3) 4 4 (3) 100.0 % 0.0 [ -3.48, 3.48 ]
Total (95% CI) 10 4 100.0 % 0.0 [ -3.48, 3.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 LMWH vs LDA, Outcome 1 Stillbirth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 1 Stillbirth
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 0/12 100.0 % 3.55 [ 0.16, 78.56 ]
Total (95% CI) 10 12 100.0 % 3.55 [ 0.16, 78.56 ]
Total events: 1 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 LMWH vs LDA, Outcome 2 Neonatal death.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 2 Neonatal death
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 0/10 0/12 Not estimable
Total (95% CI) 10 12 Not estimable
Total events: 0 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 LMWH vs LDA, Outcome 3 Adverse perinatal outcome (composite outcome
including stillbirth, neonatal death, and major neonatal morbidity).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 3 Adverse perinatal outcome (composite outcome including stillbirth, neonatal death, and major neonatal morbidity)
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 0/12 100.0 % 3.55 [ 0.16, 78.56 ]
Total (95% CI) 10 12 100.0 % 3.55 [ 0.16, 78.56 ]
Total events: 1 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 LMWH vs LDA, Outcome 4 Perinatal mortality.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 4 Perinatal mortality
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 0/12 100.0 % 3.55 [ 0.16, 78.56 ]
Total (95% CI) 10 12 100.0 % 3.55 [ 0.16, 78.56 ]
Total events: 1 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 LMWH vs LDA, Outcome 5 Very preterm birth (28 to < 32 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 5 Very preterm birth (28 to < 32 weeks)
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 0/10 0/12 Not estimable
Total (95% CI) 10 12 Not estimable
Total events: 0 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 LMWH vs LDA, Outcome 6 Late preterm birth (32 to < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 6 Late preterm birth (32 to < 37 weeks)
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 1/12 100.0 % 1.20 [ 0.09, 16.84 ]
Total (95% CI) 10 12 100.0 % 1.20 [ 0.09, 16.84 ]
Total events: 1 (LMHW), 1 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 LMWH vs LDA, Outcome 7 Any preterm birth (birth < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 7 Any preterm birth (birth < 37 weeks)
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 2/12 100.0 % 0.60 [ 0.06, 5.69 ]
Total (95% CI) 10 12 100.0 % 0.60 [ 0.06, 5.69 ]
Total events: 1 (LMHW), 2 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 5.8. Comparison 5 LMWH vs LDA, Outcome 8 Birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 8 Birthweight





N Mean(SD)[g] N Mean(SD)[g] IV,Fixed,95% CI IV,Fixed,95% CI
Gris 2004 10 2930 (258) 12 2855 (284) 100.0 % 75.00 [ -151.69, 301.69 ]
Total (95% CI) 10 12 100.0 % 75.00 [ -151.69, 301.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 5.9. Comparison 5 LMWH vs LDA, Outcome 9 Low birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 9 Low birthweight
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 2/12 100.0 % 0.60 [ 0.06, 5.69 ]
Total (95% CI) 10 12 100.0 % 0.60 [ 0.06, 5.69 ]
Total events: 1 (LMHW), 2 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 5.10. Comparison 5 LMWH vs LDA, Outcome 10 Small-for-gestational age.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 10 Small-for-gestational age
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 2/12 100.0 % 0.60 [ 0.06, 5.69 ]
Total (95% CI) 10 12 100.0 % 0.60 [ 0.06, 5.69 ]
Total events: 1 (LMHW), 2 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 5.11. Comparison 5 LMWH vs LDA, Outcome 11 Apgar score less than seven at five minutes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 11 Apgar score less than seven at five minutes
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 2/10 3/12 100.0 % 0.80 [ 0.16, 3.88 ]
Total (95% CI) 10 12 100.0 % 0.80 [ 0.16, 3.88 ]
Total events: 2 (LMHW), 3 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 5.12. Comparison 5 LMWH vs LDA, Outcome 12 Respiratory distress syndrome.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 12 Respiratory distress syndrome
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 1/12 100.0 % 1.20 [ 0.09, 16.84 ]
Total (95% CI) 10 12 100.0 % 1.20 [ 0.09, 16.84 ]
Total events: 1 (LMHW), 1 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 5.13. Comparison 5 LMWH vs LDA, Outcome 13 Neonatal jaundice.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 13 Neonatal jaundice
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 6/10 8/12 100.0 % 0.90 [ 0.47, 1.72 ]
Total (95% CI) 10 12 100.0 % 0.90 [ 0.47, 1.72 ]
Total events: 6 (LMHW), 8 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 5.14. Comparison 5 LMWH vs LDA, Outcome 14 Caesarean birth (elective).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 14 Caesarean birth (elective)
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 2/10 2/12 100.0 % 1.20 [ 0.20, 7.05 ]
Total (95% CI) 10 12 100.0 % 1.20 [ 0.20, 7.05 ]
Total events: 2 (LMHW), 2 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 5.15. Comparison 5 LMWH vs LDA, Outcome 15 Caesarean birth (emergency).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 15 Caesarean birth (emergency)
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 2/12 100.0 % 0.60 [ 0.06, 5.69 ]
Total (95% CI) 10 12 100.0 % 0.60 [ 0.06, 5.69 ]
Total events: 1 (LMHW), 2 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 5.16. Comparison 5 LMWH vs LDA, Outcome 16 Induction of labour.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 16 Induction of labour
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 3/10 0/12 100.0 % 8.27 [ 0.48, 143.35 ]
Total (95% CI) 10 12 100.0 % 8.27 [ 0.48, 143.35 ]
Total events: 3 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 5.17. Comparison 5 LMWH vs LDA, Outcome 17 Instrumental vaginal birth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 17 Instrumental vaginal birth
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 0/10 0/12 Not estimable
Total (95% CI) 10 12 Not estimable
Total events: 0 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.18. Comparison 5 LMWH vs LDA, Outcome 18 Placental abruption.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 18 Placental abruption
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 0/10 0/12 Not estimable
Total (95% CI) 10 12 Not estimable
Total events: 0 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.19. Comparison 5 LMWH vs LDA, Outcome 19 Pre-eclampsia.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 19 Pre-eclampsia
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 2/12 100.0 % 0.60 [ 0.06, 5.69 ]
Total (95% CI) 10 12 100.0 % 0.60 [ 0.06, 5.69 ]
Total events: 1 (LMHW), 2 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 5.20. Comparison 5 LMWH vs LDA, Outcome 20 Gestational diabetes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 20 Gestational diabetes
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 0/10 0/12 Not estimable
Total (95% CI) 10 12 Not estimable
Total events: 0 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.21. Comparison 5 LMWH vs LDA, Outcome 21 Postpartum haemorrhage.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 21 Postpartum haemorrhage
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 0/10 0/12 Not estimable
Total (95% CI) 10 12 Not estimable
Total events: 0 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.22. Comparison 5 LMWH vs LDA, Outcome 22 Serious maternal outcome (death; cardiac
arrest; respiratory arrest; admission to intensive care).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 22 Serious maternal outcome (death; cardiac arrest; respiratory arrest; admission to intensive care)
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 0/10 0/12 Not estimable
Total (95% CI) 10 12 Not estimable
Total events: 0 (LMHW), 0 (LDA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.23. Comparison 5 LMWH vs LDA, Outcome 23 Breastfeeding.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 23 Breastfeeding
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 4/10 5/12 100.0 % 0.96 [ 0.35, 2.64 ]
Total (95% CI) 10 12 100.0 % 0.96 [ 0.35, 2.64 ]
Total events: 4 (LMHW), 5 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 5.24. Comparison 5 LMWH vs LDA, Outcome 24 Maternal antenatal admission.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 24 Maternal antenatal admission
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 2/12 100.0 % 0.60 [ 0.06, 5.69 ]
Total (95% CI) 10 12 100.0 % 0.60 [ 0.06, 5.69 ]
Total events: 1 (LMHW), 2 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 5.25. Comparison 5 LMWH vs LDA, Outcome 25 Duration of maternal hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 25 Duration of maternal hospital stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Gris 2004 10 3.8 (0.23) 12 3.8 (0.23) 100.0 % 0.0 [ -0.19, 0.19 ]
Total (95% CI) 10 12 100.0 % 0.0 [ -0.19, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.26. Comparison 5 LMWH vs LDA, Outcome 26 Duration of neonatal hospital stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 26 Duration of neonatal hospital stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Gris 2004 10 4.1 (0.37) 12 4.1 (0.35) 100.0 % 0.0 [ -0.30, 0.30 ]
Total (95% CI) 10 12 100.0 % 0.0 [ -0.30, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.27. Comparison 5 LMWH vs LDA, Outcome 27 Admission to the neonatal intensive care unit.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 27 Admission to the neonatal intensive care unit
Study or subgroup LMHW LDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gris 2004 1/10 1/12 100.0 % 1.20 [ 0.09, 16.84 ]
Total (95% CI) 10 12 100.0 % 1.20 [ 0.09, 16.84 ]
Total events: 1 (LMHW), 1 (LDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 5.28. Comparison 5 LMWH vs LDA, Outcome 28 Duration of neonatal intensive care unit stay.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 5 LMWH vs LDA
Outcome: 28 Duration of neonatal intensive care unit stay





N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Gris 2004 1 0.8 (3) 1 0.58 (3.3) 100.0 % 0.22 [ -8.52, 8.96 ]
Total (95% CI) 1 1 100.0 % 0.22 [ -8.52, 8.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 1 Stillbirth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes





dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 0/7 Not estimable
Total (95% CI) 6 7 Not estimable
Total events: 0 (LMWH (adjusted dose)), 0 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 2 Very preterm birth
(28 to < 32 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 1/6 2/7 100.0 % 0.58 [ 0.07, 4.95 ]
Total (95% CI) 6 7 100.0 % 0.58 [ 0.07, 4.95 ]
Total events: 1 (LMWH (adjusted dose)), 2 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 3 Late preterm birth
(32 to < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 2/7 100.0 % 0.23 [ 0.01, 4.00 ]
Total (95% CI) 6 7 100.0 % 0.23 [ 0.01, 4.00 ]
Total events: 0 (LMWH (adjusted dose)), 2 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 4 Any preterm birth
(birth < 37weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 1/6 4/7 100.0 % 0.29 [ 0.04, 1.95 ]
Total (95% CI) 6 7 100.0 % 0.29 [ 0.04, 1.95 ]
Total events: 1 (LMWH (adjusted dose)), 4 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 5 Birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes










N Mean(SD)[g] N Mean(SD)[g] IV,Fixed,95% CI IV,Fixed,95% CI
Salim 2016 6 3117 (998) 7 2305 (961) 100.0 % 812.00 [ -257.81, 1881.81 ]
Total (95% CI) 6 7 100.0 % 812.00 [ -257.81, 1881.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 6 Low birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 1/6 3/7 100.0 % 0.39 [ 0.05, 2.83 ]
Total (95% CI) 6 7 100.0 % 0.39 [ 0.05, 2.83 ]
Total events: 1 (LMWH (adjusted dose)), 3 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
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Analysis 6.7. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 7 Small-for-
gestational age.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 1/6 1/7 100.0 % 1.17 [ 0.09, 14.92 ]
Total (95% CI) 6 7 100.0 % 1.17 [ 0.09, 14.92 ]
Total events: 1 (LMWH (adjusted dose)), 1 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
Analysis 6.8. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 8 Apgar score less
than seven at five minutes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 0/7 Not estimable
Total (95% CI) 6 7 Not estimable
Total events: 0 (LMWH (adjusted dose)), 0 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
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Analysis 6.9. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 9 Adherence to the
intervention.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 6/6 7/7 100.0 % 1.00 [ 0.76, 1.31 ]
Total (95% CI) 6 7 100.0 % 1.00 [ 0.76, 1.31 ]
Total events: 6 (LMWH (adjusted dose)), 7 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (fixed dose) Favours LMWH (adjusted dose)
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Analysis 6.10. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 10 Caesarean birth
(elective).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 1/6 1/7 100.0 % 1.17 [ 0.09, 14.92 ]
Total (95% CI) 6 7 100.0 % 1.17 [ 0.09, 14.92 ]
Total events: 1 (LMWH (adjusted dose)), 1 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
Analysis 6.11. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 11 Caesarean birth
(emergency).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 1/6 2/7 100.0 % 0.58 [ 0.07, 4.95 ]
Total (95% CI) 6 7 100.0 % 0.58 [ 0.07, 4.95 ]
Total events: 1 (LMWH (adjusted dose)), 2 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
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Analysis 6.12. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 12 Induction of
labour.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 3/6 5/7 100.0 % 0.70 [ 0.28, 1.77 ]
Total (95% CI) 6 7 100.0 % 0.70 [ 0.28, 1.77 ]
Total events: 3 (LMWH (adjusted dose)), 5 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
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Analysis 6.13. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 13 Instrumental
vaginal birth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 0/7 Not estimable
Total (95% CI) 6 7 Not estimable
Total events: 0 (LMWH (adjusted dose)), 0 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
Analysis 6.14. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 14 Placental
abruption.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 1/7 100.0 % 0.38 [ 0.02, 7.93 ]
Total (95% CI) 6 7 100.0 % 0.38 [ 0.02, 7.93 ]
Total events: 0 (LMWH (adjusted dose)), 1 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
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Analysis 6.15. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 15 Pre-eclampsia.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes





dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 1/7 100.0 % 0.38 [ 0.02, 7.93 ]
Total (95% CI) 6 7 100.0 % 0.38 [ 0.02, 7.93 ]
Total events: 0 (LMWH (adjusted dose)), 1 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
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Analysis 6.16. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 16 Gestational
diabetes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 1/7 100.0 % 0.38 [ 0.02, 7.93 ]
Total (95% CI) 6 7 100.0 % 0.38 [ 0.02, 7.93 ]
Total events: 0 (LMWH (adjusted dose)), 1 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
Analysis 6.17. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 17 Chorioamnionitis.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes





dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 0/7 Not estimable
Total (95% CI) 6 7 Not estimable
Total events: 0 (LMWH (adjusted dose)), 0 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
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Analysis 6.18. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 18 Postpartum
haemorrhage.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 3/7 100.0 % 0.16 [ 0.01, 2.64 ]
Total (95% CI) 6 7 100.0 % 0.16 [ 0.01, 2.64 ]
Total events: 0 (LMWH (adjusted dose)), 3 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
Analysis 6.19. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 19 Serious maternal
outcome (death, cardiac arrest, respiratory arrest, admission to intensive care).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 0/6 0/7 Not estimable
Total (95% CI) 6 7 Not estimable
Total events: 0 (LMWH (adjusted dose)), 0 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
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Analysis 6.20. Comparison 6 LMWH (adjusted dose) vs LMWH (fixed dose), Outcome 20 Admission to
neonatal intensive care unit.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 6 LMWH (adjusted dose) vs LMWH (fixed dose)




dose) LMWH (fixed dose) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Salim 2016 1/6 2/7 100.0 % 0.58 [ 0.07, 4.95 ]
Total (95% CI) 6 7 100.0 % 0.58 [ 0.07, 4.95 ]
Total events: 1 (LMWH (adjusted dose)), 2 (LMWH (fixed dose))
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH (adjusted dose) Favours LMWH (fixed dose)
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Analysis 7.1. Comparison 7 Leukocyte immunisation vs placebo, Outcome 1 Stillbirth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes





tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
Analysis 7.2. Comparison 7 Leukocyte immunisation vs placebo, Outcome 2 Neonatal death.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
174Care prior to and during subsequent pregnancies following stillbirth for improving outcomes (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.3. Comparison 7 Leukocyte immunisation vs placebo, Outcome 3 Adverse perinatal outcome
(composite outcome including stillbirth, neonatal death, and major neonatal morbidity).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
Analysis 7.4. Comparison 7 Leukocyte immunisation vs placebo, Outcome 4 Perinatal mortality.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
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Analysis 7.5. Comparison 7 Leukocyte immunisation vs placebo, Outcome 5 Very preterm birth (28 to < 32
weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
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Analysis 7.6. Comparison 7 Leukocyte immunisation vs placebo, Outcome 6 Late preterm birth (32 to < 37
weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 1/2 100.0 % 0.33 [ 0.02, 5.33 ]
Total (95% CI) 2 2 100.0 % 0.33 [ 0.02, 5.33 ]
Total events: 0 (Leukocyte immunisation), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
Analysis 7.7. Comparison 7 Leukocyte immunisation vs placebo, Outcome 7 Any preterm birth (birth < 37
weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 1/2 100.0 % 0.33 [ 0.02, 5.33 ]
Total (95% CI) 2 2 100.0 % 0.33 [ 0.02, 5.33 ]
Total events: 0 (Leukocyte immunisation), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
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Analysis 7.8. Comparison 7 Leukocyte immunisation vs placebo, Outcome 8 Birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes










N Mean(SD)[g] N Mean(SD)[g] IV,Fixed,95% CI IV,Fixed,95% CI
Christiansen 1994 2 3735 (21.21) 2 2540 (664.68) 100.0 % 1195.00 [ 273.35, 2116.65 ]
Total (95% CI) 2 2 100.0 % 1195.00 [ 273.35, 2116.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
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Analysis 7.9. Comparison 7 Leukocyte immunisation vs placebo, Outcome 9 Low birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 1/2 100.0 % 0.33 [ 0.02, 5.33 ]
Total (95% CI) 2 2 100.0 % 0.33 [ 0.02, 5.33 ]
Total events: 0 (Leukocyte immunisation), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
Analysis 7.10. Comparison 7 Leukocyte immunisation vs placebo, Outcome 10 Small-for-gestational age.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
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Analysis 7.11. Comparison 7 Leukocyte immunisation vs placebo, Outcome 11 Apgar score less than seven
at five minutes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
Analysis 7.12. Comparison 7 Leukocyte immunisation vs placebo, Outcome 12 Adherence to the
intervention.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 2/2 2/2 100.0 % 1.00 [ 0.49, 2.05 ]
Total (95% CI) 2 2 100.0 % 1.00 [ 0.49, 2.05 ]
Total events: 2 (Leukocyte immunisation), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours leukocyte immunisation
180Care prior to and during subsequent pregnancies following stillbirth for improving outcomes (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.13. Comparison 7 Leukocyte immunisation vs placebo, Outcome 13 Caesarean birth (elective).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
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Analysis 7.14. Comparison 7 Leukocyte immunisation vs placebo, Outcome 14 Caesarean birth
(emergency).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 1/2 100.0 % 0.33 [ 0.02, 5.33 ]
Total (95% CI) 2 2 100.0 % 0.33 [ 0.02, 5.33 ]
Total events: 0 (Leukocyte immunisation), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
Analysis 7.15. Comparison 7 Leukocyte immunisation vs placebo, Outcome 15 Induction of labour.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
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Analysis 7.16. Comparison 7 Leukocyte immunisation vs placebo, Outcome 16 Instrumental vaginal birth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
Analysis 7.17. Comparison 7 Leukocyte immunisation vs placebo, Outcome 17 Placental abruption.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
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Analysis 7.18. Comparison 7 Leukocyte immunisation vs placebo, Outcome 18 Pre-eclampsia.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes





tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
Analysis 7.19. Comparison 7 Leukocyte immunisation vs placebo, Outcome 19 Gestational diabetes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
184Care prior to and during subsequent pregnancies following stillbirth for improving outcomes (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.20. Comparison 7 Leukocyte immunisation vs placebo, Outcome 20 Chorioamnionitis.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes





tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
Analysis 7.21. Comparison 7 Leukocyte immunisation vs placebo, Outcome 21 Serious maternal outcome
(death; cardiac arrest; respiratory arrest; admission to intensive care).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 7 Leukocyte immunisation vs placebo




tion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1994 0/2 0/2 Not estimable
Total (95% CI) 2 2 Not estimable
Total events: 0 (Leukocyte immunisation), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours leukocyte immunisation Favours placebo
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Analysis 8.1. Comparison 8 Intravenous IgG vs placebo, Outcome 1 Stillbirth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 1 Stillbirth
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 1/2 1/3 34.8 % 1.50 [ 0.18, 12.46 ]
Christiansen 2002 0/1 1/1 65.2 % 0.33 [ 0.03, 4.19 ]
Total (95% CI) 3 4 100.0 % 0.74 [ 0.16, 3.40 ]
Total events: 1 (Intravenous IgG), 2 (Placebo)
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Intravenous IgG vs placebo, Outcome 2 Neonatal death.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 2 Neonatal death
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Intravenous IgG vs placebo, Outcome 3 Adverse perinatal outcome (composite
outcome including stillbirth, neonatal death, and major neonatal morbidity).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 3 Adverse perinatal outcome (composite outcome including stillbirth, neonatal death, and major neonatal morbidity)
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 1/2 1/3 34.8 % 1.50 [ 0.18, 12.46 ]
Christiansen 2002 0/1 1/1 65.2 % 0.33 [ 0.03, 4.19 ]
Total (95% CI) 3 4 100.0 % 0.74 [ 0.16, 3.40 ]
Total events: 1 (Intravenous IgG), 2 (Placebo)
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Intravenous IgG vs placebo, Outcome 4 Perinatal mortality.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 4 Perinatal mortality
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 1/2 1/3 34.8 % 1.50 [ 0.18, 12.46 ]
Christiansen 2002 0/1 1/1 65.2 % 0.33 [ 0.03, 4.19 ]
Total (95% CI) 3 4 100.0 % 0.74 [ 0.16, 3.40 ]
Total events: 1 (Intravenous IgG), 2 (Placebo)
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Intravenous IgG vs placebo, Outcome 5 Very preterm birth (28 to < 32 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 5 Very preterm birth (28 to < 32 weeks)
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 Intravenous IgG vs placebo, Outcome 6 Late preterm birth (32 to < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 6 Late preterm birth (32 to < 37 weeks)
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 1/3 100.0 % 0.44 [ 0.03, 7.52 ]
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 100.0 % 0.44 [ 0.03, 7.52 ]
Total events: 0 (Intravenous IgG), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 8.7. Comparison 8 Intravenous IgG vs placebo, Outcome 7 Any preterm birth (birth < 37 weeks).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 7 Any preterm birth (birth < 37 weeks)
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 1/3 100.0 % 0.44 [ 0.03, 7.52 ]
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 100.0 % 0.44 [ 0.03, 7.52 ]
Total events: 0 (Intravenous IgG), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 8.8. Comparison 8 Intravenous IgG vs placebo, Outcome 8 Low birthweight.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 8 Low birthweight
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 1/2 0/3 100.0 % 4.00 [ 0.24, 67.71 ]
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 100.0 % 4.00 [ 0.24, 67.71 ]
Total events: 1 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 8.9. Comparison 8 Intravenous IgG vs placebo, Outcome 9 Small-for-gestational age.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 9 Small-for-gestational age
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 1 1 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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190Care prior to and during subsequent pregnancies following stillbirth for improving outcomes (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.10. Comparison 8 Intravenous IgG vs placebo, Outcome 10 Apgar score less than seven at five
minutes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 10 Apgar score less than seven at five minutes
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.11. Comparison 8 Intravenous IgG vs placebo, Outcome 11 Respiratory distress syndrome.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 11 Respiratory distress syndrome
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 1 1 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.12. Comparison 8 Intravenous IgG vs placebo, Outcome 12 Neonatal jaundice.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 12 Neonatal jaundice
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 1 1 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intravenous IgG Favours placebo
Analysis 8.13. Comparison 8 Intravenous IgG vs placebo, Outcome 13 Adherence to the intervention.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 13 Adherence to the intervention
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 2/2 3/3 41.7 % 1.00 [ 0.53, 1.87 ]
Christiansen 2002 5/5 3/3 58.3 % 1.00 [ 0.64, 1.56 ]
Total (95% CI) 7 6 100.0 % 1.00 [ 0.69, 1.44 ]
Total events: 7 (Intravenous IgG), 6 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 8.14. Comparison 8 Intravenous IgG vs placebo, Outcome 14 Caesarean birth (elective).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 14 Caesarean birth (elective)
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 1/2 1/3 100.0 % 1.50 [ 0.18, 12.46 ]
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 100.0 % 1.50 [ 0.18, 12.46 ]
Total events: 1 (Intravenous IgG), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intravenous IgG Favours placebo
Analysis 8.15. Comparison 8 Intravenous IgG vs placebo, Outcome 15 Caesarean birth (emergency).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 15 Caesarean birth (emergency)
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intravenous IgG Favours placebo
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Analysis 8.16. Comparison 8 Intravenous IgG vs placebo, Outcome 16 Induction of labour.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 16 Induction of labour
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 1/1 0/1 100.0 % 3.00 [ 0.24, 37.67 ]
Total (95% CI) 3 4 100.0 % 3.00 [ 0.24, 37.67 ]
Total events: 1 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 8.17. Comparison 8 Intravenous IgG vs placebo, Outcome 17 Instrumental vaginal birth.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 17 Instrumental vaginal birth
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 1/3 72.0 % 0.44 [ 0.03, 7.52 ]
Christiansen 2002 1/1 0/1 28.0 % 3.00 [ 0.24, 37.67 ]
Total (95% CI) 3 4 100.0 % 1.16 [ 0.21, 6.35 ]
Total events: 1 (Intravenous IgG), 1 (Placebo)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 8.18. Comparison 8 Intravenous IgG vs placebo, Outcome 18 Placental abruption.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 18 Placental abruption
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.19. Comparison 8 Intravenous IgG vs placebo, Outcome 19 Pre-eclampsia.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 19 Pre-eclampsia
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Favours intravenous IgG Favours placebo
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Analysis 8.20. Comparison 8 Intravenous IgG vs placebo, Outcome 20 Gestational diabetes.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 20 Gestational diabetes
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.21. Comparison 8 Intravenous IgG vs placebo, Outcome 21 Chorioamnionitis.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 21 Chorioamnionitis
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.22. Comparison 8 Intravenous IgG vs placebo, Outcome 22 Postpartum haemorrhage.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 22 Postpartum haemorrhage
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 1 1 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.23. Comparison 8 Intravenous IgG vs placebo, Outcome 23 Serious maternal outcome (death;
cardiac arrest; respiratory arrest; admission to intensive care).
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 23 Serious maternal outcome (death; cardiac arrest; respiratory arrest; admission to intensive care)
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 1995 0/2 0/3 Not estimable
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 3 4 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.24. Comparison 8 Intravenous IgG vs placebo, Outcome 24 Admission to the neonatal intensive
care unit.
Review: Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Comparison: 8 Intravenous IgG vs placebo
Outcome: 24 Admission to the neonatal intensive care unit
Study or subgroup Intravenous IgG Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christiansen 2002 0/1 0/1 Not estimable
Total (95% CI) 1 1 Not estimable
Total events: 0 (Intravenous IgG), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Favours intravenous IgG Favours placebo
A P P E N D I C E S
Appendix 1. Search terms for ICTRP and ClinicalTrials.gov
Search terms were: ’stillbirth AND previous’; ’miscarriage AND previous’; ’abortion AND previous’; and ’pregnancy loss AND previous’.
NB: The terms ’miscarriage’, ’pregnancy loss’, and ’abortion’ were included to account for varying definitions of stillbirth in terms
of gestational age (e.g. some reports may define ’miscarriage’ as a fetal death < 24 weeks, which would consequently include some
stillbirths, according to our definition of 20 weeks’ gestation or more).
C O N T R I B U T I O N S O F A U T H O R S
Aleena M Wojcieszek, Vicki Flenady, and Philippa Middleton designed the review with contribution from all authors.
Aleena M Wojcieszek led the drafting of the review, data analyses, interpretation, and reporting of results with Vicki Flenady, Philippa
Middleton and Emily Shepherd.
Aleena M Wojcieszek and Emily Shepherd screened search records from the initial searches (carried out in 2016) and completed all
data extractions and ’Risk of bias’ assessments.
Aleena M Wojcieszek, Zohra Lassi, and Margaret Murphy screened search records from the updated searches (carried out in 2018) and
Aleena M Wojcieszek and Zohra Lassi completed the data extractions and ’Risk of bias’ assessments.
Aleena M Wojcieszek contacted trialists for further information and developed and compiled data requests.
Aleena M Wojcieszek and Vicki Flenady undertook GRADE assessment of the quality of evidence.
All authors contributed to the interpretation of results and formulation of conclusions.
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Philippa Middleton, Vicki Flenady, Emily Shepherd and Zohra Lassi provided a methodological perspective;
Robert M Silver, David Ellwood and Alexander Heazell provided a clinical perspective (obstetrics), and Trish Wilson and Margaret
Murphy provided a clinical perspective (midwifery).
D E C L A R A T I O N S O F I N T E R E S T
Aleena M Wojcieszek: none known.
Emily Shepherd: none known.
Philippa Middleton: none known.
Zohra S Lassi: none known.
Trish Wilson: none known.
Margaret M Murphy: none known.
Alexander EP Heazell: Alexander EP Heazell’s salary is funded by his National Institute of Health Research (NIHR) Clinician Scientist
Award (CS-2013-13-009) although this review is not directly funded by this award. He also receives salary support from Tommy’s
Charity as Director of the Tommy’s Stillbirth Research Centre, University of Manchester. This review is part of this programme of
work into improving care in pregnancies after stillbirth. Alexander E P Heazell is the Clinical Lead for a specialist antenatal service for
women who have experienced a stillbirth in previous pregnancy.
David A Ellwood: David Ellwood has received sitting fees from the Australian Medical Council but this work is not related to this
Cochrane Review. He has received payment for providing expert witness reviews for medico-legal cases - these cases are in no way
related to the topic under review. I am the co-Director of an NHMRC Centre for Research Excellence - the centre is related to stillbirth
and will cover all aspects of research on this topic.
Robert M Silver: Robert M Silver has been awarded NIH grants unrelated to this work. He is a member of the International stillbirth
Alliance Scientific Research Committee. He has carried out paid consultancy for Gestavision (a company developing a diagnostic for
pre-eclampsia) and has received payment for grand rounds at several universities.
Vicki Flenady: none known
S O U R C E S O F S U P P O R T
Internal sources
• Mater Research Institute, The University of Queensland, Australia.
• Robinson Research Institute, The University of Adelaide, Australia.
• Women’s & Children’s Health Research Institute, The University of Adelaide, Australia.
• National Institute for Health Research: Alexander Heazell: National Institute of Health Research (NIHR) Clinician Scientist
Award (CS-2013-13-009), UK.
199Care prior to and during subsequent pregnancies following stillbirth for improving outcomes (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources
• National Health and Medical Research Council (NHMRC), Australia.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
Our protocol (Wojcieszek 2016) stated that we would carry out searches of ClinicalTrials.gov and the WHO International Clinical
Trials Registry Platform ( ICTRP) using the term ’stillbirth’. We subsequently noted that, given varying nomenclature in the literature
and varying definitions of stillbirth by gestational age, additional search terms were warranted (e.g. some reports may define ’miscarriage’
as a fetal death < 24 weeks’ gestation, which would consequently include some stillbirths, according to our definition of 20 weeks’
gestation or more). We added the terms ’pregnancy loss’, ’abortion’, and ’miscarriage’ to ensure full capture of potentially relevant
populations of parents.
In the original protocol we had not planned subgroup analyses for the timing of the start or duration of the intervention (pre-pregnancy
versus during pregnancy versus during delivery) or target of intervention (mother versus partner). Although data in this review did not
permit completion of these analyses, we will consider them in future updates if new trials are added.
In our original protocol, we included the ’Adverse perinatal outcome (composite outcome including stillbirth, neonatal death, and
major neonatal morbidity)’. In the review, we expand this to include examples of major neonatal morbidity (hypoxic-ischaemic
encephalopathy; intracranial haemorrhage; retinopathy of prematurity; necrotising enterocolitis).
In the original protocol we had stated that we would include each of the preterm birth outcomes (any preterm birth, very preterm
birth, and late preterm birth) in the GRADE assessment of the quality of evidence. As a maximum of seven outcomes can be included
in GRADE assessments, we selected any preterm birth exclusively for inclusion in these assessments.
Finally, in the original protocol we had stated that types of participants would include ’women’. So that fathers and partners were not
excluded, we subsequently expanded the population of interest to ’parents’, and liaised with the Cochrane Pregnancy and Childbirth’s
Information Specialist to ensure that relevant trials would be captured by the outlined search strategy.
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